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 4 
INTRODUCTION 
 
Integrase (IN) of HIV-1, ribonuclease H (RNase H) of HIV-1 and NS5B RNA 
polymerase RNA dependent (NS5b) of HCV are three enzymes that belong to two 
different classes,1-3 but have in common the presence of divalent metal ions, such as 
Mg2+, in their catalytic core domine. Each of these enzymes utilized the Mg2+ ions for 
catalyse the reactions in which are involves. These metal ions are chelated by a 
highly conserved motive that consisted in three acidic amino acid residues namely D-
X4-D motive. In IN this motive is represented by D64, D116 and E152 aminoacids; 
the Mg2+ ions are coordinated by D64 and D116 along with water molecole, whereas 
E152 that lies closed to D64 dose not partecipate in metal binding. 4 In RNase H this 
motive is represented by D443, E478, D498 and D549 amino acids, 5 whereas in 
NS5B is represented by D220, D318 and D319 amino acids. 6 The architetture of the 
amino acids within the catalytic site and the geometry of the catalytic metals are 
highly conserved among a superfamily of nuclease and polynucleotidyl trasferase.  
2,4-Diketo acids (DKAs) are the most important class of IN, RNase H and NS5B 
inhibitors and provided the first proof-of-concept of antiviral agents in the cell based 
assay. The mechanism of action of these inhibitors is likely a consequence of the 
interaction with metals in the active site, resulting in a functional impairment by 
chelating of critical metal cofactors. 7 The discovery of DKA was based on the 
hypothesis of metal cation/DKA motif coordination that provides a solution to the 
two-metal-ions active site binding pharmacophore. Selective DKA could be 
designed, incrising bulk and complexity of DKA substituents that could relax the 
requirement for either single or double metal ion interaction, but also confer 
selectivity by steric exclusion. Among the polynucleotidyl trasferase, RNase H 
shows high similarities with the structure of HIV-1 IN, which has been study for 
long times as a target for drug development and for which, a new drug was recently 
introduced in clinical practice. 8 Given the structural similarities between the 
domines of these three viral enzimes, several DKAs initially developed as IN 
inhibitors were also screened against RNase H or NS5b and viceversa. 
Here I report the design, synthesis and comparative evaluation of series of molecules 
that contain the DKA moiety like pharmacophore, and that are able to inhibit each of 
this three enzimes selectively. 
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First chapter 
 
INTEGRASE OF HIV-1 
 
Human immunodeficiency virus type-1 (HIV-1) and acquired immunedeficiency 
disease (AIDS) have cost the lives of millions of people world wide since the 
epidemic began. Currently the World Health Organization estimates that 33,3 million 
peoples are infected with HIV-1, constituting a global pandemic illness with 
significant social and economic impact (Figure 1). 9  
 
Figure 1. Adults and children estimated to be living with HIV (2009) 
In response to this medical crisis, the scientific and medical communities have 
discovered and developed antiretroviral (ARV) drugs that directly target viral 
enzymes or processes essential for viral replication (Figure 2). These ARV drugs, 
most of which are small molecule, include nucleoside/tide reverse transcriptase 
inhibitors (NRTIs, 8 approved drugs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs, 4 approved drugs), protease inhibitors (PIs, 9 approved drugs), and most 
recently the entry inhibitor maraviroc, and the integrase inhibitor (INSTIs), 
raltegravir. Moreover, a peptidic inhibitor, enfuvirtide, targets viral fusion. 
Combinations of ARV drugs used as highly active antiretroviral therapy (HAART) 
have become the standard of care for HIV therapy and have produced significant 
declines in the morbidity and mortality associated with HIV-1 infection, especially in 
those countries where access to ARV medications is widely available. 
Among the three enzymes encoded by HIV-1, protease (PR), reverse transcriptase 
(RT), and integrase (IN), the latter was until recently an “orphan” in terms of 
approved ARV drugs. Only in the 2007, the FDA approved raltegravir (RAL, MK-
0518, Isentress®, Merck Inc.), a strand transfer inhibitor of IN (INSTI), for the 
treatment of HIV-1 infection for just ARV treated subjects. 10 RAL was also 
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approved by the FDA for use in firstline ARV therapy in June 2009 and is 
undergoing further phase 3 studies in ARV treatment-naïve subjects. A second 
INSTI, elvitegravir (EVG, GS-9137, JTK-303, discovered by Japan Tobacco and 
developed by Gilead Sciences, Inc.) is undergoing phase 3 studies in ARV treatment-
experienced subjects. 11 S/GSK-1349572 is another INSTI, which recently entered 
phase 2 testing, suggesting that additional drugs may become available in this new 
class. 12 
Viral integration is a particularly desirable target because, like other retroviruses, 
HIV-1 requires integration into the host genome for its replication and propagation. 
Moreover, HIV-1 integrase has no human equivalent and offers the possibility of a 
high drug specificity with limited cellular toxicity. 13 
 
1.1 Biology of integrase of HIV-1 enzyme. 
1.1.1 Structure and function of HIV-1 integrase enzyme. 
Despite its acute importance for antiretroviral drug discovery and decades of 
rigorous research, the complete structure of IN, either as a separete protein or in the 
context of the functional intasome, is laking. The structural organization of the IN 
active site is unknown. Because clinically useful INSTIs preferentially bind to and 
inhibit the intasome complex compared to free IN, the mechanism of drug action is 
poorly undestood. 14  
IN recognized and acts on the termini of the linear double-strand DNA molecule, 
produced during the reverse trascription, and mediate its integration into the host 
DNA of the infected cell to produced functional provirus. Integration is the final step 
before irreversibile and productive HIV-1 infection of a target cell is achieved. 15 IN, 
encoded by HIV-1 pol gene, is a 32 kDa enzyme costituited by 288 amino acids. IN 
is divided into three structural and functional domine: the N-terminus domine 
(NTD), the catalytic core domine (CCD), and the C-terminus domine (CTD). 16  
The N-terminal domain of the integrase (amino acids 1-50) is characterized by two 
pairs of highly conserved histidine and cysteine residues (histidine residues 12 and 
16; cysteine residues 40 and 43) that form a “HH-CC” or zinc finger motif that 
involves the chelation of one zinc atom per integrase monomer. The N-terminal 
domain is required for high-order multimerization that is stimulated by zinc. 17 A 
zinc atom is required to stabilize the folded structure of the N-terminal domain of 
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HIV-1 integrase and is necessary for optimal enzymatic activity.  
The catalytic core domain includes amino acids 51- 212 of HIV-1 integrase. The 
catalytic core domain forms a dimer in solution and in the functional enzyme; the 
monomer structure of the catalytic core is similar to the folds of RNaseH. The 
catalytic core domain is required for the cleavage and formation of phosphodiester 
bonds. The active site of the catalytic core domain contains three highly conserved 
acidic amino acids forming a catalytic triad (residues D64, D116, and E152, also 
known as the D, D E motif), which coordinate two divalent metal ions and are 
absolutely essential for efficient integrase enzymatic activity. 18 Each of these amino 
acids is required for the catalysis of viral integration into host DNA; substitution of 
one of these residues significantly reduces the enzymatic activity of HIV-1 integrase. 
Interestingly, although the catalytic core domain can also catalyze the disintegration 
reaction (the reverse of integration) by itself, the N-terminal and C-terminal domains 
of integrase are also required for the 3′ processing and strand-transfer reactions. The 
C-terminal domain (amino acids 213-288) is the least conserved of the three 
domains. The HIV-1 C-terminal domain shares some structural homology with the 
SH3 class of DNA-binding domain, can bind DNA nonspecifically, and is required 
for both the 3′ processing and strand-transfer activities of HIV-1 integrase. 19  
 
1.1.2 Integration of HIV-1 into the human genome. 
The role of IN during HIV-1 replication begins in the cytoplasm after completation 
of reverse trascription. The resulting double strand intermediate DNA undergoes two 
reaction catalyzed by IN. IN selectively recruits an unperfected reverse-trascripted 
DNA in the cytoplasm, and binds its LTR sequence. 15 After the binding, IN 
catalyzed the removal of the highly conserved GT dinucleotides at 3’-end and, in 
consequence, the formation of reactive 3’-OH ends in both strands of the viral c-
DNA, by a nucleophilic attack of the phosphodiester bond between the 
deoxyguanosine and deoxyadenosine, in a reaction called 3’-processing (3’-P). With 
the 3’-P, IN formed together with viral DNA and a series of host (barrier to 
autointegration factor-1 (BAF), interactor-1, heat shock protein 60 (HSP60), high 
mobility group protein A-1 (HMG-A1), and lens epithelium derived growht factor 
(LEDGF/p75) 20 and viral (matrix, Vpr, p7/nucleocapsid and RT) 21 protein a 
preintegration complex (PIC), which is activelly trasported to the nucleous where the 
second reaction called strand transfer (ST) occurs. 
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ST reaction consists in a nucleophilic attack by the two reactive 3’-OH recessed ends 
of the viral DNA (DNA donor), formed during 3’-P, to the host DNA (DNA 
acceptor); the 3’-OH ends of viral DNA are taken closely by coordination, for 
making possible the reaction with the mayor groove of the genomic host DNA. The 
gap formed, after the nucleophilic attack, between the 5’-end of DNA donor and 3’-
end of DNA acceptor is filled probably by the cellular DNA repair enzymes, 
finishing the integration process. 22 
The completion of the ST reaction produces a functional integrated proviral DNA 
which begin the template for transcription of new viral RNAs, needed for translation 
of viral proteins and enzymes, and transcription of new full length viral RNAs, 
required for packaging into new virions. Each integrated provirus allows for the 
production of thousands of new virions, amplifying the initial infection and leads the 
infected CD4+ T-cell to the death. Without successful integration, viral replication 
would leading to a rapid decline due to the lack of amplification of the infection. The 
development of INSTIs nevertheless required over a decade of basic research before 
representatives of this drug class began to emerge in the clinic.  
 
1.2 Pharmacophore analysis and mechanisms of ST integrase inhibitors. 
IN inhibitors include compounds that exhibit a broad structural diversity. However, 
different compounds seem to follow a common pattern: almost all the compounds 
identified contain metal-chelating motifs. Based on pharmacophore analysis of 
several integrase inhibitors, their structural features can be divided into two domains: 
(i) the enzyme-binding domain and (ii) the catalytic triad domain. 
The enzyme-binding domain facilitates and potentially stabilizes inhibitor binding to 
the integrase enzyme, thereby allowing the catalytic triad domain to be presented to 
the catalytic triad. The enzyme-binding domain is highly flexible, composes by 
aromatic hydrophobic group(s), and can tolerate aromatic moieties of various sizes. 
The enzyme-binding domain of the inhibitors can be viewed as “anchoring residues” 
that binds to the complementary region in the integrase enzyme (corresponding to the 
“inhibitor binding” region); furthermore it also facilitates the transport of the 
integrase inhibitor across the cell membrane. The structural flexibility of the enzyme-
binding domain allows the attachment of additional hydrophobic residues that further 
facilitate cell membrane permeability as well as enhance the binding of the molecule 
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to the hydrophobic regions of IN. The catalytic triad domain of integrase inhibitor is 
highly conserved and shares a common motif. A general feature of this domain is 
that they all contain divalent metal ion chelating motifs such as catechol, 1,2-diols, β-
dicarbonyls, α-hydroxy acids, or quinolinols. Another important feature concern the 
planar configuration of the catalytic triad domain with the enzyme-binding domain. 
13 Among all known IN inhibitors, only the α,γ-diketo acids (DKA) are valid 
bioligical inhibitors. The INSTs are thought to engage metal ion cofactors in the IN 
active site by interactions with uniquely positioned oxygen atoms of the 
pharmacophore. Recently its publicated the first crystal structures of the full-length 
IN from the prototipe foamy virus in complex with its cognate viral DNA; this was 
refine using diffraction data collected on crystals soaked in presence of Mg2+ and the 
clinical INST RAL or EVG. On the basis of the structures, the two INSTs seem to 
have similar mode of binding and action. Their metal chelating oxygen atoms orient 
towards the metal cofactor of the active site, whereas the halobenzyl groups fit 
within a tight poket created by displacement of the 3’ adenosine. The two drugs are 
implicated in different interaction with the enzyme: RAL makes Van der Waals 
interactions with the bases of invariant CA dinucleotide in addiction with 
hydrophobic and stacking interaction with the side chains of Pro 214 and Tyr 212 
with its isopropyl and methyl-oxadiazole groups; EVG through its quinolone base 
and isopropyl group, interact with Pro 214. The intasome become inactive after the 
displacement of reactive 3’ viral DNA end from the active site. The extensive 
contacts with the viral DNA end observed in these structures determine why the 
INSTs preferentially interact and inhibit the DNA-bound form of HIV-1 IN. 14 
 
1.3 Development of ST integrase inhibitors: DKA. 
The discovery of small molecole was greatly enhanced after the publication by the 
Merck researcher of the in vitro assay for the analysis of IN activity and IN 
inhibitors. 23 The following years were characterized by an intensive research of 
natural product and synthetic molecule that are able to inhibit IN. The first natural 
products were identify among the fungal compounds, 24 like equisitina, and were 
characterized by the presence of pharmacophoric mojety like!β-hydroxyketo group, 
diketo group (DKA) or a carboxylate group. These compounds were not selective 
inhibitors of ST, but can inhibit also the 3’-P reaction. The first selective ST 
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inhibitors was 5-CITEP (1), discovered by Shionogi in 1999. 25  
 
This compound presents the triazole cycle as bioisoster of carboxylic acid group; 
furthermore 5-CITEP was the first compound for which the crystal structure in 
complex with CCD subunit was available. Thanks to this knowledge, was possible to 
define the mechanism of inhibition of DKA: the DKA mojety are able to chelate the 
Mg2+ ions presentes in the catalytic core domain. The indole base was demostrated to 
enhance the metal dependency, infact its substitution with benzyl base induced the 
decrease of inhibitory activity. To 5-CITEP follows a series of compound that were 
characterized by the presence of DKA mojety and were designed on the bases of 
crystal structure of 5-CITEP with CCD. Another important inhibitor was the Merck 
inhibitor L-731,988 (2), a pyrrolydiketo acid with a p-fluorobenzyl group bounded to 
the pyrrolic nitrogen. 26 This compound along with L-708,906, demonstrated an 
increase of ST inhibition on cell based assay and was utilized for selected resistance 
mutation. 
 
Noteworthy are also Merck naphthyiridine componds like L-870,810 27 (3) and L-
870-812 28 (4) that represents the evolution of the first compounds because contains a 
p-fluorobenzyl amide instead of carboxylic acid and the α,γ-diketo acid mojety was 
fused in the naphthyridine ring. The first was brought up in clinical trials until phase 
II. Its study was discontinous for its hepatotoxicity observed in long-term safety 
study. The second was the most extensively characterized compound of this series 
but for its capability to develop primary resistance after only one month of treatment, 
was abandoned.  
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Successful development and approval of an HIV-1 INSTI for the treatment of HIV-1 
infection was ultimately achieved with the discovery of RAL (5) by the Merck 
research laboratories, a pyrimidine compound, that present a new scaffold compared 
with the previous inhibitors. RAL was approved for clinical used by FDA in 2007. 
Another important compound introduced in phase III of clinical trials is EVG (6) 
discovered by Japan Tobacco; its structure derived from quinolinone atibiotic. 
Recentlt another compound is introduced in phase II of clinical trials, the 
naphthyridinone S/GSK 1349572 (7) 29 discovered by Shonogi and Glaxo Smith 
Kline. 
 
 
 
 
 
1.3.1 Raltegravir. 12 
RAL is the first INSTs have been introduced in clinical practice in the 2007 after the 
approval by FDA. From the chemical point of view, RAL is a 5-
hydroxydihydropyrimidin-6-one-4-carboxamide belonging to the DKA class. The 
pharmacophore, or the catalityc triade domain, is not represented by the 
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characteristic sequence of the α,γ-diketo acid mojety, but in this case the metal 
chelating group is conceal in the pyrimidinone cycle; for guarantee the chelation of 
the metal ions in the pharmacophoric group of RAL are respected the sequence and 
the kind of atoms that characterized the α,γ-diketo acid mojety. Infact the carbonyl 
group on 6 position and the hydroxyl group in 5 position of the pyrimidine ring, and 
the carboxyl group of the 4-fluorobenzyl amide imitate the two carbonyl group and 
the carboxyl acid respectively, of the α,γ-diketo acid mojety (see structure 5). Merck 
had discovered a series of DKA scaffolds active against HIV-1 IN and the HCV 
NS5b RNA-dependent RNA polymerase and mechanistically these compounds were 
expected to act similarly against these enzymes, namely via the chelation of active 
site metals. An interesting and key observation of this work was that a 
dihydroxypyrimidine caboxamide derived from DKAs in the HCV program that had 
no activity against HCV NS5B, acted as a potent, reversible and selective HIV 
INSTI with an IC50 of 85 nM in an enzymatic IN ST assay. Optimization of the SAR 
on the carboxamide led to the identification of p-flurobenzyl as the optimal amide 
residue and a gem-dimethyl as the optimal 2-substituent for the dihydroxypyrimidine 
core. Further optimization of capping groups of the amine portion of the scaffold 
demonstrated that heteroaromatic groups were the most potent. Five membered ring 
heterocycles were also investigated and compounds bearing 2 or 3 heteroatoms were 
the most potent in cell based antiviral assays, particularly those with a heteroatom in 
the 2 position. The compound that ultimately became known as RAL was an 
oxadiazole with three heteroatoms and was one of the most potent compounds 
investigated in cell based assays with an IC95 of 31 nM in the presence of 50% 
human serum. RAL was highly selective against other enzymes working through 
Mg2+ based mechanisms being inactive against HCV polymerase, HIV RT and 
RNaseH, and human, α, β!and"γ polymerases, and showed no activity up to 10#µM 
concentration on a panel of 150 enzymes, channels and receptors. RAL also did not 
have activity against the major cytochrome P450 isoforms including 1A2, 2C9, 2D6, 
3A4 and 2C9 nor did its how time dependent inhibition of 3A4. Binding affinity on 
cardiac HERG channels was >50#µM, suggestive of a good cardiac safety profile. 
Pharmacokinetic studies in animals showed good bioavailability with a multiphasic 
elimination, including a relatively short phase and a prolonged phase. Studies of 
metabolism demonstrated that RAL was primarily eliminated as a glucuronidated 
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metabolite through bile and urine with the glucoronidation occurring on the 5-
hydroxyl group of the pyrimidinone ring. Based on the need to keep the plasma 
concentration above the cell culture 95% inhibitory concentration (CIC95) and 
considering a variety of key factors including the biphasic elimination, the metabolic 
stability, protein binding and plasma clearance, the human dosing regimen of RAL 
was predicted to be twice daily (BID). Metabolism of RAL occurs primarily through 
glucoronidation and not via Cyp3A4 therefore RAL cannot be boosted with ritonavir 
as is the case for EVG. The most common side effects are upset stomach, headache, 
tiredness, itching, diarrhea, constipation, flatulence, and sweating.  
Based on the clinical trials studies, RAL has been shown to be a potent, well tolerate 
drug that can be combined with existing ARVs to provide highly efficacious 
treatment to both ARV experienced and naïve subjects. Further clinical studies will 
define the strengths and weaknesses of RAL and of the INSTI class ingeneral.  
 
1.3.2 Elvitegravr. 
Elvitegravir is a second INSTI in phase 3 clinical development in ARV treatment-
experienced subjects and is also undergoing phase 2 development in ARV naïve 
subjects as part of a fixed dose combination regimen. EVG was discovered by 
researchers at Japan Tobacco who described a new pharmacophore, specifically 4-
quinolone-3-glycoxylicacid, which maintained the coplanarity observed in DKA 
INSTIs. Compounds containing the 4-quinolone-3-carboxylic acid motif, but not the 
4-quinolone-3-glycoxylic acid, were inhibitors of IN, with the coplanar monoketo 
acid motif in 4-quinolone-3-carboxylic acids providing an alternative to the DKA 
motif (see structure 6). Elvitegravir showed potent anti-HIV activity in vitro against 
HIV-1 of multiple subtypes (EC50 ranging from 0.1 to 1.26 nM) as well as against 
HIV-2 strains (EC50 1.4–2.8 nM), and both SIV and murine leukemia viruses. 
Elvitegravir, like raltegravir has also shown potent antiviral activity in vivo against 
HIV-1 carrying resi stance mutations to multiple antiretroviral drug classes. 
Development of EVG, has focused on boosting it to QD dosing via inhibition of 
CyP3A4 metabolism. The clinical study demonstrated that EVG is metabolized by 
CYP3A4 and that the plasma concentration of elvitegravir can be boosted by the 
addition of ritonavir. EVG pharmacokinetics was significantly improved when the 
drug was boosted with ritonavir; infact its plasma half-time was increased from three 
 14 
to nine hours in the presence of ritonavir, thereby permitting once-daily dosing of 
this new integrase inhibitor 13. Tha most common side effect is loss of appetite. 
 
1.3.3 Resistance to Raltegravir and Elvitegravir. 
Drug resistance in HIV-1 evolves due to the lack of proof reading activity of HIV 
reverse transcriptase. Consequently, nearly every viral genome contains at least one 
mutation, some of which can impart drug resistance. During the development of 
INSTIs, a significant amount of information has accumulated on the IN mutations 
leading to drug resistance (Table 1). As currently understood, resistance to INSTIs 
can be mediated by a number of IN mutations that can be considered “primary” resi 
stance mutations which are all located in the CCD of IN, close to the INSTI binding 
site. Within this set of mutations, which occur at codons T66, E92, Y143, Q148 and 
N155, varying effects on susceptibility to EVG and RAL are observed. Numerous 
additional IN mutations, some of which are natural poly- morphisms and most of 
which are also found in the CCD, comprise secondary resistance mutations which 
increase phenotypic resistance when added to primary mutations. Many of these 
secondary mutations have only limited effects on susceptibility to EVG and RAL 
when present on their own. Some secondary resistance mutations have been noted in 
the CTD of IN including mutations at codons S230 and R263; however, no resistance 
mutations have been described in the NTD of IN. In many respects, resistance to 
INSTIs has features in common with that observed for other ARV drug classes, 
notably the accumulation of mutations leads to higher levels of resistance.  
 
Table 1. HIV-1 integrase mutations selected by INSTIs in vitro. 
Compound Group Selected mutations in IN of HIV-1 
RAL Merck E138A, G140A, Q148K 
RAL Merck T66A, Q95K, Y143C or T66A, Y143R or N155H 
RAL Tibotec E138K, G140A, Q148R 
EVG Kyoto University H51Y, E92Q, S147G, E157Q or T66I, Q95K, E138K Q146P, S147G 
EVG Gilead T66I, F121Y or T66I, S153Y or T66I, R263K 
EVG GSK T66I/A/K, V72A, E92Q/V, P145S, Q146S/L, Q148K/R 
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EVG Merck T66A, V72I, N155S or Q148R 
EVG Tibotec 
T66I alone or R20K, T66I, L74M, S230R or T66I, A128T, E138K, 
Q148R, S230R or E92Q alone or T66A, E92Q or E92Q, E138K, 
Q148R 
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1.4 Aim 
The research group where I spent my PhD period by several years is involved in 
design and synthesis of organic compounds inhibitors of IN of HIV-1. This approch 
is started at the end of the nineties, with the synthesis of curcumina analogues 
polyoxydryl compounds that exhibited high activity in enzyme and cell-based 
assaies. 30 
 
 
8 
 
IC50 = 0.2 µM (3’P) 
IC50 = 0.3 µM (ST) 
EC50 = 4 µM 
 
Afterwards, the Merck Inc. had finished a random screening on about 250000 
compounds, from which was emerged a new hit compound (2, L-731,988) 
characterized by a diketoacid mojety linked on a phenylmethyl pyrrolic group, 
proven to be a potent inhibitor on ST, in cell-based assay too. 
 
 
These interesting results lead us to design a series of 6-(1-arylmethyl-1H-pyrrol-2-
yl)-2,4-dioxo-5-hexenoic acids that risen from a superposition of cinnamoyl and 
dioxobutanoic mojeties (Fig. 8). 
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Figure 8. Different features of 6-(1-arylmethyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids. 
 
All new synthesized compounds was tested by research group of Prof. Y. Pommier at 
National Institute of Healt in Bethesda, USA. 
From an initial analysis of obtained biologycal data, some mojety was resulted 
essential to have actived compounds against IN of HIV-1. In particular is emerged 
that: 
1 a cinnamoyl group is presented both in natural and synthetic compound; 
2 the α,β-diketo group characterized the aryldiketoacids series; 
3 The carboxylic acid function is found in natural (L-cicoric acid), diketoacid 
compound (L-731,988) and cinnamoyl derivative (8); 
4 an aromatic portion is presented in all compounds. 
Among the serie of pyrrolyldiketoacid derivatives synthesized by us, the best resultes 
was obtained with the 2,6-difluorosubstitutes derivative 9. 
 
 
9 
 
9 has demonstrated an IC50 value of 0.15 µM, EC50 value of 0.022 µM, CC50 value of 
>50 µM and a selective index > 2273 that lead it to be three times more active of 
Merck derivative L-731,988. 
On the bases of this structural analysis, my research group has decided to preserve 
Aromatic portion 
Cinnamoyl group 
Diketoacid Mojety 
Carboxylic acid  
function 
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unchanged the essential structural features for the antiviral activity, or rather the 
cinnamoyl group, the α,β-diketo group, the carboxylic acid function and the 
aromatic portion. In particolar, the cinnamoyl group was built in a rigid ring as the 
oxoquinolonyl system, to generate conformational blocked analogue of 9, to increase 
the interaction with the enzymatic active site and the biologycal activities. 
In this way was designed and synthesized the quinolonyldioxobutanoic acids 10. 
 
 
10 
 
Initially was led studies on the substitution on benzene ring of quinolonyl system, to 
obtain selective compound active on ST; after that was studied the substitution on 
nitrogen atom of quinolonyl system, in particular was found that the best substituent 
was the benzyl group and specifically the 4-fluorobenzyl derivative 11.  
 
 
11 
 
The results obteined with derivative 11 was excellent: infact, it presents an IC50 value 
of 0.013 µM for ST inhibition and an EC50 value of 1.17 µM. 
Noteworthy, passed between 9 to 10 series it possible to note an increase of activity 
on ST inhibition, assessable of 2-3 order of magnitude. 
Analizing the activities data, compound 11 shows an interesting inhibitory activity in 
enzymatic assay, but a more restricted activity in cell-based assay on infected cell by 
HIV-1. 
On the bases of this beckground, my research work was to develop the IN inhibitors 
with three different approaches: 
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1. carry on the design and synthesis of quinolonyldioxobutanoic acids 
analogue of 11, to increase the selectivity for ST reaction and the activity in 
cell-based assay on infected cell by HIV-1; 
2. designed and synthesized a new scaffolds ables to chelate the two metal 
ions present in the active site of the enzyme and given an inhibitory activity 
in cell-based assay on infected cell by HIV-1; 
3. develop INSTIs that can be tested for its microbicide activity. 
In the following paragraphs, I’m going to describe how these three different 
approaches was developed.  
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1.5 Quinolonyldiketo acids 
1.5.1 Introduction 
Recent studies on quinolinonyl diketo acid derivatives led us to discover the 
bifunctional compound 12 as a potent IN inhibitor for both 3′-P and ST.32 Moreover, 
12 inhibits HIV-1 replication in acutely infected cells.32  
 
Docking studies on the binding mode of 12 to the IN catalytic site also suggested a 
peculiar interaction of the drug involving both the acceptor and the donor DNA 
binding sites of the enzyme. This hypothesis was confirmed by our recent cross-
linking experiment studies that pointed out a specific interaction of 12 with K156 
and K159 amino acid residues of the IN catalytic core domain.15 This binding mode 
could account for the high potency of 12 against both 3′-P and ST. The aim of the 
present project was the design of new quinolinone derivatives endowed with a 
selective activity against ST. This project could provide new information regarding 
the interactions of quinolinonyl diketo acids with the IN active site and consequently 
increase our knowledge about the catalytic mechanisms of IN, which in the absence 
of structural information on IN-DNA and drug molecular structures are still far from 
being totally elucidated. In the present paragraph, I describe novel quinolinonyl 
diketo acid derivatives 13a-i, 14a-i, 15a,b and 16a,b designed by replacement of the 
6-diketo acid chain of 12, responsible for binding to the donor DNA binding site, 
with smaller substituents in the 6-, 7-, or 8-position of the quinolinone ring.  
These substituents should exhibit reduced binding to the donor viral cDNA site due 
to their small size/length or to their limited ability to form hydrogen bonds. Thus, 
these structural modifications should provide novel quinolinonyl diketo acid 
derivatives with increased ST selectivity. Furthermore, I have delved into the 
substitution in 7-position of the quinolinone ring with different cyclic and linear 
bases, designed and synthesized novel quinolinonyl diketo acid derivatives 13j-q, 
14j-q analogues of 13i and 14i and 17a,b and 18a,b analogues of 12, in which is 
presented a lipophilic and basic portion that may counterbalance the polarity of the 
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diketoacid mojety and enhanced the activity in cell-based assay on infected cell by 
HIV-1. 
 
Table 2. Compound 13a-q, 14a-q, 15a,b, 16a,b, 17a,b and 18a,b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cpd R6 R7 R8 X  Cpd R6 R7 R8 X 
13a H H H Et  14a H H H H 
13b F H H Et  14b F H H H 
13c H F H Et  14c H F H H 
13d F H F Et  14d F H F H 
13e Cl H H Et  14e Cl H H H 
13f H Cl H Et  14f H Cl H H 
13g H H Cl Et  14g H H Cl H 
13h Cl Cl H Et  14h Cl Cl H H 
13i H 1-Pyrrolydinyl H Et  14i H 1-Pyrrolydinyl H H 
13j H 1-Pyperazinyl H Et  14j H 1-Pyperazinyl H H 
13k H N-Methyl-1- Pyperazinyl H Et  14k H N-Methyl-1- Pyperazinyl H H 
13l H N-Ethyl-1- Pyperazinyl H Et  14l H N-Ethyl-1- Pyperazinyl H H 
13m H N-Acethyl-1- Pyperazinyl H Et  14m H N-Acethyl-1- Pyperazinyl H H 
13n H 1-Thiomorpholinyl H Et  14n H 1-Thiomorpholinyl H H 
13o H 1-Morpholinyl H Et  14o H 1-Morpholinyl H H 
13p H N-(3-chloroprop-1-yl)-1-
pyperazinlyl 
H Et  14p H N-(3-chloroprop-1-yl)-1-
pyperazinlyl 
H H 
13q H N,N-dimethylamine H Et  14q H N,N-dimethylamine H H 
15a Cl H - Et  16a Cl H - H 
15b H Cl - Et  16b H Cl - H 
17a - N,N-dimethylamine - Et  18a - N,N-dimethylamine - H 
17b - N-Methyl-1- Pyperazinyl - Et  18b - N-Methyl-1- Pyperazinyl - H 
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1.5.2 Results and discussion 
Synthesis of derivatives 13a-q, 14a-q, 15a,b, 16a,b, 17a,b and 18a,b is outlined in 
Schemes 1–4. 3-Acetyl-4(1H)-quinolinones 19a-h were prepared by reaction of the 
proper aniline with ethyl orthoformate and ethyl acetoacetate, which were thermally 
condensed in the presence of an inert heating medium (Dowtherm A) under argon 
atmosphere, according to the Yoshizawa procedure. 33 Then, 17a-h were alkylated 
with 4-fluorobenzylbromide in alkaline medium (K2CO3) to give the N-1 substituted 
quinolones 18a-h. These compounds were condensed with diethyl oxalate in the 
presence of sodium ethoxide to provide ethyl esters 13a-s, which were in turn 
hydrolyzed with 6 N NaOH to afford the corresponding acids 14a-s (Scheme 1).  
 
Scheme 1. a 
 
a Reagents and conditions: (i) ethyl orthoformate, ethyl acetoacetate, Dowtherm A, 95-254 °C, 8 h; 
(ii) 4-fluorobenzyl bromide, K2CO3, DMF, 100 °C, 1 h; (iii) diethyl oxalate, C2H5ONa, THF, room 
temp, 2 h; (iv) 1 N NaOH, THF/CH3OH, room temp, 40 min. 
 
Synthesis of 1-unsubstituted derivatives 15a,b and 16a,b was achieved in a similar 
fashion by coupling of 4-quinolinones 19e,f with diethyl oxalate in the presence of 
the sodium ethoxide, followed by alkaline hydrolysis of the resulting ethyl esters 
15a,b to provide acids 16a,b (Scheme 2). 
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Scheme 2. a 
 
a Reagents and conditions: (i) diethyl oxalate, C2H5ONa, THF, room temp, 2 h; (ii) 1 N NaOH, 
THF/CH3OH, room temp, 40 min. 
 
Derivatives 13i-q and 14i-q were synthesized as described in Scheme 3. Derivatives 
17i-q were obtained in few minutes with good yields by substitution of fluorine atom 
of 17c with the appropriate base in the presence of NEt3 or in aqueous solution under 
microwave irradiation. 17i-s was then condensed with ethyl oxalate, and the ester 
13i-s that formed was hydrolyzed to afford the required acid 14i-s.  
Scheme 3. a 
 
a Reagents and conditions: (i) base, Et3N, DMF, microwave, 100 W, 153 °C, 10 min, or N,N-
dimethylamine acq. sol. 40%, 100 W, 175 °C, 10 min; (ii) diethyl oxalate, C2H5ONa, THF, room 
temp, 2 h; (iii) 1 N NaOH, THF/CH3OH, room temp, 40 min. 
 
The derivatives 17a,b and 18a,b were synthesized as described in Scheme 4, starting 
from the commercially available 4-nitro-2-chlorobenzoic acid that reacted with 
carbonyldiimidazole (CDI) to form the activated amide that reacted with Meldrum’s 
acid (2,2–dimethyl-1,3-dioxano-4,6-dione) to form the product of substitution that 
was hydrolized in presence of HCl 10 % to obtain the acethyl derivative 21. 
Subsequently, It was sujected to a reduction reaction, which the nitro group was 
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reduced to amino group in presence of Pd/C and H2 at atmospheric pressure and 
room temperature obtaining the derivative 22, that was the substratum for the 
cyclization reaction with ethyl orthoformate and ethyl acetoacetate, which were 
thermally condensed in the presence of an inert heating medium (Dowtherm A) 
under argon atmosphere, according to the Yoshizawa procedure. 33 The 3,6-Diacetyl-
4(1H)-quinolinone 23 was alkylated in presence of 4-fluorobenzylbromide in 
alkaline medium (K2CO3) to give the N-1 substituted quinolones 24. Derivatives 
25a,b were obtained in few minutes with good yields by substitution of fluorine atom 
of 17c with N-methylpyperazine in the presence of NEt3 or N,N-dimethylamine in 
aqueous solution under microwave irradiation. 25a,b was then condensed with ethyl 
oxalate, and the ester 17a,b that formed was hydrolyzed to afford the required acid 
18a,b. 
 
Scheme 4. a 
 
a Reagents, conditions and yields: (i) 1) CDI,CH2Cl2, room temp, 2 h; 2) Meldrum’s acid, room 
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temp,72 h, 3) HCl 10% , room temp, 2 gg, 10 %; (ii) Pd/C, H2, ethyl acetate, 1 Atm, room temp, 2.5 h, 
98 %; (iii) ethyl orthoformate, ethyl acetoacetate, Dowtherm A, 95-254 °C, 8 h; 50 %; (iv) 4-
fluorobenzylbromide, K2CO3, DMF, 100 °C, 1 h, 17 %; (v) N-Methylpyperazine, Et3N, DMF, 
microwave, 100 W, 153 °C, 10 min, 50 %, or N,N-dimethylamine acq. sol. 40%, 100 W, 175 °C, 10 
min, 51%; (vi) diethyl oxalate, C2H5ONa, THF, room temp, 2 h, 76%; (vii) NaOH 1N, THFa, CH3OH, 
room temp, 5 min, 77 %. 
 
Derivatives 13a-q, 14a-q, 15a,b, 16a,b, 17a,b and 18a,b were tested in vitro for ST 
inhibition in the presence of magnesium (Mg2+) using a recently described high 
throughput electrochemiluminescent (HTECL) assay. 30 IC50 values were generated 
from duplicate experiments (Table 3). Compounds 13a-q, 14a-q, 15a,b, 16a,b, 17a,b 
and 18a,b were also tested for ST and 3′-P using gel-based assays carried out in the 
presence of Mg2+. IC50 values were calculated using dose response curves and are 
summarized in Table 3.  
 
Table 3. Activities data for compound 13a-q, 14a-q, 15a,b, 16a,b, 17a,b and 18a,b. 
 
 
 
     
     
ANTI-IN activity IC50a ANTIVIRAL activity 
Cpd R6 R7 R8 X Mg2+b Mg2+ c Mg2+ 
c 
CC50d EC50e SIf 
13a H H H Et 0.67  0.79, 0.44  135 ntg ntg  
13b F H H Et 0.58  0.23, 0.44  >333  >200  >50  
13c H F H Et 1.3  1.2, 2.9  >333  >200  >50  
13d F H F Et 26  5.2  >333  >200  >50  
13e Cl H H Et 21  3.0  >333  ntg ntg  
13f H Cl H Et 14  3.6  >333  ntg ntg  
13g H H Cl Et 32  5.2  >333  >200  >50  
13h Cl Cl H Et 3.9  1.8  135  72  >50  
13i H 1-Pyh H Et 2.3  2.7  110  >200  4.1  48.8 
13j H 1-Pyperazinyl H Et 24.4 ntg >333 ntg ntg  
13k H N-Methyl-1-Pyperazinyl H Et ntg ntg ntg ntg ntg  
13l H N-Ethyl-1-Pyperazinyl H Et ntg ntg ntg ntg ntg  
13m H N-Acethyl-1-Pyperazinyl H Et ntg ntg ntg ntg ntg  
13n H 1-Thiomorpholinyl H Et ntg ntg ntg ntg ntg  
13o H 1-Morpholinyl H Et ntg ntg ntg ntg ntg  
13p H N-(3-chloroprop-1-yl)-1-
pyperazinlyl 
H Et ntg ntg ntg ntg ntg  
13q H N,N-dimethylamine H Et 0.37 ntg 39 ntg ntg  
15a Cl H H Et 3.3  2.1  120  ntg  ntg  
15b H Cl H Et >111  224  >333  ntg ntg  
17a - N,N-dimethylamine H Et 2.9 ntg 41 ntg ntg  
17b - N-Methyl-1-Pyperazinyl H Et ntg ntg ntg ntg ntg  
14a H H H H 0.040  0.06, 14  >200  1.17  >171 
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0.16  
14b F H H H 0.030  0.14  2.3  >200  >50  
14c H F H H 0.020  0.050  4.4  >200  >50  
14d F H F H 0.018  0.16  16  >200  >50  
14e Cl H H H 0.028  0.40  6.4  >200  46.1  4.3 
14f H Cl H H 0.019  0.11  4.0  >200  >50  
14g H H Cl H 0.023  0.51  44  >200  >50  
14h Cl Cl H H 0.033  0.075  11, 34  156  3.2  62.5 
14i H 1-Pyrrolidinyl H H 0.028  0.18  14, 
9.0  
>200  0.17  >1176 
14j H 1-Pyperazinyl H H 2.01 ntg 65 ntg ntg  
14k H N-Methyl-1-Pyperazinyl H H ntg ntg ntg ntg ntg  
14l H N-Ethyl-1-Pyperazinyl H H ntg ntg ntg ntg ntg  
14m H N-Acethyl-1-Pyperazinyl H H ntg ntg ntg ntg ntg  
14n H 1-Thiomorpholinyl H H ntg ntg ntg ntg ntg  
14o H 1-Morpholinyl H H ntg ntg ntg ntg ntg  
14p H N-(3-chloroprop-1-yl)-1-
pyperazinlyl 
H H ntg ntg ntg ntg ntg  
14q H N,N-dimethylamine H H 0.054 ntg 2.7 ntg ntg  
16a Cl H H H >111  56  166  ntg ntg  
16b H Cl H H 37  17  >333  ntg  ntg  
18a H N,N-dimethylamine H H 0.15 ntg 5.1 ntg ntg  
18b H N-Methyl-1-Pyperazinyl H H ntg ntg ntg ntg ntg  
a Inhibitory concentration 50% (µM) determined from dose response curves. b Experiments performed 
in duplicate using the high throughput electrochemiluminescent (HTECL) assay (ST assay in the 
presence of Mg2+). c Experiments performed in a gel-based assay in the presence of Mg2+ (see Figure 
8). d Cytotoxic concentration 50% (µM). e Effective concentration 50% (µM). f Selectivity index 
(CC50/EC50). g nt: not tested. 
 
The newly synthesized DKAs 13a-i, 14a-i, 15a,b, 16a,b exhibited high potency 
against IN with high selectivity against ST, thus confirming the hypothesis that the 
removal of the diketo acid branch in the 6-position of the quinolinone ring of 12 can 
lead to ST-selective inhibitors (14a-i showed 3′-P/ST ratios ranging from 45 to 667). 
The acid derivatives 14a-i were more potent than the corresponding esters 13a-i 
(Figure 8A and Figure 8B, compare compounds 14h and 13h), and the 1-p-F-benzyl 
substituted quinolinones (13e,f and 14e,f) were markedly more active than their 
unsubstituted counterparts (15a,b and 16a,b). This trend is consistent with the results 
obtained previously on the bifunctional DKA (BDKA) series.30 In particular, the 
relevant role played by the p-F-benzyl moiety at the 1-position of the quinolinone 
ring was previously noted for the DKA derivatives. The newly synthesized acid 
derivatives 14a-i were potent inhibitors, showing IC50 values in the range of 18-40 
nM for the ST step (Table 3). The most active compound of this series is 14d with a 
ST IC50 value of 18 nM, which is comparable to reference drugs 2 and 3. Removal of 
the diketo acid chain from the 6-position of our BDKA lead molecule (compound 
12) 30 led to compound 14a that retains the potent anti-IN activity of the parent 
derivative with an IC50 value of 40 nM for ST (Table 3). However, 14a is a more ST 
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selective inhibitor than 12.14 Introduction of a halogen (F or Cl) in the 6-, 7-, or 8-
position of 14a led to compounds 14b-g, which show similar anti-IN activities (IC50) 
18-30 nM, (Table 3) as their unsubstituted counterpart 14a. Interestingly, the anti-IN 
activities appear to be influenced by the position of the halogen. Indeed, inhibitory 
activities decrease in the following order:  
8-F(Cl) ∼ 7-F(Cl) > 6-F(Cl) and 7-Cl > 8-Cl > 6-Cl. 
The introduction of a second chlorine atom in the structure of the potent inhibitor 14f 
led to 14h, which is approximately 1.5 times less potent than the parent counterpart. 
Similarly, replacement of the chlorine atom of 14f with a pyrrolidine ring led to 14i, 
which is approximately 1.5 times less potent than the parent compound. In 
conclusion, the activities of compounds with a substituent in the 7-position decrease 
in the following order: Cl > F > 1-pyrrolidinyl > H (Table 3). Compounds 13a-i and 
13a-i also inhibited integrase with similar potency in the presence of Mg2+ or Mn2+ 
(data not shown). The activity in the presence of Mg2+ in addition to the selectivity 
for ST represents a trademark of the most potent DKAs active against HIV 
replication in cells.  
Activities data relatively the newly synthesized DKAs 13j-q, 14j-q, 17a,b, 18a,b are 
uncomplete, thus it cannot possible to formulate valid structure-activity relationships. 
Now are availabled enzymatic activity data only for compounds 13-14j,q and 17-
18a. On the strength of the available data is possible to affirm that the acid 
derivatives 14j-q and 18a were more potent than the corresponding esters 13j,q and 
17a and exhibited high potency against IN with high selectivity against ST. The 
substitution with the dimethylamine on quinolinone ring led to compound 14q that 
mantein the inhibitory activity on enzymatic assay if compare with the lead 14i; this 
trend is not followed by derivative 14j in which the enzymatic activity is decreased 
of hundred times. Compound 18a is a derivative of 12, compared with the BDKA 
lead molecule 12 its enzymatic activity is diminished of ten times, but with the 
insertion of dimethylamine substituent is increased the selectivity for ST respect to 
3’-P reaction. 
Cytotoxicity and antiviral activities of compounds 13a-i, 14a-i, 15a,b, and 16a,b are 
presented in Table 3. Among the tested compounds, derivatives 13a,i, and 14a,e,h,i 
show EC50 < 50 µM when tested against HIV-1-infected H9/ HTLVIIIB cells. In 
particular, 13i and 14a,h,i are active in the micromolar range, with SI ranging from 
48.8 to >1176. The most potent derivative of this series is 14i (EC50) 0.17 µM and SI 
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> 1176). Compound 14i is in fact more potent than reference derivatives 2 and 12. In 
general, all the active compounds were characterized by low cytotoxicity against 
human histiocytic lymphoma (U937) cell line, showing CC50 values in the range of 
99 to >200 µM. 
 29 
1.5.3 Conclusions 
I designed, synthesized, and tested a series of novel quinolinonyl diketo acid 
derivatives in both enzyme- and cellbased assays as anti-HIV-1 agents to selectively 
target the ST step of integration. We were able to generate such new compounds, 
which are potent ST-selective IN inhibitors and active against HIV-1 replication in 
acutely infected cells. These compounds could be useful tools to study the 
mechanism of action of HIV-1 IN. 
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1.5.4 Experimental section 
 
Chemistry 
General. Melting points were determined with a Büchi 530 capillary apparatus and 
are uncorrected. Infrared (IR) spectra were recorded on a Perkin-Elmer Spectrum-
one spectrophotometer. 1H NMR spectra were recorded on a bruker AC 400 
specrtometer. Merk silica gel 60 F254 plates were used for analytical TLC. Column 
chromatogrephies were performed on silica gel (Merck; 70-230 mesh) or alumina 
(Merck; 70-230 mesh). Concentration of solution after reactions and extractions 
involved the use of a rotary evaporator operating at reduced pressure of 
approximately 20 Torr. Analytical results agreed to within ±0.40% of the theoretical 
values. 
Microwave irradiation experiments. Microwave reactions were conduced using a 
CEM Discover system unit (CEM. Corp., Matthews, NC). The machine consists of a 
continuous focused microwave-power delivery system with operator selectable 
power output from 0 to 300 W. The temperature of the contents of the vessel was 
monitored using a calibrated infrared temperature control mounted under the reaction 
vessel. All experiments were performed using a stirring option whereby the contents 
of the vessel are stirred by means of a rotating magnetic plate located below the floor 
of the microwave cavity and a Teflon-coated magnetic stir bar in the vessel. 
 
Synthesis of 1-(2-chloro-4-nitrophenyl)ethanone (21). To a suspention of 2-
chloro-4-nitrobenzoic acid commercially available (10 g, 0.0496 mol) in 
dichloromethane (46.6 mL) was added CDI (8.3 g, 0.051 mol) and stirred at room 
temp for 2 h (until begin a solution). To the obtained solution was added Meldrum’s 
acid (7.15 g, 0.0496 mol) and stirred for 72 h at room temp. Afterwards, was added 
59.5 mL of HCl 10%, and the suspention was stirred and heated at reflux for 8 h. 
After cooling, the organic layer was collected, washed with acq. sol NaHCO3 5%, 
brine and dried on Na2SO4 anydrus, obtaining 2.23 g of crude product as orange oil. 
Purification of crude products was performed by chromatography on silica gel 
column (chloroform/ethyl acetate 1:2 as eluent) to give 310 mg of pure 21 (8% 
yield). Chemical and physical of derivative 21 are reported in Table 4. 
 
Synthesis of 1-(4-amino-2-chlorophenyl)ethanone (22). A solution of starting 
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material 21 (4.31 g, 0.0216 mol) in 282 mL of ethyl acetate was stirred in presence 
of 720 mg of 10% Pd/C under H2 atmosphere at atmospheric pressure and room 
temperature for 2.5 h. The mixture was then filtered and the Pd residue washed with 
ethyl acetate. The combined organic layer were concentrated at reduced pressure to 
yield 3.36 g of pure product as yellow oil (98% yield). Chemical and physical of 
derivative 22 are reported in Table 4. 
 
General Procedure for the Synthesis of 3-Acetyl-4(1H)-quinolinones 19a-h, 23. 
Ethyl orthoformate (4.0 g, 27 mmol), ethyl acetoacetate (3.5 g, 27 mmol), the 
appropriate substituted aniline (27 mmol), and Dowtherm A (5.6 mL) were charged 
in a three-necked flask equipped with a water separator. This mixture was stirred 
under argon atmosphere, while the temperature was increased to 95 °C in 1 h, then 
gradually up to 162 °C in a further hour. Then the mixture was stirred at this 
temperature for 6 h. After this time, the resulting solution was added in portions 
during 3 h into 42 mL of Dowtherm A stirred in a three-necked flask equipped with 
thermometer and water separator and heated at 253-254 °C. After addition the 
mixture was heated at the same temperature for 2 h. Then the mixture was cooled at 
90 °C, treated with isopropanol (10 mL), cooled at 30 °C, filtered, and washed with 
isopropanol and light petroleum ether in turn to give pure derivatives 19a-h, 23. 
Chemical and physical data of derivatives 19a-h and 23 are reported in Table 4.  
 
General Procedure for the Synthesis of 1-(4-fluorophenyl)methyl-4(1H)-
quinolinones 20a-h, 24. A mixture of the proper 19a-h or 23 derivative (1.1 mmol), 
4-fluorophenylmethyl bromide (610 mg, 3.3 mmol), and anhydrous K2CO3 (210 mg, 
1.5 mmol) in dry DMF (10 mL) was stirred at 100 °C for 1 h. After the mixture was 
cooled, water was added (40 mL) and the precipitate that formed was filtered, 
washed with water and light petroleum ether in turn, and then dried under IR lamp to 
provide pure derivatives 20a-h, 24. Chemical and physical data of derivatives 20a-h 
and 24 are reported in Table 4.  
 
General Procedure for the Synthesis of 7-(base)-4(1H)-quinolinones (20i-p, 25b). 
A mixture of 20c or 24 (8.5 mmol), base (25.6 mmol), and NEt3 (7.7 mmol) in dry 
DMF (40 mL) was irradiated with microwave at 153 °C for 10 min (applied potency 
100 W), in an open vessel equipped with a condenser. After cooling, the reaction 
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mixture was diluted with water (100 mL) and treated with 1 N HCl until pH 7. The 
solid that formed was collected by filtration. Purification of crude product was 
performed by chromatography on silica gel column (chloroform/ethanol 10:1 as 
eluent) to give of pure 20i-p, 25a. Chemical and physical data of derivatives 20i-p 
and 25a are reported in Table 4.  
 
General procedure for the synthesis of 7-(dimethylamino)-4(1H)-quinolinones 
(20q, 25a). A mixture of dimethylamine in H2O (40%, 0.0013 mol), and quinolinone 
20c or 24 (0.00045 mol) was irradiated with microwave at 175 °C, 100 Watt, for 10 
minutes. After cooling the reaction mixture was diluited with water. The formed 
precipitate was collected by filtration on gouch, washed with water, and diethylic 
ether. Purification of crude products was performed by chromatography on silica gel 
column (chloroform/ethanol 5:1 as eluent) to give pure products. Chemical and 
physical data of derivatives 20q and 25a are reported in Table 4. 
 
General Procedure for the Synthesis of Diketo Esters 13a-q, 15a,b and 17a,b. 
Sodium ethoxide (390 mg, 5.5 mmol) was added into a well stirred mixture of the 
appropriate acetyl derivative 19e,f, 20a-q or 25a-b (2.7 mmol) and diethyl oxalate 
(790 mg, 5.4 mmol) in anhydrous THF (2.7 mL) under nitrogen atmosphere. The 
mixture was stirred at room temperature for 2 h, then was poured into n-hexane (50 
mL). The collected precipitate was vigorously stirred for 30 min in 1 N HCl (50 mL). 
The yellow solid that formed was filtered, washed with water, and dried under IR 
lamp to afford the pure diketo esters 13a-q, 15a,b and 17a,b. Yield (%), melting 
point (°C), recrystallization solvent, IR, 1H NMR are reported for each of the 
following compounds. 
 
4-[1-(4-Fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-2-
butenoic Acid Ethyl Ester (13a). 82%; 175-177 °C; ethanol; IR ν 3400 (OH), 1721 
(C=O ester), 1661, 1635, and 1607 (C=O ketone) cm-1. 1H NMR (CDCl3) δ 1.44 (t, 
3H, CH3), 4.42 (q, 2H, CH2CH3), 5.48 (s, 2H, CH2), 7.06-7.26 (m, 4H, benzene H), 
7.37-7.65 (m, 3H, quinolinone C6-H, C7-H, and C8-H), 8.16 (s, 1H, butenoate C3-
H), 8.56 (m, 1H, quinolinone C5-H), 8.77 (s, 1H, quinolinone C2-H), 15.50 (bs, 1H, 
OH).  
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4-[6-Fluoro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2- hydroxy-4-oxo-
2-butenoic Acid Ethyl Ester (13b). 92%; 152-153 °C; toluene/cyclohexane; IR ν 
1740 (C=O ester), 1650 and 1624 (C=O ketone) cm-1; 1H NMR (DMSO-d6) δ 1.29 (t, 
3H, CH3), 4.30 (q, 2H, CH2CH3), 5.78 (s, 2H, CH2), 7.16-7.20 (m, 2H, benzene H), 
7.29-7.37 (m, 2H, benzene H), 7.66 (m, 1H, quinolinone C7-H), 7.81 (m, 1H, 
quinolinone C8-H), 7.97 (m, 1H, quinolinone C5-H), 8.00 (s, 1H, butenoate C3-H), 
9.13 (s, 1H, quinolinone C2-H), 15.33 (bs, 1H, OH).  
 
4-[7-Fluoro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid Ethyl Ester (13c). 84%; 151-152 °C; benzene/cyclohexane; IR ν 
1726 (C=O ester), 1644 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 1.30 (t, 3H, 
CH3), 4.30 (q, 2H, CH2CH3), 5.72 (s, 2H, CH2), 7.17-7.21 (m, 2H, benzene H), 7.31-
7.40 (m, 3H, benzene H and quinolinone C6-H), 7.62 (m, 1H, quinolinone C8-H), 
7.97 (s, 1H, butenoate C3-H), 8.36 (m, 1H, quinolinone C5-H), 9.10 (s, 1H, 
quinolinone C2-H), 14.00 (bs, 1H, OH).  
 
4-[8-Fluoro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid Ethyl Ester (13d). 83%; 179-180 °C; benzene/cyclohexane; IR ν 
3300 (OH), 1744 (C=O ester), 1648 and 1604 (CdO ketone) cm-1. 1H NMR (DMSO-
d6) δ 1.27 (t, 3H, CH3), 4.30 (q, 2H, CH2CH3), 5.78 (s, 2H, CH2), 7.14-7.24 (m, 4H, 
benzene H), 7.48-7.53 (m, 1H, quinolinone C6-H), 7.59-7.69 (m, 1H, quinolinone 
C7-H), 7.97 (s, 1H, butenoate C3-H), 8.17-8.19 (m, 1H, quinolinone C5-H), 9.01 (s, 
1H, quinolinone C2-H), 15.50 (bs, 1H, OH).  
 
4-[6-Chloro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid Ethyl Ester (13e). 34%; 131-133 °C; washed with cyclohexane; IR 
ν 3400 (OH), 1722 (C=O ester), 1700 and 1628 (C=O ketone) cm-1. 1H NMR 
(DMSO-d6) δ 1.33 (t, 3H, CH3), 4.33 (q, 2H, CH2CH3), 5.71 (s, 2H, CH2), 7.14-7.34 
(m, 4H, benzene H), 7.71-7.77 (m, 2H, quinolinone C7-H and C8-H), 7.91 (s, 1H, 
butenoate C3-H), 8.25 (m, 1H, quinolinone C5-H), 9.09 (s, 1H, quinolinone C2-H), 
12.70 (bs, 1H, OH).  
 
4-[7-Chloro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid Ethyl Ester (13f). 76%; 173-175 °C; washed with isopropanol; IR 
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ν 3300 (OH), 1727 (C=O ester), 1647 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 
1.30 (t, 3H, CH3), 4.32 (q, 2H, CH2CH3), 5.76 (s, 2H, CH2), 7.16-7.25 (m, 2H, 
benzene H), 7.36-7.38 (m, 2H, benzene H), 7.54 (m, 1H, quinolinone C6-H), 7.88 
(m, 1H, quinolinone C8-H), 7.96 (s, 1H, butenoate C3-H), 8.29 (m, 1H, quinolinone 
C5-H), 9.08 (s, 1H, quinolinone C2-H), 12.70 (bs, 1H, OH).  
 
4-[8-Chloro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid Ethyl Ester (13g). 98%; 164-165 °C; toluene; IR ν 3400 (OH), 
1749 (C=O ester), 1644 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 1.29 (t, 3H, 
CH3), 4.30 (q, 2H, CH2CH3), 6.09 (s, 2H, CH2), 7.14-7.16 (m, 4H, benzene H), 7.15 
(m, 1H, quinolinone C6-H), 7.82 (m, 1H, quinolinone C7-H), 7.91 (s, 1H, butenoate 
C3-H), 8.34 (m, 1H, quinolinone C5-H), 8.81 (s, 1H, quinolinone C2-H), 15.25 (bs, 
1H, OH).  
 
4-[6,7-Dichloro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-
oxo-2-butenoic Acid Ethyl Ester (13h). 98%; 144-145 °C; toluene/cyclohexane; IR 
ν 1727 (C=O ester), 1638 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 1.35 (t, 3H, 
CH3), 4.38 (q, 2H, CH2CH3), 5.82 (s, 2H, CH2), 7.18-7.30 (m, 2H, benzene H), 7.43-
7.46 (m, 2H, benzene H), 7.98 (s, 1H, butenoate C3-H), 8.14 (s, 1H, quinolinone C8-
H), 8.41 (s, 1H, quinolinone C5-H), 9.14 (s, 1H, quinolinone C2-H), 16.00 (bs, 1H, 
OH).  
 
4-[1-(4-Fluorophenyl)methyl-7-(pyrrolidin-1-yl)-4(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13i). 82%; 170 °C (dec); methanol; 
IR ν 3300 (OH), 1735 (C=O ester), 1621 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 
1.31 (t, 3H, CH3), 1.98-2.10 (m, 4H, pyrrolidine H), 3.32-3.36 (m, 1H, pyrrolidine 
H), 4.30 (q, 2H, CH2CH3), 5.64 (s, 2H, CH2), 6.37-6.39 (m, 1H, quinolinone C8-H), 
6.77-6.79 (m, 1H, quinolinone C6-H), 7.29-7.32 (m, 2H, benzene H), 7.45-7.48 (m, 
2H, benzene H), 8.12-8.16 (m, 2H, quinolinone C5-H and butenoate C3-H), 8.79 (s, 
1H, quinolinone C2-H), 13.50 (bs, 1H, OH).  
 
4-[1-(4-Fluorophenyl)methyl-7-(pyperazin-1-yl)-4-(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13j): 98%; 150-152 °C; washed with 
isopropanole; IR: cm-1  3347 (OH enole), 1711 (C=O ester), 1666 (C=O ketone). 1H 
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NMR: (DMSO-d6) δ 1.32-1.29 (t, 3H, CH3CH2), 3.33 (m, 4H, pyperazine H), 3.38 
(m, 4H, pyperazine H), 4.33-4.28 (q, 4H, CH2CH3), 5.71 (s, 2H, CH2 benzyl), 6.86 
(s, 1H, C8-H quinolinone), 7.23-7.17 (m, 3H, benzene H and C6-H quinolinone), 
7.44-7.40 (m, 2H, benzene H), 8.00 (s, 1H, CH enole), 8.11-8.09 (d, 1H, C5-H 
quinolinone), 9.00 (s, 1H, C2-H quinolinone). 
 
4-[1-(4-Fluorophenyl)methyl-7-(N-methylpyperazin-1-yl)-4-(1H)-quinolinon-3-
yl]-2-hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13k): 99%; 96-99 °C; washed 
with isopropanole; IR: cm-1  3381 (OH enole), 1713 (C=O ester), 1605 (ketone); 1H 
NMR: (DMSO-d6) δ 1.02 (s, 3H, CH3 pyperazine); 1.23-1.22 (t, 3H, CH3CH2); 2.33 
(m, 4H, pyperazine H); 3.24  (m, 4H, pyperazine H);  4.11-4.10 (q, 4H, CH2CH3); 
5.54 (s, 2H, CH2 benzyl); 6.72 (s, 1H, C8-H quinolinone); 7.07-7.05 (d, 1H, C6-H 
quinolinone); 7.19 (m, 2H, benzene H); 7.29 (m, 2H, benzene H);  8.08-8.06 (d, 1H, 
C5-H quinolinone); 8.55 (s, 1H, CH enole);  8.61 (s, 1H, C2-H quinolinone). 
 
4-[1-(4-Fluorophenyl)methyl-7-(N-ethylpyperazin-1-yl)-4-(1H)-quinolinon-3-yl]-
2-hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13l): 99%; 200 °C (dec); washed 
with isopropanole; IR: cm-1  3388 (OH enole), 1711 (C=O ester), 1606 (ketone). 1H 
NMR: (DMSO-d6) δ 1.15-1.18 (t, 3H, CH3CH2 pyperazine), 1.24-1.18 (t, 3H, 
CH3CH2), 2.19 (q, 3H, CH2CH3 pyperazine), 2.39 (m, 4H, pyperazine H), 3.24 (m, 
4H, pyperazine H), 4.12-4.10 (q, 4H, CH2CH3), 5.55 (s, 2H, CH2 benzyl), 6.72 (s, 
1H, C8-H quinolinone), 7.07-7.01 (m, 2H, CH enole and C6-H quinolinone), 7.20-
7.18 (m, 2H, benzene H), 7.29 (m, 2H, benzene H), 8.08-8.05 (d, 1H, C5-H 
quinolinone), 8.54 (s, 1H, C2-H quinolinone).  
 
4-[1-(4-Fluorophenyl)methyl-7-(N-acethylpyperazin-1-yl)-4-(1H)-quinolinon-3-
yl]-2-hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13m): 91%; 178-180 °C; 
washed with isopropanole; IR: cm-1 3409 (OH enole), 1716 (C=O ester), 1604 
(ketone). 1H NMR: (DMSO-d6) δ 1.22-1.26 (t, 3H, CH3CH2), 2.03 (s, 3H, CH3 
acethylpyperazine), 3.26 (m, 4H, pyperazine H), 3.54 (m, 4H, pyperazine H), 4.12-
4.10-4.14 (q, 4H, CH2CH3), 5.56 (s, 2H, CH2 benzyl), 6.75 (s, 1H, C8-H 
quinolinone), 7.01 (s, 1H, CH enole), 7.04-7.06 (d, 1H, C6-H quinolinone), 7.18-
7.22 (m, 2H, benzene H), 7.28-7.32 (m, 2H, benzene H), 8.08-8.10 (d, 1H, C5-H 
quinolinone), 8.53 (s, 1H, C2-H quinolinone). 
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4-[1-(4-Fluorophenyl)methyl-7-(tiomorpholin-1-yl)-4-(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13n): 99%; 170 °C; washed with 
isopropanole; IR: cm-1 3388 (OH enole), 1711 (C=O ester), 1606 (ketone). 1H NMR: 
(DMSO-d6) δ 1.24-1.18 (t, 3H, CH3CH2), 3.24 (m, 4H, tiomorpholine H), 3.72  (m, 
4H, tiomorpholine H), 4.12-4.10 (q, 4H, CH2CH3), 5.56 (s, 2H, CH2 benzyl), 6.77 (s, 
1H, C8-H quinolinone), 7.37-7.08 (m, 6H, CH enole, C6-H quinolinone and benzene 
H), 8.10 (d, 1H, C5-H quinolinone), 8.60 (s, 1H, C2-H quinolinone). 
 
4-[1-(4-Fluorophenyl)methyl-7-(morpholin-1-yl)-4-(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13o): 76%; 175-177 °C; trituration on 
diethyl ether; IR: cm-1 3388 (OH enole), 1711 (C=O ester), 1606 (ketone). 1H NMR: 
(DMSO-d6) δ 1.24-1.18 (t, 3H, CH3CH2), 3.24 (m, 4H, morpholine H), 3.72  (m, 4H, 
morpholine H), 4.12-4.10 (q, 4H, CH2CH3), 5.56 (s, 2H, CH2 benzyl), 6.77 (s, 1H, 
C8-H quinolinone), 7.37-7.08 (m, 6H, CH enole, C6-H quinolinone and benzene H), 
8.10 (d, 1H, C5-H quinolinone), 8.60 (s, 1H, C2-H quinolinone). 
 
4-[1-(4-Fluorophenyl)methyl-7-(N-(3-chloroprop-1-yl)-1-pyperazinlyl)-4-(1H)-
quinolinon-3-yl]-2-hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13p): 77%; 175-
177 °C; washed with acetone; IR: cm-1 3488 (OH enole), 1723 (C=O ester), 1617 
(ketone). 1H NMR: (DMF-d7) δ 1.35-1.39 (t, 3H, CH3CH2), 1.96-1.99 (q, 2H, 
ClCH2CH2CH2N pyperazine), 2.48-2.54 (m, 6H, pyperazine H and ClCH2CH2CH2N 
pyperazine), 3.38-3.39 (m, 4H, pyperazine H), 3.73-3.76 (q, 4H, CH2CH3), 4.35-4.39 
(q, 2H, ClCH2CH2CH2N pyperazine), 5.87 (s, 2H, CH2 benzyl), 6.98 (s, 1H, C8-H 
quinolinone), 7.22-7.29 (m, 3H, C6-H quinolinone and benzene H), 7.58-7.62 (m, 
2H, benzene H), 8.10 (m, 2H, CH enole and C5-H quinolinone), 9.14 (s, 1H, C2-H 
quinolinone). 
 
4-[1-(4-Fluorophenyl)methyl-7-(dimethylamino)-4-(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid Ethyl Ester (13q): 98%; 150 °C (dec); washed 
with isopropanole; 1H NMR: (DMF-d7) δ 1.32-1.28 (t, 3H, CH3CH2), 3.00 (s, 6H, 
CH3 dimethylamine), 4.22-4.16 (q, 4H, CH2CH3), 5.65 (s, 2H, CH2 benzyl), 6.52 (s, 
1H, C8-H quinolinone), 6.89-6.87 (s, 1H, C6-H quinolinone), 7.18 (s, 1H, CH 
enole), 7.25-7.21 (m, 2H, benzene H), 7.48-7.45 (m, 2H, benzene H), 8.20-8.18 (d, 
1H, C5-H quinolinone), 8.70 (s, 1H, C2-H quinolinone). 
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4-(6-Chloro-4(1H)-quinolinon-3-yl)-2-hydroxy-4-oxo-2-butenoic Acid Ethyl 
Ester (15a). 57%; 209-211 °C; ethanol; IR ν 3300 (NH and OH), 1734 (C=O ester), 
1684 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 1.31 (t, 3H, CH3), 4.25 (q, 2H, 
CH2), 7.40-8.00 (m, 3H, quinolinone C7-H, C8-H and butenoate C3-H), 8.20 (m, 1H, 
quinolinone C5-H), 8.50 (s, 1H, quinolinone C2-H), 12.75 (bs, 2H, NH and OH).  
 
4-(7-Chloro-4(1H)-quinolinon-3-yl)-2-hydroxy-4-oxo-2-butenoic Acid Ethyl 
Ester (15b). 77%; 187-189 °C; washed with isopropanol; IR ν 3200, 3064 (NH and 
OH), 1726 (C=O ester), 1700 and 1624 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 
1.30 (t, 3H, CH3), 4.30 (q, 2H, CH2), 7.47 (m, 1H, quinolinone C6-H), 7.68 (s, 1H, 
quinolinone C8-H), 7.94 (s 1H, butenoate C3-H), 8.18 (m, 1H, quinolinone C5-H), 
8.77 (s, 1H, quinolinone C2-H), 13.00 (bs, 1H, NH and OH).  
 
4,4’-[7-(Dimethylamino)-1-(4-fluorobenzyl)-4-oxo-(1H)-quinolinon-3,6-diyl] bis 
2-hydroxy-4-oxobut-2-enoic Acid Ethyl Ester (17a): 77%; 185 (dec) °C; washed 
with isopropanole; IR: cm-1 3300 (OH enole), 1720 (C=O ester); 1H NMR: (DMSO-
d6) δ 1.31-1.29 (t, 3H, CH3CH2), 2.81 (s, 3H, CH3 dimethylamine), 4.30-4.30 (q, 2H, 
CH3CH2), 5.70 (s, 2H, CH2 benzyl), 6.69 (s, 1H, C8-H quinolinone), 7.24-7.20 (t, 
2H, benzene H), 7.42-7.41 (m, 2H, benzene H), 7.99 (bs, 1H, CH enole), 8.20 (s, 1H, 
C5-H quinolinone), 9.05 (s, 1H, C2-H quinolinone). 
 
4,4’-[7-(N-methylpyperazin-1-yl)-1-(4-fluorobenzyl)-4-oxo-(1H)-quinolinon-3,6-
diyl] bis 2-hydroxy-4-oxobut-2-enoic Acid Ethyl Ester (17b): 82%; >240 °C; 
washed with isopropanole; IR: cm-1 3407 (OH enole), 1717 (C=O ester), 1634 (C=O 
ketone); 1H NMR: (DMSO-d6) δ 1.22-1.25 (t, 3H, CH3CH2), 2.17 (s, 3H, CH3 
pyperazine), 2.40 (s, 4H, pyperazine), 2.99 (s, 4H, pyperazine), 4.10-4.11 (q, 2H, 
CH3CH2), 5.58 (s, 2H, CH2 benzyl), 6.90 (s, 1H, C8-H quinolinone), 7.24-7.20 (m, 
3H, benzene H and CH enole), 7.32-7.38 (m, 2H, benzene H), 8.29 (s, 1H, C5-H 
quinolinone), 8.56 (s, 1H, C2-H quinolinone). 
 
General Procedure for the Synthesis of Diketo Acids 14a-i, 16a,b and 18a,b. A 
mixture of 1 N NaOH (6.5 mL) and the appropriate ester 13a-q, 15a,b or 17a,b (1.3 
mmol) in 1:1 THF/methanol (12 mL) was stirred at room temperature for 40 min and 
then poured onto crushed ice. The aqueous layer was separated and treated with 1 N 
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HCl until pH 3 was reached, and the yellow solid that formed was collected by 
filtration, then washed with water, hot dry ethanol, and light petroleum ether to 
afford pure acids 14a-i, 16a,b and 18a,b. Yield (%), melting point (°C), 
recrystallization solvent, IR, 1H NMR are reported for each of the following 
compounds. 
 
4-[1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-2-butenoic 
Acid (14a). 50%; 207-209 °C; washed with anhydrous ethanol; IR ν 3400 (OH), 
1732 (C=O acid), 1619 (C=O ketone) cm-1. 1H NMR (CDCl3) δ 5.79 (s, 2H, CH2), 
7.22-7.38 (m, 4H, benzene H), 7.53-8.34 (m, 5H, quinolinone C6-H, C7-H, C8-H 
and butenoate C3-H), 9.16 (s, 1H, quinolinone C2-H), 15.50 (bs, 2H, OH).  
 
4-[6-Fluoro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid (14b). 95%; 183-184 °C; washed with anhydrous ethanol; IR ν 
3100 (OH), 1730 (C=O acid), 1613 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 5.76 
(s, 2H, CH2), 7.16-7.20 (m, 2H, benzene H), 7.33-7.36 (m, 2H, benzene H), 7.65 (m, 
1H, quinolinone C7-H), 7.80 (m, 1H, quinolinone C8-H), 7.94-7.97 (m, 2H, 
quinolinone C5-H and butenoate C3-H), 9.10 (s, 1H, quinolinone C2-H), 14.67 (bs, 
2H, OH).  
 
4-[7-Fluoro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid (14c). 95%; 162-163 °C; washed with anhydrous ethanol; IR ν 
3300 (OH), 1719 (C=O acid), 1635 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 5.70 
(s, 2H, CH2), 7.14-7.21 (m, 2H, benzene H), 7.31-7.37 (m, 3H, benzene H 
andquinolinone C6-H), 7.60 (m, 1H, quinolinone C8-H), 7.93 (s,1H, butenoate C3-
H), 8.34 (m, 1H, quinolinone C5-H), 9.05 (s,1H, quinolinone C2-H), 14.60 (bs, 2H, 
OH).  
 
4-[8-Fluoro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid (14d). 78%; 180-181 °C; washed with hot anhydrous ethanol; IR ν 
3300 (OH), 1732 (C=O acid), 1634 and 1602 (C=O ketone) cm-1. 1H NMR (DMSO-
d6) δ 5.86 (s, 2H, CH2), 7.12-7.23 (m, 4H, benzene H), 7.45-7.50 (m, 1H, 
quinolinone C6-H), 7.57-7.62 (m, 1H, quinolinone C7-H), 7.70 (s, 1H, butenoate C3-
H), 8.16-8.18 (m, 1H, quinolinone C5-H), 8.96 (s, 1H, quinolinone C2-H), 14.30 (bs, 
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2H, OH).  
 
4-[6-Chloro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid (14e). 71%; 194-197 °C; DMF/water; IR ν 3385 (OH), 1710 (C=O 
acid), 1663 and 1622 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 5.72 (s, 2H, CH2), 
7.18-7.32 (m, 4H, benzene H), 7.75-7.85 (m, 2H, quinolinone C7-H and C8-H), 8.22 
(m, 1H, C5-H quinolinone), 7.90 (s, 1H, butenoate C3-H), 9.08 (s, 1H, quinolinone 
C2-H), 13.00 (bs, 2H, OH).  
 
4-[7-Chloro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid (14f). 64%; 188-190 °C; washed with isopropanol; IR ν 3400 (OH), 
1734 (C=O acid), 1646 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 5.75 (s, 2H, 
CH2), 7.21-7.36 (m, 4H, benzene H), 7.55 (m, 1H, quinolinone C6-H), 7.83-7.85 (m, 
2H, quinolinone C8-H and butenoate C3-H), 8.30 (m, 1H, quinolinone C5-H), 9.07 
(s, 1H, quinolinone C2-H), 13.00 (bs, 2H, OH).  
 
4-[8-Chloro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-oxo-
2-butenoic Acid (14g). 82%; 175-177 °C; washed with anhydrous ethanol; IR ν 
3300 (OH), 1742 (C=O acid), 1637 and 1603 (C=O ketone) cm-1. 1H NMR (DMSO-
d6) δ 6.08 (s, 2H, CH2), 7.00-7.30 (m, 4H, benzene H), 7.44-7.46 (m, 1H, 
quinolinone C6-H), 7.81-7.83 (m, 2H, butenoate C3-H and quinolinone C7-H), 8.33-
8.35 (m, 1H, quinolinone C5-H), 8.89 (s, 1H, quinolinone C2-H), 14.70 (bs, 2H, 
OH).  
 
4-[6,7-Dichloro-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-
oxo-2-butenoic Acid (14h). 86%; 175-177 °C; washed with isopropanol; IR ν 3300 
(OH), 1722 (C=O acid), 1630 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 5.75 (s, 
2H, CH2), 7.17-7.22 (m, 2H, benzene H), 7.32-7.39 (m, 2H, benzene H), 7.88 (s, 1H, 
quinolinone C8-H), 8.06 (s, 1H, butenoate C3-H), 8.32 (s, 1H, quinolinone C5-H), 
9.05 (s, 1H, quinolinone C2-H), 16.00 (bs, 2H, OH).  
 
4-[1-(4-Fluorophenyl)methyl-7-(pyrrolidin-1-yl)-4(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid (14i). 87%; 197-199 °C; washed with isopropanol; 
IR ν 3300 (OH), 1718 (C=O acid), 1614 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 
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2.06-2.13 (m, 4H, pyrrolidine H), 3.26-3.30 (m, 4H, pyrrolidine H), 5.77 (s, 2H, 
CH2), 6.42-6.45 (m, 1H, quinolinone C8-H), 6.81-6.85 (m, 1H, quinolinone C6-H), 
7.18-7.25 (m, 2H, benzene H), 7.49-7.52 (m, 2H, benzene H), 8.02 (s, 1H, butenoate 
C3-H), 8.15-8.17 (m, 1H, quinolinone C5-H), 9.09 (s, 1H, quinolinone C2-H), 14.00 
(bs, 2H, OH).  
 
4-[1-(4-Fluorophenyl)methyl-7-(pyperazin-1-yl)-4-(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid (14j): 98%; 224 °C; washed with isopropanole; IR: 
cm-1 3500-2000 (OH acid), 1700 (C=O acid), 1649 (C=O keton). 1H NMR: (DMSO-
d6) δ 3.35 (m, 4H, pyperazine H), 3.46 (m, 4H, pyperazine H), 5.64 (s, 2H, CH2 
benzyl), 6.82 (s, 1H, C8-H quinolinone), 7.20-7.12 (m, 3H, benzene H, C6-H 
quinolinone), 7.41-7.37 (m, 2H, benzene H), 8.08 (d, 1H, C5-H quinolinone), 8.42 (s, 
1H, CH enole), 8.75 (s, 1H, C2-H quinolinone), 16.00-14.00 (bs, 2H, OH). 
 
4-[1-(4-Fluorophenyl)methyl-7-(N-methylpyperazin-1-yl)-4-(1H)-quinolinon-3-
yl]-2-hydroxy-4-oxo-2-butenoic Acid (14k): 99%; 224 °C; washed with 
isopropanole; IR: cm-1 3500-2000 (OH acid), 1700 (C=O acid), 1599 (C=O ketone). 
1H NMR: (DMSO-d6) δ 2.38 (s, 3H, CH3 pyperazine), 2.66 (m, 4H, pyperazine H), 
3.35 (m, 4H, pyperazine H), 5.67 (s, 2H, CH2 benzyl), 6.81 (s, 1H, C8-H 
quinolinone), 7.29-7.08 (m, 3H, benzene H, C6-H quinolinone), 7.31-7.48 (m, 2H, 
benzene H); 7.69 (bs, 1H, CH enole), 8.08-8.06 (d, 1H, C5-H quinolinone), 8.93 (s, 
1H, C2-H quinolinone), 16.00-14.00 (bs, 2H, OH). 
 
4-[1-(4-Fluorophenyl)methyl-7-(N-ethylpyperazin-1-yl)-4-(1H)-quinolinon-3-yl]-
2-hydroxy-4-oxo-2-butenoic Acid (14l): 99%; >240 °C; washed with isopropanole; 
IR: cm-1 3500-2000 (OH acid), 1700 (C=O acid), 1578 (C=O ketone). 1H NMR: 
(DMSO-d6) δ 1.06 (t, 3H, CH3CH2 pyperazine), 2.22 (q, 3H, CH2CH3 pyperazine), 
2.39 (m, 4H, pyperazine H), 3.35 (m, 4H, pyperazine H), 5.65 (s, 2H, CH2 benzyl), 
6.78 (s, 1H, C8-H quinolinone), 7.12 (s, 1H, C6-H quinolinone), 7.20 (m, 2H, 
benzene H), 7.37 (m, 2H, benzene H), 7.69 (bs, 1H, CH enole), 8.07-8.05 (d, 1H, C5-
H quinolinone), 8.90 (s, 1H, C2-H quinolinone), 16.00-14.00 (bs, 2H, OH).  
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4-[1-(4-Fluorophenyl)methyl-7-(N-acethylpyperazin-1-yl)-4-(1H)-quinolinon-3-
yl]-2-hydroxy-4-oxo-2-butenoic Acid (14m): 90%; 195-197 °C; washed with 
acetonitrile; IR: cm-1 3392-2000 (OH enole and acid), 1716 (C=O acid), 1599 (C=O 
ketone). 1H NMR: (DMSO-d6) δ 2.05 (s, 3H, CH3 acethylpyperazine), 3.32 (m, 4H, 
pyperazine H), 3.55 (m, 4H, pyperazine H), 5.71 (s, 2H, CH2 benzyl), 6.81 (s, 1H, 
C8-H quinolinone), 7.22 (m, 3H, benzene H and C6-H quinolinone), 7.40 (m, 2H, 
benzene H), 7.97 (bs, 1H, CH enole), 8.10 (d, 1H, C5-H quinolinone), 9.01 (s, 1H, 
C2-H quinolinone), 16.00-14.00 (bs, 2H, OH). 
 
4-[1-(4-Fluorophenyl)methyl-7-(tiomorpholin-1-yl)-4-(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid (14n): 30%; 190 °C; washed with isopropanole; 
IR: cm-1 3500-2000 (OH acid), 1711 (C=O acid), 1606 (C=O ketone). 1H NMR: 
(DMSO-d6) δ 2.53 (m, 4H, tiomorpholine H), 3.79 (m, 4H, tiomorpholine H), 5.58 
(s, 2H, CH2 benzyl), 6.66 (s, 1H, C8-H quinolinone), 7.16-7.10 (m, 4H, CH enole, 
C6-H quinolinone and benzene H), 7.35-7.32 (m, 2H, benzene H), 7.23-7.21 (d, 1H, 
C5-H quinolinone), 8.78 (s, 1H, C2-H quinolinone), 16.00-14.00 (bs, 2H, OH). 
 
4-[1-(4-Fluorophenyl)methyl-7-(morpholin-1-yl)-4-(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid (14o): 99%; 187-189 °C; washed with 
isopropanole; IR: cm-1 3500-2000 (OH acid), 1726 (C=O acid), 1600 (C=O ketone). 
1H NMR: (DMSO-d6) δ 3.27 (m, 4H, morpholine H), 3.71  (m, 4H, morpholine H), 
5.70 (s, 2H, CH2 benzyl), 6.83 (s, 1H, C8-H quinolinone), 7.29-7.10 (m, 3H, C6-H 
quinolinone and benzene H), 7.32-7.48 (m, 2H, benzene H), 7.99 (bs, 1H, CH enole), 
8.11-8.09 (d, 1H, C5-H quinolinone), 9.02 (s, 1H, C2-H quinolinone), 16.00-14.00 
(bs, 2H, OH). 
 
4-[1-(4-Fluorophenyl)methyl-7-(N-(3-chloroprop-1-yl)-1-pyperazinlyl)-4-(1H)-
quinolinon-3-yl]-2-hydroxy-4-oxo-2-butenoic Acid (14p): 100%; 175-177 °C; 
washed with THF; IR: cm-1 3410-2000 (OH), 1717 (C=O ester), 1655 (ketone). 1H 
NMR: (DMF-d7) δ 2.18 (q, 2H, ClCH2CH2CH2N pyperazine), 2.73-2.79 (m, 6H, 
pyperazine H and ClCH2CH2CH2N pyperazine), 3.59 (m, 4H, pyperazine H), 3.91-
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3.92 (q, 2H, ClCH2CH2CH2N pyperazine), 6.03 (s, 2H, CH2 benzyl), 7.16 (s, 1H, C8-
H quinolinone), 7.38-7.45 (m, 3H, C6-H quinolinone and benzene H), 7.74-7.78 (m, 
2H, benzene H), 8.37-8.39 (m, 2H, CH enole and C5-H quinolinone), 9.27 (s, 1H, 
C2-H quinolinone), 16.00-14.00 (bs, 2H, OH). 
 
4-[1-(4-Fluorophenyl)methyl-7-(dimethylamino)-4-(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic Acid (14q): 98%; 203-205 °C; washed with 
isopropanole; 1H NMR: (DMF-d7) δ 3.22 (s, 6H, CH3 dimethylamine), 6.00 (s, 2H, 
CH2 benzyl), 6.82 (s, 1H, C8-H quinolinone), 7.15-7.12 (s, 1H, C6-H quinolinone), 
7.46-7.42 (m, 2H, benzene H), 7.76 (m, 2H, benzene H), 8.37-8.35 (d, 1H, C5-H 
quinolinone), 8.41 (s, 1H, CH enole), 9.27 (s, 1H, C2-H quinolinone), 16.00-14.00 
(bs, 2H, OH). 
 
4-(6-Chloro-4(1H)-quinolinon-3-yl)-2-hydroxy-4-oxo-2-butenoic Acid (16a). 
50%; 220 °C (dec); toluene/cyclohexane; IR ν 3400, 3200 (NH and OH), 1718 (C=O 
acid), 1640 and 1611 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 7.72-7.75 (m, 2H, 
quinolinone C7-H and C8-H), 8.13 (s, 1H, butenoate C3-H), 8.53 (m, 1H, 
quinolinone C5-H), 8.80 (s, 1H, quinolinone C2-H), 13.00 (bs, 3H, NH and OH).  
 
4,4’-[7-(Dimethylamino)-1-(4-fluorobenzyl)-4-oxo-(1H)-quinolinon-3,6-diyl] bis 
2-hydroxy-4-oxobut-2-enoic Acid (18a): 77%; >240 °C; washed with isopropanole; 
IR: cm-1 3300-2000 (OH acid), 1578 (C=O acid); 1H NMR: (DMSO-d6) δ 2.82 (s, 
3H, CH3 dimethylamine), 5.70 (s, 2H, CH2 benzyl), 6.71 (s, 1H, C8-H quinolinone), 
7.24-7.20 (t, 2H, benzene H), 7.42-7.41 (m, 2H, benzene H), 7.90 (bs, 1H, CH 
enole), 8.22 (s, 1H, C5-H quinolinone), 9.02 (s, 1H, C2-H quinolinone), 16.00-14.00 
(bs, 2H, OH). 
 
4,4’-[7-(N-methylpyperazin-1-yl)-1-(4-fluorobenzyl)-4-oxo-(1H)-quinolinon-3,6-
diyl] bis 2-hydroxy-4-oxobut-2-enoic Acid (18b): 32%; >240 °C; washed with 
isopropanole; IR: cm-1 3338-2000 (OH enole and acid), 1700 (C=O acid), 1595 
(C=O ketone). 
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Table 4. Chemical and physical data of derivatives 19a-h, 20a-q, 21, 22, 23, 24 and 
25a,b. 
 
 
a Recrystallization solvents: (a) aceton, (b) ethanol, (c) isopropanol, (d) toluene, (e) 
toluene/cyclohexane, (f) benzene/cyclohexane, (g) benzene, (h) methanol. 
 
 
 
 
 
 
 
 
Cpd R6 R7 R8 mp (°C) Recryst solventa Yield (%) 
19a H H H 242-244 a  56 
19b F H H >300  b  29 
19c H F H 270-271 c  41 
19d F H F 268-270 b  40 
19e Cl H H >300  b  29 
19f H Cl H >300  b  96 
19g H H Cl >300  b  55 
19h Cl Cl H 114-115 d  19 
20a H H H 213-214 d  65 
20b F H H 234-235 e  94 
20c H F H 186-187 e  100 
20d F H F 193-194 f  78 
20e Cl H H 214-216 e  92 
20f H Cl H 185-187 e  73 
20g H H Cl 215-217 g  92 
20h Cl Cl H 235-237 d  49 
20i H 1-Pyrrolydinyl H 175-177 e  56 
20j H 1-Pyperazinyl H 230-232 d 32 
20k H N-Methyl-1-Pyperazinyl H 223-224 d 14 
20l H N-Ethyl-1-Pyperazinyl H 220-223 d 21 
20m H N-Acethyl-1-Pyperazinyl H >240 d 52 
20n H 1-Thiomorpholinyl H 220-223 g 52 
20o H 1-Morpholinyl H 227 g 35 
20p H N-(3-chloroprop-1-yl)-1-pyperazinlyl H 230 d 54 
20q H N,N-dimethylamine H 225 e 100 
21 - - - oil oil 8 
22 - - - - - 98 
23 acethyl Cl H >240 h 50 
24 acethyl Cl H 128-130 g 17 
25a acethyl N,N-dimethylamine H 180 e 51 
25b acethyl N-Methyl-1-Pyperazinyl H >240 h 82 
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Biology 
Compounds 13a-q, 14a-q, 15a,b, 16a,b, 17a,b and 18a,b were tested for their ability 
to inhibit HIV-1 integrase in vitro using a gel-based assay in addition to a 96-well 
plate-based high throughput electrochemiluminescent assay.30 In the gel assay, a 5′-
end-labeled 21-mer double-stranded DNA oligonucleotide corresponding to the last 
21 bases of the U5 viral LTR is used to follow both 3′-P and ST. Briefly, a DNA-
enzyme complex is preformed by mixing the drug at the destre concentration with 
400 nM recombinant HIV-1 integrase in a buffer containing 50 mM MOPS, pH 7.2, 
7.5 mM MnCl2, and 14.3 mM β-mercaptoethanol. The integration reaction is then 
initiated by the addition of 20 nM 5′-labeled double-stranded DNA template and 
continued in a total volume of 10 µL for 60 min at 37 °C. The reaction samples are 
stopped by adding the same volume of electrophoresis denaturing dye and loaded on 
20% 19/1 acrylamide denaturing gel. Gels were exposed overnight and analyzed 
using a Molecular Dynamics hosphorimager (Sunnyvale, CA). The 96-well plate-
based high throughput electrochemiluminescent assay was performed using a 
BioVeris M series analyzer (Gaithersburg, MD) as described previously.30 Briefly, 
DNA substrates were obtained from BioVeris and used according to the 
manufacturer’s recommendations. Donor DNA is incubated for 30 min at 37 °C in 
the presence of 250 nM recombinant HIV-1 integrase. After addition of the drug, the 
integration reaction is initiated by addition of target DNA. Reaction is carried out for 
60 min at 37 °C and then read on the BioVeris M series analyzer.  
The anti-HIV drug testing was performed in 96-well plates with a defined, 
previously titered inoculum of a laboratory strain (HTLV-IIIB) to minimize the 
inoculum effect. In brief, all compounds were dissolved in dimethyl sulfoxide and 
diluted in cell culture medium at concentrations ranging from 0.1 to 50 µM. 
Exponentially growing human T lymphocytes (H9 cell line) were added at 5000 
cells/well. After the infectivity of a virus stock (HTLV-IIIB) is quantified, an aliquot 
containing 1 x 105 50% tissue culture infectious dose (TCID50) per 5000 H9 cells 
per well is used as inoculum in each set of in vitro infections of H9 cells. Uninfected 
cells with the compound served as a toxicity control, and infected and uninfected 
cells without the compound served as basic controls. Culture were incubated at 37 °C 
in a 5% CO2 atmosphere for 4 days. Supernatant fluid of infected wells (in the 
absence of drug and at each of a number of drug concentrations) is harvested. HIV 
p24 antigen is quantified, and the 50% inhibitory concentration (IC50) of drug is 
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determined using the median effect equation.  
Cytotoxicity of test compounds has been evaluated on human histiocytic lymphoma 
(U937) cell line obtained from American Type Culture Collection (ATCC, 
Rockville, MD). Cells were plated in a 96 well-plate at a concentration of 5 x 103/mL 
in RPMI-1640 without phenol red, supplemented with 20% fetal calf serum and 
antibiotics. Two hours after plating, compounds were added at different 
concentrations ranging from 1 to 200 µM and cells were incubated at 37 °C for 24 h. 
Then cells were incubated at 37 °C for 3 h with 1 mg/mL of MTT (Sigma-Aldrich, 
Milan, Italy). After incubation, the remaining water insoluble formazan was 
solubilized in absolute isopropanol containing 0.1 N HCl. Absorbance of converted 
dye was measured in an ELISA plate reader at a wavelength of 570 nm. The 
cytotoxicity of the compounds was calculated as the percentage reduction of the 
viable cells compared with the drug-free control culture. The drug concentration 
required to reduce the cell viability by 50% has been called IC50. 
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1.6 New scaffolds 
1.6.1 Introduction 
Studies led on the diketoacid compounds have highlighted their limited capacity to 
cross cell membrane and lower activities in cell-based assay on infected cell by HIV-
1. Infact, compounds sintesized by us 31, 32 have a marked inhibitory activity in 
enzymatic assay, but a more limited activity in cell-based assay on infected cell by 
HIV-1. The molecular portion that negatively influenced the EC50 value is the diketo 
acid mojety, which carry out two opposing functions: the first and most important 
one, of farmacofore; the second one of group that block the crossing of cell 
membrane. Contemporaneously, the scientific research is oriented to developp 
scaffolds that can include the diketo acid portion into an etherocyclic ring like 
dihydroxypyrimidinone, 10 naphthyridine ring, 27, 28, 29 pyrrolopyridine, 34 
dihydroisoindolone ring 35; furthermore, in these compounds the carboxylic acid 
function is replaced by a 4-fluorobenzylamide or a hydroxamic acid functions.  
On the bases of these knowledge, I have designed and synthesized newly inhibitors 
that do not present the spitting α,γ-diketoacid motif, but molecules in which this 
motif is disguised in the oxoquinolonyl ring, so that are kept to the fondamental 
distances between the different atoms or groups (O, N, etc) responsable of the 
chelation of Mg2+ ions and the inhibitor activity on IN of HIV-1.  
The designe of newly compounds were realized on structural knowledge of utilized 
in clinical practice inhibitor, Raltegravir, so I have made a superposition of 
farmacophoric group of RAL with that of the most active compound synthesyzed by 
us 11 (figure 9) to focused the attention on the essential structural features for the 
activity. 
 
Figure 9. Superposition of Raltegravir (blu) and 11 (red). 
 
From this preliminary analysis, is emerged that the following groups are essential for 
activities: a first carbonyl group, an enolic OH, and a second carbonyl group. 
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In RAL the first carbonyl group is represented by the amidic carbonyl bloked in the 
pyrimidinonic ring, so the first modification on the structure 11 is the replaced of 
carboxylic function of the diketoacid mojety with a amide function (26 and 27).  
Another derivatives are designed by the schift of two positions of the 1,3-
diketobutyric acid chain in the oxoquinolonil ring, obtaining derivatives 28a-d and 
29a-e, in which the phenolic OH or anilinic NH2 and the quinolonic carbonyl are 
superpositioned with the enolic OH and carbonyl of 4-fluorobenzylamide of RAL 
respectively. The third chelating group are represented by the carbonyl of 4-
fluorobenzylamide (29a-e) or of carboxylic acid (28a-d). 
A third series of derivatives are obtained by a insertion of a second phenolic OH in 
position 6 of benzene ring leading to a designe of 5,6-dihidroxyquinolonil derivative 
30 and 5,6-dihydroxybenzopyranone derivative 31. The two OH in position 5 and 6 
are superpositioned with the pyrimidinonic amidic carbonyl and enolic OH of RAL. 
Finally I have designed derivatives 32 and 33 that are structural analogues of RAL in 
which the dihydropyrimidinone ring are substituted with a 4-oxoquinolonil (32) or 
with a 2-oxoquinolonil (33) ring. 
 
Table 1. compound 26, 27, 28a-d and 29a-e. 
 
 
 
Cpd R1 R2 
26 CH3 CH3 
27 
 
28a H OH 
28b Et OH 
28c Et OEt 
28d 
 
OH 
29a H OH 
29b Et OH 
29c Et OEt 
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29d 
 
OH 
29e Et NH2 
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1.6.2 Results and discussion 
Synthesis of derivatives 26, 27, 28a-d, 29a-e, 30, 31, 32, and 33 is outlined in 
Schemes 1–8. 
Compounds 26 and 27 (Scheme 1) were synthesized utilizing the same procedure 
emploied for the quinolonyldiketo acids 31, 32 until the formation of alkilation 
product; infact the 3-acethylquinolone 34 were prepared by reaction of aniline with 
ethyl orthoformate and ethyl acetoacetate, which were thermally condensed in the 
presence of an inert heating medium (Dowtherm A) under argon atmosphere, 
according to the Yoshizawa procedure. 33 Then, 34 was alkylated with 4-
fluorobenzylbromide in alkaline medium (K2CO3) to give the N-1 substituted 
quinolone 35. For the insertion of amidic portion, quinolinone 35 were reacted with 
the appropriate oxamate. At the first time the reaction was led in according with the 
literature, 36 in presence of LDA (lithium diisopropylamide) in THF at –72 °C, but 
the low temperature had decreased the solubility of quinolinone 35 and was 
impossible to isolate the final product. Therefore, the reaction was performed at 
room temperature in presence of another kind of alkaline medium (potassium tert 
butoxide) obtaining the desire products 26 and 27.  
 
Scheme 1. a 
 
a Reagents, conditions and yields: (i) ethyl orthoformate, ethyl acetoacetate, Dowtherm A, 95-254 °C, 
8 h, 56% (ii) 4-fluorobenzyl bromide, K2CO3, DMF, 100 °C, 1 h, 65% (iii) oxamate, THFa, putassium 
tert-butoxide, room temp, 20 min, 80%. 
 
Compound 28a-c and 29a-c (Scheme 2) was synthesized in according with literature 
procedure. 37 The commercially available 3-aminocyclohexanone was reacted with 
diethyl ethoxymethylenemalonate at 130 °C obatining an intermediate that was 
thermally condensed in presence of an inert heating medium (diphenyl eter) under 
argon atmosphere yielding product 36. The next oxidation reaction, in presence of 
molecular iodine in ethanol at reflux temperature, leading to the key intermediate 37 
that was alkylated in alkaline medium (K2CO3) to the corresponding N-
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ethylquinolinone 38, that in turn was alkylated to the N-ethyl-5-ethoxyquinolinone 
39. Compounds 37, 38 and 39 were hydrolyzed in alkaline medium (sodium 
hydroxide) to the corresponding acid 28a-c, that was then converted to the 
corresponding amide 29a-c under microwave irradiation (100 °C, 150 Watt, 10 min) 
in presence of PS-carbodiimide, HOBT (hydroxybenzotriazole), N-methylpirrolidone 
and 4-fluorobenzylamine. 38 
 
Scheme 2. a 
 
a Reagents, conditions and yields: (i): EMME, 130 °C, 3 h; 74%; (ii): diphenyl eter, reflux,1 h, 58%; 
(iii): iodine, EtOH, reflux, 17 h, 76%; (iv): K2CO3, CH3CH2I, DMF, 80 °C, 12 h, 43%; (v): K2CO3, 
CH3CH2I, DMF, 80 °C, 12 h, 83%; (vi): NaOH 10%, 100°C, 1h; (vii): HOBT, PS- carbodimmide, p-
fluorobenzylamine, NMP, MW (100°C, 150 W, 200 PSI, 10 min). 
 
Compound 28d and 29d was synthesized in according with the Scheme 3. The 
commercially available 3-nitro-4-bromoanisole was reducted to the corresponding 1-
bromo-4-methoxyaniline 40 for a redox reaction in presence of SnCl2, H2O, HClconc 
and ethanol 96° at room temperature. The amine was reacted with diethyl 
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ethoxymethylenemalonate at 130 °C obatining an intermediate that was condensed in 
presence of an acidic medium (Eaton’s reagent; 39 CH4O3SO5P2, 7,7% w/w P2O5 in 
metansulfonic acid) under argon atmosphere yielding product 41. To obtaining the 
compound 42 was performed a Sonogashira coupling in presence of CuI, 
Cl2Pd(PPh3)2, NEt3 and 3-butin-1-ole at reflux temperature for 3 days. 39 The 
compound 28d was obtained converted 42 to the demethylated compound 43 for 
deprotection by BBr3 at –45 °C, that was successively hydrolyzed to the desire acid. 
Amide 29d was yielded with the same procedure of amides 29a-c. 
 
Scheme 3. a 
 
a Reagents, conditions and yields: (i): SnCl2, H2O, HClconc, ethanol 96°, room temp, 1 night, 98%; (ii): 
EMME, 130 °C, 3 h; 74%; (iii): Eaton’s reagent, 90 °C, 5 h, 60%; (iv): CuI, Cl2Pd(PPh3)2, NEt3, 3-
butin-1-ole, reflux, 3 days, 40%; (v): BBr3 at –45 °C, 12 h, 30%; (vi): NaOH 10%, 100°C, 1h, 98%; 
(vii): HOBT, PS- carbodimmide, p-fluorobenzylamine, NMP, MW (100°C, 150 W, 200 PSI, 10 min), 
35%. 
 
Compound 29d (Scheme 4) was synthesized in according with literature procedure. 
37 Compound 36 was obtained with the same procedure of Scheme 1. The insertion of 
5-amine group was performed in three steps: an addiction reaction to the carbonyl 
group in presence of hydroxilamine hydrochloride at reflux temperature (44), 
followed by a reaction of pretection (ethylchloroformate, pyridine, room temp) to 
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fournish a condensed isoxazole ring 45, which was oxidized with KI, I2, ethanole 
absolute at reflux temperature to yield derivative 46. The nitrogen atom of 46 was 
alkylated in alkaline medium (K2CO3) to 47, that was subjected to a reductive 
dehalogenation catalized by Pd/C 10% in presence of H2 (3 Atm) and triethylamine 
at 40 °C obtaining the ethyl ester 48 that was directly converted to the corresponding 
amide 29e under microwave irradiation (120 °C, 100 Watt, 15 min) in presence of 4-
fluorobenzylamine. 40 
 
Scheme 4. a 
a Reagents, conditions and yields: (i): hydroxilamine hydrochloride, reflux, 3 h, 78%; (ii): 
ethylchloroformate, pyridine, room temp, 30 min, 76%; (iii): KI, I2, EtOH, reflux, 1 h, 43%; (iv): 
K2CO3, CH3CH2I, DMF, 80 °C, 12 h, 43%; (v): Pd/C, H2 3 Atm, NEt3, 40 °C, 7 h, 30%; (vi): p-
fluorobenzylamine, MW (120°C, 100 W, 200 PSI, 15 min). 
 
Compound 30 was synthesized in according with the Scheme 5. Compound 49, 
synthesized according with the literature, 41 was converted to the quinolinone 50 with 
the same procedure of Scheme 3. Quinolinone 50 was alkylated in alkaline medium 
(K2CO3) to fournish N-methylquinolinone 51, that was subjected to a reductive 
dehalogenation catalized by Pd/C 10% in presence of H2 (3 Atm) and triethylamine 
at 40 °C obtaining the ethyl ester 52 that was directly converted to the corresponding 
amide 53 under microwave irradiation (120 °C, 100 Watt, 15 min) in presence of 4-
fluorobenzylamine. 40 Compound 30 was obtained for deprotection with BBr3 at –45 
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°C. 
 
Scheme 5. a 
 
a Reagents, conditions and yields: (i): EMME, 130 °C, 3 h; 74%; (ii): Eaton’s reagent, 90 °C, 5 h, 
55%; (iii): K2CO3, CH3CH2I, DMF, 80 °C, 12 h, 45%; (iv): Pd/C, H2 3 Atm, NEt3, 40 °C, 7 h, 87%; 
(vii): p-fluorobenzylamine, MW (120°C, 150 W, 200 PSI, 15 min), 35%; (iv): BBr3 at –45 °C, 12 h, 
30%. 
 
Compound 31 was synthesized in according with the Scheme 6. The commercially 
available 2-hydroxy-6-methoxyacetophenone was oxydized to the corresponding 
quinone 54 in presence of hydrogen peroxyde. The new formed hydroxyl group was 
alkylated in alkaline medium (K2CO3) to fournish O-methyl derivative 55 that was 
cyclized in presence of CS2 (carbonium disulfide) in alkaline medium (t-BuOK) to 
yield the 4-hydroxybenzo-2-tiopyranone 56. The insertion of the 4-
fluorobenzylamine group was obtained firstly converting the 2-tiopyranone in the 
corresponding 2-methyltiopyranone 57, and than oxydizing it to the better leaving 
group methylsulfoxyde in presence of metachloroperbenzoic acid, obtaining 
compound 58, which was reacted with 4-fluorobenzyl amine yielding compound 59. 
The desire compound 31 was obtained for deprotection of methoxide group in 5 and 
6 positions of benzopyranone ring of 59 in presence of BBr3 under inert atmosphere. 
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Scheme 6. a 
 
a Reagents, conditions and yields: (i): H2O2 35%, PTSA, acetic acid, 50 °C, 24 h, 27%; (ii): dimethyl 
sulfate, K2CO3, acetone, room temp, 2 h, 48%; (iii): CS2, putassium tert-butoxyde, THFa, 45 °C, 3 h, 
45%; (iv): CH3I, K2CO3, acetone, reflux, 30 min, 100%; (v): metachloroperbenzoic acid, 
dichloromethane, room temp, 63%; (vi): 4-fluorobenzyl amine, aceto nitrile, room temp, 1,5 h, 28%; 
(vii): BBr3 at –45 °C, 12 h, 16%. 
 
Compound 32 was obtained in two steps from isatine and chloroacethylbenzyl amide  
(Scheme 7) in according with the leterature. 42 Compound 60 was than converted to 
compound 32 with a trasposition reaction involving the isatine ring in alkaline 
medium (CH3ONa). 
 
Scheme 7. a 
 
a Reagents, conditions and yields: (i): K2CO3, DMFa, 1,5 h, 87%; (ii): CH3ONa, CH3OHa, 2 h, 120 °C; 
10%. 
 
Compound 33 was obtained in three steps (Scheme 8) in according with the 
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literature. 43 First, o-nitro-benzaldehyde and diethylmalonate react in a classical 
Knoevenagel reaction. Then compound 62 is obtained via a one pot reduction and 
cyclization. Finally, aminolysis of the remaining ester function, with the 4-
fluorobenzyl amine, yielding compound 33. 
 
Scheme 8. a 
 
a Reagents, conditions and yields: (i): Diethylmalonate, NaHCO3, acetic anidrhyde, 100 °C, 6 h, 45%; 
(ii): PtO2, H2 (1 Atm), acetic acid, room temp, 22 h, 27%; (iii): 4-fluorobenzyl amine, 100 °C, 4 h, 
83%. 
 
Derivatives 26, 27, 28a-d, 29a-e, 30, 31, 32 and 33 were tested in vitro for ST 
inhibition in the presence of magnesium (Mg2+) using a recently described high 
throughput electrochemiluminescent (HTECL) assay. 30 IC50 values were generated 
from duplicate experiments (Table 5). Compounds 26, 27, 28a-d, 29a-e, 30, 31, 32 
and 33 were also tested for ST and 3′-P using gel-based assays carried out in the 
presence of Mg2+. IC50 values were calculated using dose response curves and are 
summarized in Table 5. 
 
Table 5. Activities data for compounds 26, 27, 28a-d, 29a-e, 30, 31, 32 and 33. 
 
 
 ANTI-IN activity IC50
a ANTIVIRAL activity 
Cpd Mg2+ b Mg2+ c Mg2+ c CC50d EC50e SIf 
26 0.92 ntg 34.2 ntg 3.9  
27 ntg ntg ntg ntg ntg  
28a 55 ntg >333 ntg >50  
28b >333 ntg >333 ntg >50  
28c >333 ntg >333 ntg >50  
28d ntg ntg ntg ntg ntg  
29a >333 ntg >333 ntg >50  
29b >333 ntg >333 ntg >50  
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29c >333 ntg >333 ntg >50  
29d >333 ntg >333 ntg >50  
29e >333 ntg >333 ntg >50  
30 >333 ntg >333 ntg >50  
31 106 ntg >111 ntg >50  
32 ntg ntg ntg ntg ntg  
33 ntg ntg ntg ntg ntg  
a Inhibitory concentration 50% (µM) determined from dose response curves. b Experiments performed 
in duplicate using the high throughput electrochemiluminescent (HTECL) assay (ST assay in the 
presence of Mg2+). c Experiments performed in a gel-based assay in the presence of Mg2+. d Cytotoxic 
concentration 50% (µM). e Effective concentration 50% (µM). f Selectivity index (CC50/EC50). g nt: not 
tested. 
 
Activities data relatively the newly synthesized compounds 26, 27, 28a-d, 29a-e, 30, 
31, 32 and 33 are uncompleted, thus it can not possible to formulate valid structure-
activity relationships. 
Compouds that exhibite better activities data are 26, 28a and 31.  
Compound 26 is closely related to the quinolonildiketoacids, 31 of which the 
inhibitory activity in enzymatic assay and cell-based assay are well known. 
However, is interesting that the amide function conveies activity as well as 
carboxylic acid function. This trend reflected those of the dihydroxypyrimidine like 
RAL. 
In the series of 28a-d and 29a-e the enzymatic activity is dependent on the presence 
of carboxylic acid function, fenolic OH and unsubstituted quinolonic NH. Infact the 
only compound that shows an interesting activity data on enzymatic assay is 28a, 
while other compounds that are substituted on fenolic OH and/or quinolonic NH 
(28b-d) and presented the 4-fluorobenzylamide function (29a-e) instead of 
carboxylic acid function are completely inactive. 
Compound 31 is not structurally related to other compound and its activity in 
enzymatic assay is an interesting starting point for the development of new INSTIs. 
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1.6.3 Conclusions 
I designed, synthesized, and tested a series of novel derivatives in both enzyme- and 
cellbased assays as anti-HIV-1 agents to selectively target the ST step of integration. 
We were able to generate such new compounds, some of which (26, 28a and 31) are 
ST-selective IN inhibitors and active (26) against HIV-1 replication in acutely 
infected cells. These compounds could be useful tools to develop new INSTIs and to 
study the mechanism of action of HIV-1 IN. 
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1.6.4 Experimental section 
 
Chemistry 
General. Melting points were determined with a Büchi 530 capillary apparatus and 
are uncorrected. Infrared (IR) spectra were recorded on a Perkin-Elmer Spectrum-
one spectrophotometer. 1H NMR spectra were recorded on a bruker AC 400 
specrtometer. Merk silica gel 60 F254 plates were used for analytical TLC. Column 
chromatogrephies were performed on silica gel (Merck; 70-230 mesh) or alumina 
(Merck; 70-230 mesh). Concentration of solution after reactions and extractions 
involved the use of a rotary evaporator operating at reduced pressure of 
approximately 20 Torr. Analytical results agreed to within ±0.40% of the theoretical 
values. 
Microwave irradiation experiments. Microwave reactions were conduced using a 
CEM Discover system unit (CEM. Corp., Matthews, NC). The machine consists of a 
continuous focused microwave-power delivery system with operator selectable 
power output from 0 to 300 W. The temperature of the contents of the vessel was 
monitored using a calibrated infrared temperature control mounted under the reaction 
vessel. All experiments were performed using a stirring option whereby the contents 
of the vessel are stirred by means of a rotating magnetic plate located below the floor 
of the microwave cavity and a Teflon-coated magnetic stir bar in the vessel. 
3-Acetyl-4(1H)-quinolinone 34. Ethyl orthoformate (4.0 g, 27 mmol), ethyl 
acetoacetate (3.5 g, 27 mmol), aniline (27 mmol), and Dowtherm A (5.6 mL) were 
charged in a three-necked flask equipped with a water separator. This mixture was 
stirred under argon atmosphere, while the temperature was increased to 95 °C in 1 h, 
then gradually up to 162 °C in a further hour. Then the mixture was stirred at this 
temperature for 6 h. After this time, the resulting solution was added in portions 
during 3 h into 42 mL of Dowtherm A stirred in a three-necked flask equipped with 
thermometer and water separator and heated at 253-254 °C. After addition the 
mixture was heated at the same temperature for 2 h. Then the mixture was cooled at 
90 °C, treated with isopropanol (10 mL), cooled at 30 °C, filtered, and washed with 
isopropanol and light petroleum ether in turn to give pure derivative 34. Chemical 
and physical data of derivative 34 are reported in Table 6.  
 
1-(4-Fluorophenyl)methyl-4(1H)-quinolinone 35. A mixture of 34 (1.1 mmol), 4-
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fluorophenylmethyl bromide (610 mg, 3.3 mmol), and anhydrous K2CO3 (210 mg, 
1.5 mmol) in dry DMF (10 mL) was stirred at 100 °C for 1 h. After the mixture was 
cooled, water was added (40 mL) and the precipitate that formed was filtered, 
washed with water and light petroleum ether in turn, and then dried under IR lamp to 
provide pure derivatives 35. Chemical and physical data of derivatives 35 are 
reported in Table 6. 
 
General procedure for synthesis of 4-[1-((4-flurophenyl)methyl)-4-oxo-4(1H)-
quinolon-3-yl]-2-hydroxy-4-oxobut-2-enamide 26, 27. Potassium tertbuthoxide 
(380 mg, 3.4 mmol) was added into a well stirred mixture of 35 (1.7 mmol) and the 
appropriate oxamate (3.4 mmol) in anhydrous THF (2.7 mL) under nitrogen 
atmosphere. The mixture was stirred at room temperature for 2 h, then was poured 
into n-hexane (50 mL). The collected precipitate was vigorously stirred for 30 min in 
1 N HCl (50 mL). The yellow solid that formed was filtered, washed with water, and 
dried under IR lamp to afford the pures 26 and 27. Yield (%), melting point (°C), 
recrystallization solvent, IR, 1H NMR are reported for each of the following 
compounds. 
 
4-[1-((4-Flurophenyl)methyl)-4-oxo-4(1H)-quinolon-3-yl]-2-hydroxy-N,N-
dimethyl-4-oxobut-2-enamide (26). 80%; 190-195 °C; ethanol; IR ν 1630 (C=O 
amide), 1611 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 2.92-2.94 (m, 3H, CH3 
amide), 4.39 (s, CH2 ketone), 5.76-5.78 (s, 2H, CH2 benzyl), 7.17-7.22 (m, 2H, 
benzene H), 7.35-7.38 (m, 2H, benzene H), 7.46 (bs, CH enole), 13.00 (bs, 3H, NH 
and OH). 
 
4-[1-((4-Flurophenyl)methyl)-4-oxo-4(1H)-quinolon-3-yl]-2-hydroxy-pyperidin-
4-oxobut-2-enamide (27). 81%; 153 °C; benzene/cyclohexane; IR ν 1630 (C=O 
amide), 1601 (C=O ketone) cm-1. 1H NMR (Acetone-d6) δ 1.43-1.74 (m, 6H, 
pyperidine H), 3.50-3.60 (m, 4H, pyperidine H), 5.83 (d, 2H, CH2 benzyl), 7.15-7.19 
(m, 2H, benzene H), 7.43-7.51 (m, 3H, benzene H and quinolinone C8-H), 7.64 (bs, 
1H, CH enole), 7.69-7.76 (m, 2H, quinolinone C6-H and C7-H), 8.41-8.43 (d, 1H, 
quinolinone C5-H), 9.02 (s, 1H, quinolinone C2-H), 13.00 (bs, 1H, OH). 
 
Ethyl 4,5-dioxo-1,4,5,6,7,8-exahydroquinolin-3-carboxylate (36). A suspention of 
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commercially available 3-aminocyclohexanone (5 g, 45 mmol) in ethyl 
ethoxymethylenemalonate (10.7 g, 45 mmol) was heated for 3 h at 130 °C. The 
reaction mixture was concentrated at reduced pressure obtained 15 g of crude 
product as a brown oil that was utilized for the following reaction without further 
purification. The crude product was dissolved in diphenyl ether (93 mL) and refluxed 
for 1 h. The reaction mixture was poured into n-hexane (60 mL) and the precipitate 
collected by filtration, washed with n-hexane obtaining 2.4 g of pure 36 as a brown 
solid. Chemical and physical data of derivatives 36 are reported in Table 7. 
 
Ethyl 5-hydroxy-4-oxo-4(1H)-dihydroquinolin-3-carboxylate (37). 36 (9.3 mmol) 
was dissolved into 97 mL of ethanol, I2 (25.8 mmol) was added and the mixture 
refluxed for 17 h. After cooling the reaction mixture was concentrated at reduced 
pressure and the residue washed with ethyl acetate, H2O, acetone and petroleum 
ether obtaining 1.03 g of crude product 37 as a brown solid. Chemical and physical 
data of derivatives 37 are reported in Table 7. 
 
Greneral procedure for alkylation (38, 39, 47 and 51). A mixture of appropriate 
substrate 37, 38, 46 37 or 50 (1.1 mmol), alkyl iodide (3.3 mmol), and anhydrous 
K2CO3 (1.5 mmol) in dry DMF (10 mL) was stirred at 100 °C. After the mixture was 
cooled, water was added (40 mL) and the precipitate that formed was filtered, 
washed with water and light petroleum ether in turn, and then dried under IR lamp to 
provide pure derivatives 38, 39, 47 and 51. Chemical and physical data of derivatives 
38, 39, 47 and 51 are reported in Table 7 and 8. 
  
General procedure for hydrolysis (28a-d). A mixture of the appropriate ethyl ester 
37, 38, 39 or 43 (1.4 mmol) in 42 mL of NaOH acquous solution 10% was heated for 
1h at 100 °C. After colling the mixture was treated with 1 N HCl until pH 1-2 was 
reached, the acquous extract with CHCl3, the organic layer washed with brine, dried 
over Na2SO3 and evaporated at reduced pressure yielding pure 28a-d. Yield (%), 
melting point (°C), recrystallization solvent, IR, 1H NMR are reported for each of the 
following compounds. 
 
5-Hydroxy-4-oxo-4(1H)-dihydroquinolin-3-carboxylic acid (28a). IR ν 2833 (OH 
and NH), 1702 (C=O acid), 1640 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 6.84-
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6.86 (d, 1H, quinolinone C8-H), 7.20-7.22 (d, 1H, quinolinone C6-H), 7.69-7.73 (t, 
1H, quinolinone C7-H), 8.85 (s, 1H, quinolinone C2-H), 12.60 (s, 1H, OH), 13.60 
(bs, 1H, NH). 
 
5-Hydroxy-1-ethyl-4-oxo-4(1H)-dihydroquinolin-3-carboxylic Acid (28b). 42%; 
245 °C; ethanol; IR ν 3345 (OH), 1705 (C=O acid), 1635 (C=O ketone) cm-1. 1H 
NMR (CDCl3) δ 1.52 (t, 3H, CH2CH3), 4.38 (m, 4H, CH2CH3), 6.79 (m, 2H, 
quinolinone C6-H and quinolinone C8-H), 7.51 (t, 1H, quinolinone C7-H), 8.46 (m, 
1H, quinolinone C2-H), 14.66 (bs, 1H, COOH). 
 
5-Ethoxy-1-ethyl-4-oxo-4(1H)-dihydroquinolin-3-carboxylic Acid (28c). 55%; 
213 °C; Ethanol; IR ν 2969 (OH), 1712 (C=O acid), 1620 (C=O ketone) cm-1. 1H 
NMR (CDCl3) δ 1.60 (m, 6H, CH2CH3), 4.30 (m, 4H, CH2CH3), 6.97 (m, 1H, 
quinolinone C6-H), 7.14 (m, 1H, quinolinone C8-H), 7.71 (m, 1H, quinolinone C7-
H), 8.72 (m, 1H, quinolinone C2-H), 15.62 (bs, 1H, COOH). 
 
General procedure for amide formation (29a-d). A suspention of appropriate acid 
28a-d (0.57 mmol), NMP (2 mL), HOBT (0.57 mmol), PS-carbodiimide (1.36 g) and 
4-fluorobenzylamine was reacted under microwave irradiation (100 °C, 150 Watt) 
for 10 min. The mixture was filtered on Si-carbonate, washed with methanol 
alternated with CHCl3, obtaining a crude producte that was purified by silica gel 
column chromatography using ethyl acetate/ethanol 3:1 as eluent obtaining pure 29a-
d. Yield (%), melting point (°C), recrystallization solvent, IR, 1H NMR are reported 
for each of the following compounds. 
 
5-Hydroxy-N-((4-fluorophenyl)methyl)-4-oxo-4(1H)-dihydroquinolin-3-
carboxamide (29a). IR ν 3366-2161 (OH and NH), 1629 (C=O amide) cm-1. 1H 
NMR (DMSO-d6) δ 4.53-4.55 (d, 2H, CH2 benzylamide), 6.72-6.74 (d, 1H, 
quinolinone C6-H), 7.09-7.11 (d, 1H, quinolinone C8-H), 7.14, 7.19 (m, 2H, benzene 
H), 7.37-7.41 (m, 2H, benzene H), 7.59-7.63 (t, 2H, quinolinone C7-H), 8.76 (s, 1H, 
quinolinone C2-H), 9.70 (m, 1H, NH), 13.74 (s, 1H, OH). 
 
5-Hydroxy-1-ethyl-N-((4-fluorophenyl)methyl)-4-oxo-4(1H)-dihydroquinolin-3-
carboxamide (29b). 28%; 210 °C; benzene/cyclohexane; IR ν 3263 (NH), 3038 
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(OH), 1654 (C=O ketone), 1601 (C=O amide) cm-1. 1H NMR (CDCl3) δ 1.57 (t, 3H, 
CH2CH3), 4.30 (q, 2H, CH2CH3), 4.66 (s, 2H, CH2-benzyl), 6.87 (m, 1H, quinolinone 
C6-H), 6.92 (m, 1H, quinolinone C8-H), 7.04 (m, 2H, benzene H), 7.37 (m, 2H, 
benzene H), 7.61 (m, 1H, quinolinone C7-H), 8.81 (m, 1H, quinolinone C2-H), 9.89 
(bs, 1H, NH). 
 
5-Ethoxy-1-ethyl-N-((4-fluorophenyl)methyl)-4-oxo-4(1H)-dihydroquinolin-3-
carboxamide (29c). 32%; 165 °C; benzene/cyclohexane; IR ν 2925 (NH), 1649 
(C=O ketone), 1601 (C=O amide) cm-1. 1H NMR (CDCl3) δ 1.51-1.67 (m, 6H, 
CH2CH3), 4.23-4.29 (m, 4H, CH2CH3), 4.64 (s, 2H, CH2-benzyl), 6.88 (m, 1H, 
quinolinone C6-H), 6.99 (m, 2H, benzene H), 7.06 (m, 1H, quinolinone C8-H), 7.54 
(m, 2H, benzene H), 7.59 (m, 1H, quinolinone C7-H), 8.73 (m, 1H, quinolinone C2-
H), 12.2 (bs, 1H, NH). 
 
N-((4-fluorophenyl)methyl)-7-hydroxy-2-(2-hydroxyethyl)-6-oxo-6H-
pyrrol[3,2,1-ij]quinolin-5-carboxamide (29d). 30%; 200-205 °C; methanol; IR ν 
3389 (OH), 3247 (NH), 1675 (C=O ketone), 1634 (C=O amide) cm-1. 1H NMR 
(DMSO-d6) δ 3.17-3.20 (t, 2H, CH2CH2OH), 3.77 (t, 2H, CH2CH2OH), 4.60 (s, 2H, 
CH2-benzyl), 4.50 (bs, 1H, OH), 6.93 (s, 1H, Pyrrole-β-protone), 7.00 (m, 1H, 
quinolinone C6-H), 7.16-7.20 (m, 2H, benzene H), 7.41-7.45 (m, 3H, quinolinone 
C8-H and benzene H), 7.96-7.98 (m, 1H, quinolinone C7-H), 9.35 (m, 1H, 
quinolinone C2-H), 9.80 (bs, 1H, NH), 11.5 (s, 1H, OH). 
 
2-Bromo-5-methoxyaniline (40). To a solution of SnCl2 . 2H2O, (3.0 mmol) in 
72.26 mL of HClconc was added 62 mL of ethanol 96° and 3-nitro-4-bromoanisole 
(8.6 mmol) slowly. The reaction mixture was stirred at room temperature for 1 night, 
diluted with a little of water, treated with NaOH 6 N until pH 8 was reached. The 
mixture was filtered on boukner, the solid washed with THF and the filtrate 
concentrated at reduced pressure. The residue was extract with ethyl acetate, the 
organic layer washed with brine, dried over Na2SO3 and concentrated under reduced 
pressure to obtain 5 g of crude product 40 that was utilized for the following reaction 
without further purification (98% yield). Chemical and physical data of derivatives 
40 are reported in Table 7. 
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General procedure for cyclization with Eaton’s Reagent (41, 50). A suspention of 
the appropriate amine 40 or 49 41 (45 mmol) in ethyl ethoxymethylenemalonate (10.7 
g, 45 mmol) was heated for 3 h at 130 °C. The reaction mixture was concentrated at 
reduced pressure obtained crude product that was utilized for the following reaction 
without further purification. The crude product (8.06 mmol) was dissolved in 40 mL 
of Eaton reagent’s (CH4O3SO5P2, 7.7% w/w P2O5 in methanesulfonic acid, 4 eq) at 
room temperature under inert atmosphere. After dissolution the mixture was stirred 
at 90 °C for 5 h under inert atmosphere. After cooling, was added crushed ice and the 
mixture was treated with NaOH 6 N until pH 7-8 was reached. The residue was 
extract with ethyl acetate, the organic layer washed with brine, dried over Na2SO3 
and concentrated under reduced pressure to obtain crude product 41 and 50 that was 
purified by silica gel column chromatography using ethyl acetate/ethanol 10:1 as 
eluent obtaining pure 41 and 50. Chemical and physical data of derivatives 41 and 50 
are reported in Table 7 and 8. 
 
Ethyl 2-(2-hydroxyethyl)-7-methoxy-6-oxo-6H-pyrrol[3,2,1-i,j]quinolin-5-
carboxylate (42). Starting material 41 (3.07 mmol) was dissolved into 13.7 mL of 
absolute ethanol. CuI (0.307 mmol), Cl2Pd(PPh3)2 (0.0307 mmol), NEt3 (6.14 mmol) 
and 3-buthyn-2-ole (4.6 mmol) were added. The reaction mixture was stirred at 
reflux temperature for 3 days making every day repeated addiction in 8h of the 
reactants. After cooling to room temperature, the reaction mixture was poured into 
H2O, treated with HCl 1 N until pH 1-2 was reached. The residue was extract with 
ethyl acetate, the organic layer washed with brine, dried over Na2SO3 anhydrous and 
concentrated under reduced pressure to obtain crude product 42 that was purified by 
silica gel column chromatography using ethyl acetate/ethanol 10:1 as eluent 
obtaining 450 mg of pure 42 (40% yield). Chemical and physical data of derivative 
42 are reported in Table 7 and 8. 
 
2,5-dihydroxy-6-methoxyacetophenone (54). To a solution of 2-hydroxy-6-
methoxyacetophenone (3 mmol) in 7 mL of acetic acid was aded H2O2 (6 mmol) and 
PTSA (0.3 mmol). The solution was stirred for 24 h at 50 °C. After cooling, acetic 
acid was removed by evaporation at reduced pressure and the resulting was extract 
with ethyl acetate. The organic layer was washed with brine and dried over Na2SO3 
anhydrous and concentrated under reduced pressure to obtain crude product 54 as 
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yellow oil, that was purified by silica gel column chromatography using ethyl 
acetate/chloroform 1:3 as eluent obtaining 150 mg of pure 54 (27% yield). Chemical 
and physical data of derivative 54 are reported in Table 9. 
 
2-Hydroxy-5,6-dimethoxyacetophenone (55). A mix of 54 (5 mmol), K2CO3 (5.3 
mmol), in 3 mL of acetone anhydrus was stirred for 10 min at room temperature. 
Dimethyl sulfate (5 mmol) was added and the reaction mixture was stirred at room 
temperature for 2 h. Acetone was removed by evaporation at reduced pressure and 
the resulting was extract with ethyl acetate. The organic layer was washed with brine 
and dried over Na2SO3 anhydrous and concentrated under reduced pressure to obtain 
crude product 54 as dark oil, that was purified by silica gel column chromatography 
using ethyl acetate/chloroform 1:10 as eluent obtaining 550 mg of pure 55 (48% 
yield). Chemical and physical data of derivative 55 are reported in Table 9. 
 
5,6-Dimethoxy-4-hydroxybenzo-2-tiopyranone (56). A solution of 55 (18.5 
mmol), CS2 (18.5 mmol) in 13 mL of THFa was added to a suspention of t-BuOK 
(55 mmol) under inert atmosphere. The reaction was stirred at 45 °C for a night. 
After cooling, THF was removed by evaporation at reduced pressure and the 
resulting was extract with chloroform. The organic layer was washed with brine and 
dried over Na2SO3 anhydrous and concentrated under reduced pressure to obtain 
crude product 56 as dark red solid (45% yield), that was utilized for the next reaction 
without further purification. Chemical and physical data of derivative 56 are reported 
in Table 9. 
 
5,6-Dimethoxy-2-methyltiobenzopyran-4-one (57). To a solution of 56 (4.5 mmol) 
in 15 mL of acetone anhydrus was added K2CO3 (5 mmol) and CH3I (20 mmol). The 
reaction mixture was stirred at reflux temperature for 30 min. After cooling H2O was 
added, acetone evaporated at reduced pressure and the resulting material was extract 
with ethyl acetate, the organic layer was washed with brine and dried over Na2SO3 
anhydrous and concentrated under reduced pressure to obtain crude product 57 as 
dark red solid (100% yield), that was utilized for the next reaction without further 
purification. Chemical and physical data of derivative 57 are reported in Table 9. 
 
5,6-Dimethoxy-2-(methylsulfo)benzopyran-4-one (58). To a solution of 57 (1.19 
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mmol) in 10 mL of dichloromethane at 0 °C was added m-chloroperbenzoic acid 
(1.48 mmol). The ice bath was remuved and the reaction was stirred at room 
temperature for 1 h. The formed solid was remuved by filtration and the filtrate was 
washed with aq. NaCO3 5%, H2O, and NaHSO4ss. The organic layer was dried over 
Na2SO4 anhydrus and evaporated at reduced pressure obtaining 200 mg of crude 
product 58 (62% yield) that was utilized for the next reaction without further 
purification. Chemical and physical data of derivative 58 are reported in Table 9. 
 
5,6-Dimethoxy-2-(4-fluorobenzylamine)benzopyran-4-one (59). To a solution of 
58 (0.7 mmol) in 5 mL of acetonitrile was added 4-fluorobenzylamine (0.9 mmol). 
The reaction mixture was stirred at room temperature for 1.5 h. The solvent was 
evaporated at reduced pressure and the residue solved with ethyl acetate. The organic 
layer washed with HCl 1 N, brine and dried over Na2SO4 anhydrus and evaporated at 
reduced pressure obtaining crude product 59 as brown solid, that was purified by 
silica gel column chromatography using ethyl acetate as eluent obtaining 70 mg of 
pure 59 (28% yield). Chemical and physical data of derivative 59 are reported in 
Table 9. 
 
General procedure for dealkylation (30, 31, 43). To a solution of appropriate 
alkyloxy derivative 42, 53 or 59 (0.25 mmol) in 4.5 mL of CH2Cl2 at -45 °C was 
added dropwise a solution of BBr3 1M in the same solvent (1.2 mmol). The reaction 
mixture was stirred at the same temperature for 1 night. After room temperature was 
reached, the reaction mixture was poured into water and the fourmed precipitate 
collected by filtration, washed with water and diethyl ether obtaining crude product 
that was purified by silica gel column chromatography using ethyl acetate as eluent 
obtaining pure 30, 31 and 43. Chemical and physical data of derivative 43 are 
reported in Table 7. Yield (%), melting point (°C), recrystallization solvent, IR, 1H 
NMR are reported for the following compounds. 
 
N-((4-fluorophenyl)methyl)-5,6-dihydroxy-1-methyl-4-oxo-4(1H)-
dihydroquinolin-3-carboxamide (30). 30%; >270 °C; Methanol; IR ν 3408 (OH), 
3082 (NH), 1648 (C=O ketone), 1603 (C=O amide) cm-1. 1H NMR (DMSO-d6) δ 
3.96 (s, 3H, CH3), 4.54-4.55 (s, 2H, CH2-benzyl), 7.08-7.19 (m, 3H, benzene H and 
quinolinone C8-H), 7.33-7.39 (m, 3H, benzene H and quinolinone C7-H), 8.83 (s, 
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1H, quinolinone C2-H), 9.40 (bs, 1H, OH), 9.89 (bs, 1H, NH), 14.16 (bs, 1H, OH). 
 
5,6-Dihydroxy-2-(4-fluorobenzylamine)benzopyran-4-one (31). 15.6%; oil; 1H 
NMR (CDCl3) δ 4.42-4.43 (s, 2H, CH2 benzylamide), 5.31 (s, 1H, benzopyranone 
C3-H), 5.48 (bs, 1H, NH), 6.64-6.68 (d, 1H, benzopyranone C8-H), 7.07-7.10 (m, 
3H, benzopyranone C7-H and benzene H), 7.30-7.35 (m, 2H, benzene H), 13.34 and 
13.47 (bs, 1H, OH). 
 
General procedure for the reductive dehalogenation (48, 52). A solution of 
starting material 47 or 51 (1.6 mmol) in 120 mL of ethanol was stirred in presence of 
300 mg of 10% Pd/C under H2 atmosphere at 3 Atm and 40 °C for 7/1.5 h 
respectivelly. The mixture was then filtered and the Pd residue washed with ethyl 
acetate. The combined organic layer were concentrated at reduced pressure to yield 
crude product that was purified. 48: alluminium oxide column chromatography using 
ethyl acetate/ethanol 50:1 as eluent; 52: silica gel column chromatography using 
ethyl acetate as eluent. Chemical and physical of derivatives 48 and 52 are reported 
in Tables 7 and 8. 
 
General procedure for amide formation (29e, 53). Appropriate starting material 48 
or 52 (3.02 mmol) an the 4-fluorobenzylamine (30.2 mmol) was reacted under 
microwave irradiation (120 °C, 100 Watt) for 10 min. The reaction mixture was 
poured into diethyl ether, the formed solid collected by filtration, washed with ether 
yielding pure 29e and 53. Chemical and physical of derivative 53 are reported in 
Table 8. Yield (%), melting point (°C), recrystallization solvent, IR, 1H NMR are 
reported for the following compound. 
 
5-Amino-1-ethyl-N-((4-fluorophenyl)methyl)-4-oxo-4(1H)-dihydroquinolin-3-
carboxamide (29e). 30%; 250 °C; Methanol; IR ν 3263 (NH), 3008 (NH2), 1634 
(C=O ketone), 1600 (C=O amide) cm-1. 1H NMR (Acetone-d6) δ 1.48-1.52 (t, 3H, 
CH2CH3), 4.37-4.42 (q, 2H, CH2CH3), 4.62 (s, 2H, CH2-benzyl), 6.59-6.61 (m, 1H, 
quinolinone C6-H), 6.75-6.77 (m, 1H, quinolinone C8-H), 7.08-7.13 (m, 2H, 
benzene H), 7.37-7.47 (m, 3H, quinolinone C7-H and benzene H), 8.68 (m, 1H, 
quinolinone C2-H), 9.06 (bs, 1H, NH). 
60. A mixture of isatine (23mmol) K2CO3 (27 mmol) and haloderivative (27 mmol) 
 67 
in 25 mL of DMFa was stirred at 80 °C for 1.5 h. After cooling, the reaction mixture 
was purified in crushed ice and the formed precipitate was collected by filtration, 
washed with H2O and diethyl ether obtaining 5.89 g of crude product 60 (87% yield), 
that was utilized for the next reaction without further purification. Chemical and 
physical of derivative 60 are reported in Table 10. 
 
N-Benzyl-3-hydroxy-4-oxo-4(1H)-dihydroquinolin-2-carboxamide (32). To a 
solution of CH3ONa (13 mmol) in methanol anhydrus (3.3 mL) heated at 120 °C was 
added 60 (1.7 mmol). The reaction mixture was stirred at the same temperature for 2 
h. After cooling, the reaction mixture was purified in crushed ice and the formed 
precipitate was filtered off, water was acidified with HCl 1 N until pH 2 was 
reached. The formed precipitate was collected by filtration, washed with H2O and 
diethyl ether obtaining crude product 32, that was purified by silica gel column 
chromatography using ethyl acetate as eluent obtaining pure 32. Yield (%), melting 
point (°C), recrystallization solvent, IR, 1H NMR are reported for the following 
compound. 
 
N-Benzyl-3-hydroxy-4-oxo-4(1H)-dihydroquinolin-2-carboxamide (32). 10%; 
230-232 °C; trituration in diethyl eter; IR ν 3223 (OH), 3058 (NH), 1637 (C=O 
amide), 1585 (C=O ketone) cm-1. 1H NMR (DMSO-d6) δ 4.63-4.65 (d, 2H, CH2 
benzylamine), 7.21-7.41 (m, 8H, benzene H, quinolinone C6-H, C7-H and C8-H), 
7.57-7.59 (d, 1H quinolinone C5-H), 8.12-8.14 (d, 1H, NH), 11.36 (bs, 1H, OH), 
12.53 (s, 1H, NH). 
 
2-(2-Nitro-benzylidene)-malonic Acid Diethyl Ester (61). To a solution of diethyl 
malonic ester (27 mmol), acetic acid (9 mmol), and piperidine (2.7 mmol) in benzene 
(60 mL) was added 2-nitrobenzaldehyde (22.5 mmol). The reaction mixture was 
refluxed for 72 h and then evaporated. The crude product was dissolved in ethyl 
acetate, washed 4 times with aq. NaHCO3 5% and once with brine, dried over 
Na2SO4 anhydrus, filtered and evaporated. The product was purified over silica gel 
with cyclohexane/ethyl acetate 95:5 as eluent to give 61 as a colorless oil (12% 
yield). Chemical and physical of derivative 61 are reported in Table 10. 
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1-Hydroxy-2-oxo-1,2-dihydro-qoinoline-3-carboxylic Acid Ethyl Ester (62). 
Compound 61 (1.05 mmol) was dissolved in acetic acid (5 mL), and PtO2 (5 mg) was 
added. The reaction mixture was stirred 24 h at room temperature under hydrogen, 
then filtered over celite, and washed with methanol. The solvents were evaporated 
under reduce pressure. The product was purified on n-hexane for 1 night obtaining 
pure 62 as a beige powder (55% yield). Chemical and physical of derivative 62 are 
reported in Table 10. 
 
1-Hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic Acid 4-fluoro-benzylamide 
(33). Compound 62 (0.16 mmol) was dissolved in 4-fluorobenzylamine (2 mL), and 
the reactionmixture was beate at 60 °C for 4 h, and then cooled at room temperature. 
Ethyl acetate was added, and the organic layerwas washed 4 times with HCl 1 N, 
once with water, once with brine, dried over Na2SO4 anhydrus, filtered and 
evaporated. The residue was precipitated over dichloromethane and filtered to give 
33 as a beige powder. Yield (%), melting point (°C), recrystallization solvent, IR, 1H 
NMR are reported. 87%; 230-232 °C; precipitated over dichloromethane; IR ν 3255 
(OH), 3050 (NH), 1655 (C=O amide), 1609 (C=O ketone) cm-1. 1H NMR (DMSO-
d6) δ 4.55-4.59 (d, 2H, CH2 benzylamine), 7.15-7.20 (m, 2H, benzene H), 7.39-7.42 
(m, 3H, benzene H and quinolinone C6-H), 7.78-7.80 (m, 2H, quinolinone C7-H and 
C5-H), 8.04-8.06 (d, 1H quinolinone C8-H), 8.85 (s, 1H, quinolinone C4-H), 10.07 
(s, 1H, NH), 11.87 (bs, 1H, OH). 
 
Table 6. Chemical and physical data of synthesis intermediate of derivatives 26 and 
27. 
 
 
 
 
a Recrystallization solvents: (a) aceton, (b) toluene. 
 
Table 7. Chemical and physical data of synthesis intermediate of derivatives 28a-d 
and 29a-e. 
Cpd mp (°C) Recryst solventa Yield (%) 
36 170-171 a  58 
37 294-296 d 60 
38 155 b 78 
39 155  b  89 
40 oil oil  98 
41 184-185 a  60 
42 oil oil  40 
43 - - 98 
Cpd mp (°C) Recryst solventa Yield (%) 
34 242-244 a  56 
35 213-214 b  65 
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44 245-248 c  78 
45 102 b  77 
46 238 (dec) d 44 
47 179-180 e  34 
48 200-201 f  30 
a Recrystallization solvents: (a) methanol, (b) benzene/cyclohexane, (c) ethanol, (d) DMF, (e) ethyl 
acetate, (f) ethyl acetate/ethanol 
 
 
Table 8. Chemical and physical data of synthesis intermediate of derivative 30. 
 
 
 
 
 
 
 
 
a Recrystallization solvents: (a) toluene, (b) n-hexane. 
 
 
Table 9. Chemical and physical data of synthesis intermediate of derivatives 31. 
 
 
 
 
 
 
 
 
 
 
Table 10. Chemical and physical data of synthesis intermediate of derivatives 32 and 
33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cpd mp (°C) Recryst solventa Yield (%) 
49 oil oil  100 
50 178-180 a 55 
51 75-80 a 46 
52 105 b 100 
53 244 a 58 
Cpd mp (°C) Recryst solvent Yield (%) 
54 oil oil 27.5 
55 oil oil 48 
56 oil oil 45 
57 oil oil 100 
58 oil oil 62 
59 oil oil 28 
Cpd mp (°C) Recryst solvent Yield (%) 
60 190-193 - 87 
61 oil oil 12 
62 - - 55 
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Biology 
Compounds 13a-i, 14a-i, 15a,b, 16a,b, 17a,b and 18a,b were tested for their ability 
to inhibit HIV-1 integrase in vitro using a gel-based assay in addition to a 96-well 
plate-based high throughput electrochemiluminescent assay.30 In the gel assay, a 5′-
end-labeled 21-mer double-stranded DNA oligonucleotide corresponding to the last 
21 bases of the U5 viral LTR is used to follow both 3′-P and ST. Briefly, a DNA-
enzyme complex is preformed by mixing the drug at the destre concentration with 
400 nM recombinant HIV-1 integrase in a buffer containing 50 mM MOPS, pH 7.2, 
7.5 mM MnCl2, and 14.3 mM β-mercaptoethanol. The integration reaction is then 
initiated by the addition of 20 nM 5′-labeled double-stranded DNA template and 
continued in a total volume of 10 µL for 60 min at 37 °C. The reaction samples are 
stopped by adding the same volume of electrophoresis denaturing dye and loaded on 
20% 19/1 acrylamide denaturing gel. Gels were exposed overnight and analyzed 
using a Molecular Dynamics hosphorimager (Sunnyvale, CA). The 96-well plate-
based high throughput electrochemiluminescent assay was performed using a 
BioVeris M series analyzer (Gaithersburg, MD) as described previously.30 Briefly, 
DNA substrates were obtained from BioVeris and used according to the 
manufacturer’s recommendations. Donor DNA is incubated for 30 min at 37 °C in 
the presence of 250 nM recombinant HIV-1 integrase. After addition of the drug, the 
integration reaction is initiated by addition of target DNA. Reaction is carried out for 
60 min at 37 °C and then read on the BioVeris M series analyzer.  
The anti-HIV drug testing was performed in 96-well plates with a defined, 
previously titered inoculum of a laboratory strain (HTLV-IIIB) to minimize the 
inoculum effect. In brief, all compounds were dissolved in dimethyl sulfoxide and 
diluted in cell culture medium at concentrations ranging from 0.1 to 50 µM. 
Exponentially growing human T lymphocytes (H9 cell line) were added at 5000 
cells/well. After the infectivity of a virus stock (HTLV-IIIB) is quantified, an aliquot 
containing 1 x 105 50% tissue culture infectious dose (TCID50) per 5000 H9 cells 
per well is used as inoculum in each set of in vitro infections of H9 cells. Uninfected 
cells with the compound served as a toxicity control, and infected and uninfected 
cells without the compound served as basic controls. Culture were incubated at 37 °C 
in a 5% CO2 atmosphere for 4 days. Supernatant fluid of infected wells (in the 
absence of drug and at each of a number of drug concentrations) is harvested. HIV 
p24 antigen is quantified, and the 50% inhibitory concentration (IC50) of drug is 
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determined using the median effect equation.  
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Second chapter 
 
RIBONUCLEASE H OF HIV-1 
 
Among the enzymes that are codified by pol gene of HIV-1, reverse trascriptase (RT) 
is the most and longer studied. 1 RT is a multifunctional enzyme that are implicated 
in several associated activities, all of these essentials for HIV-1 infection. Infact RT 
parteciped to the life cycle of the virus as RNA- and DNA-dependent DNA 
polymerase (RDDP and DDDP, respectively), ribonuclease H (RNase H), strand 
transfer, strand dispacement synthesis and nucleotide excission. 2,3,4 To catalyse these 
reactions, RT utilized two different catalytic sites which, albeit the HIV-1 RT is 
composed by two polypetide subunits (p66 and p51), reside in p66 subunit at the 
distance of 18 base pairs from each other and are strictly inter-dependent: RT-
associated polymerase function and RNase H functon. 
As RT-associated polymerase function, RT carried out a conversion of the viral 
single strand RNA genome into a double strand DNA, which is subsequently 
traslocated into the cell nucleus and integrated into the cell host DNA. 2,3 As RNase 
H function, RT catalyzed the degradation of RNA strand of the RNA:DNA hybrid 
intermediate to permited the synthesis of double strand viral DNA. This passage is 
essential for the HIV-1 infection. 5 
Although RT is a multifunctional enzyme, all approved RT inhibitors (NRTIs and 
NNRTs) target only the RT-associated polymerase function. Therefore, the 
identification of new RT inhibitors that target other essential RT-associated function 
such as RNase H activity, could be an attractive approach to enhanced the anti-HIV-
1 drug armamentarium effectiveness. 6  
 
2.1 Biology of RNase H function 
2.1.1 Structure of reverse trascriptase 
RT is codify by pol gene as p66 polypeptide (66 kDa) that is partially cleaved by the 
viral protease into two p51 and p15 polypeptides (51 and 15 kDa, respectively). The 
active RT is an heterodimeric enzyme composed by two subunits: p66, contenents 
560 amino acidic residues, and p51, contenents 440 amino acidic residues.  
The p66 subunit contains two differents catalytic domains: the first located in the N-
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terminus, possessing RNA- and DNA-plymerase activity, and catalyzing the reverse 
trascription of viral RNA in double strand proviral DNA; the second located in the 
C-terminus, possessing ribonuclease H activity, and catalyzing the degradation of 
RNA strand of the RNA:DNA hybrid intermediate. The tridimentional structure of 
the p66 is similar to other polymerase and are compared to a closed hand consisting 
of four different domains namely palm domain (residues 86-117 and 156-237), 
fingers domain (residues 1-85 and 118-155) and thumb domain (residues 319-426) 
and by a connection domain (residues 427-560), 7 ables to envelop the viral genome 
and accomodate it in the way which can cross the active site of the enzyme.  
The p51 subunit shows a different spatial arrangiament, it has no cleft for the 
template binding and the residues requied for catalysis are buried into the subunit 
and, as a result, does not contains functional site. Infact the catalytic site of RT-
associated polymerase function is costituted by Asp110, Asp185, and Asp186 amino 
acids residues, which are highly conserved and are located in the palm domain of 
p66. On the contrary, the corresponding Asp residues in p51 are concealed and have 
lost the catalytic functions of the enzyme. 5 
Thogeter with IN and other enzyme like transposase and RuvC resolvase, RNase H 
belong to the polynucleotidyl transferase family. RNase H of HIV-1 catalyzed 
phosphoryl transfer through nucleophilic substitution reactions on phosphate ester, 
requiring the concerted action of a general base activating the nucleophile and a 
general acid protonating the leaving group. In particolar catalysis occurs by 
deprotonation of a water molecule to form a nucleophilic hydroxide group that 
attacks the scissile phosphate goup on RNA. To accomplish this reaction, RNase H 
function requred the presence of metal ions such as Mg2+ or Mn2+. Differently to 
other transposase, the structure of RNase H domain has been proposed to need two 
divalent cations that, consistetly with the phosphoryl transfer geometry, seem to be 
coordinated by the active site carboxylates D443, E478, D498 and D549. 8 
These residues composed a three amino acids DDE motive, highly conserved in 
many HIV-1 strains in the core domain of the RNase H active site: mutations in any 
of the D443, E478, D498 or D549 abolish enzyme activities. 9 
 
2.1.2 Role of RNase H function in the reverse trascriptase 
The reverse transcription of HIV-1 genome needs a primer of double strand RNA. 
This primer is furnish by the cellular apparatus and is constituted by a specific 
 79 
sequence tRNALys3 which is complementary to the primer binding site (PBS) 
localized at the 5’ end of the viral RNA. Therefore, the RT-associated RDDP 
function starts the transcription of the first molecule of DNA with negative polarity. 
The product of this first step is the hybrid RNA:DNA intermediate that will move 
from RDDP function active site to RNase H function active site. In the RNase H 
function active site the RNA strand of the hybrid is hydrlolyzed to obtain a minor-
single-strand DNA, that is then transfered to the 3’ end of the same molecule of RNA 
in correspondence to LTR sequence (intramoleular transfer) or to other copy of viral 
genome within virion (itermolecular transfer) to allow further elongation. This 
double-strand RNA:DNA segment become the primer for the elongation of the DNA 
strand catalyzed by the RDDP function of RT. The product of this second 
polymerization is newly a RNA:DNA hybrid intermediate which is partially 
hydrolized by RNase H to furnish a plus-singol-strand of DNA with a polypurine 
tract (PPT) of RNA which is not degradated. The PPT is the primer for the synthesis 
of the second DNA positive strand catalyzed by the DDDP function of RT. Now the 
removals of the PPT and tRNA primers by the RNase H function  makes possible a 
second strand transfer which occurs with the interaction of the PBS sequences of the 
two DNA strands; or rather the 3’ end of DNA (+) is transfered on the PBS in the 3’ 
end of the DNA (-) to allow the DDDP function of RT to synthesize a complete 
double strand DNA. 5 Finally, it is assumed that the replication intermediate is 
circularized and that bidirectional DNA synthesis continues, during which an RT-
associated strand displacement function is required. 
 
2.1.3 Mechanism of action of RNase H function 
The reaction catalyzed by RNase H function consist in the hydrolysis of 
phosphodiester bond of the viral RNA backbone which form an hybrid with new 
synthesized DNA strand. The reaction involved is a nucleophilic substitution carried 
out by a water molecule on the phosphodiester bond, that needs the concerted action 
of a general base activating the water molecule and a general acid protonating the 
negative charge of leaving group. The transition state has a bipyramid geometry 
which presents the five oxygen atoms in the vertices bounded to the pentavalent 
phosphorus atom. The oxygen atoms of the nocleophile and the leaving group 
occupy the axial positions while the residue oxygen atoms are in equatorial position. 
The generals base and acid need for the hydrolysis of phosphodiester bond are 
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represent by the two bivalent metal ions which interact with carboxyl groups of the 
amino acids Asp443, Glu478, Asp498 and Asp549 in the active site of RNase H 
function. One of each metal ion acts like a general base, lowering the pka value of 
the water molecule which rise up the catalytic site. The water molecule is converted 
to hydroxid ion that represents the nucleophile needed for the reaction. The other 
one, acts like a general acid activating a second water molecule, which protoning the 
negative oxygen atom in the 3’ end of the leaving group. Both metal ions contibute 
to orientate and stabilize the pentavalent transition state and to neutralize the 
emerged negative charge on the leaving group. 10 
The properties of the two metal ions are differents for each of the two differents 
positions. Infact the metal ion in the A position must have a lower value of pka for 
increasing the catalytic activity and the local concentration of the hydroxid ions; on 
the contrary, the presence of metal ions with lower pka value decrease the capacity to 
neutralize the negative charge on the leaving group by a indissociate water molecule. 
11 On the basis of this consideration, is predictable that the activity of RNase H is 
enhanced in presence of metal ions such as Mn2+ (pka= 10,6) or Co2+ (pka= 8,9) 
then with Mg+2 (pka= 11,4). But crystallographic study, cofirmed by calorimetric 
method and NMR spectoscopy, reveal that the presence of two metal ions 
contraddistinc by two ions of Mg2+ are indispensable for the activity of the RNase H 
of HIV-1. 12  
 
2.2 Inhibitors of ribonuclease H function 
During the last decades, significant progress has been made in the field of RT 
polymerase function inhibitors as antiretroviral agents and some of these compounds 
are widely used in clinical practice as drugs in the highly active anti retroviral 
therapy (HAART). 13 Conversely, specific inhibitors for RNase H function were not 
identified until recently. However, the RT-associated RNase H function was proven 
as an essential step in the virus life cycle. Thus, efforts in the development of new 
compounds targeting the RNase H activity are relevant to enhance the antiretroviral 
armamentarium. However, few specific RNase H inhibitors are known and little 
studies have been performed to assess the efficacy of these inhibitors in the treatment 
of HIV. Knowing the active site of the RNase H function and the mechanism of the 
catalysis, the inhibitors can: 
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• Modify the interaction between RNase H and the substrate; 
• Modify the alignment between the substrate in the active site; 
• Induce modification in the removal of the primer after the extension of DNA 
strand and alter the hydrolysis of the hybrid RNA:DNA. 
On the bases of different studies, are known different kind of RNase H inhibitors 
which can divided into two classes: 
A-Inhibitor with unknown binding site;  
B-Inhibitors with known binding site.  
 
To the firs group belong compounds with unclear mechanism of action.  
 
2.2.1 A-Inhibitor with unknown binding site 
QUINONES AND NAPHTHOQUINONES 
One of the first compound that was descrive to inhibite RNase H of HIV-1 is the 
Illimaquinone (1), a secondary metabolite producted by the Read sea sponge 
Smenospongia sp. This compound presents a inhibitory activity against the RNase H 
of HIV-1 about 15 µM, but is proven to inhibit also RT of HIV-2 and RNase h of 
Escherichia coli with an IC50 value ranging from 30 to 63 µM.  
 
1 
The SAR of Illimaquinone was studied synthesizing two analogue that present the 
oxydated or riduced pharmacophore, like the compound 2 and 3. The modifications 
apported to this compound leaded to a decreasing of the activity against RNase H of 
HIV-1 and RT of HIV-2 and.  
     
2                                3  
 
The binding site of illimaquinone was proven to be in close proximity to cysteine 
280 in both HIV-1 and HIV-2 RTs. 14 However, no data were reported on its efficacy 
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in the inhibition of the HIV replication cycle in cell-based assays. 
The 1,4-naphthoquinone 4 are the compound demonstrating the best inhibitory 
activity and selectivity in enzymatic assay between naphthoquinone compounds. 
Infact its IC50 against RNase H is 9.5 µM without significant activity against RDDP 
function.  
 
4 
 
The relationship between structure and activity for this compound was studuied and a 
serie of derivatives were synthesized. The new derivatives presented an hydroxyl 
group in C2, C5 or C8 positions (5, 6, 7); all the modification to 4 structure lead to a 
decreasing of RNase H inhibition. 15 
 
Among naphthoquinones, another important compound is a derivative of frangula-
emodinie, an ingredient of chinese herbes. The 8 compound was tested in in vitro test 
against RNase H of HIV-1 showing an IC50 value of 75 µM. With some 
modifications of the base structure of 8, like an introduction of bromine atom and a 
alkylation with a benzoylmethyl substituent, was synthesized compound 9 which has 
demonstrated to be more potent of 9 in test against RNase H function, infact its IC50 
value is about 14 µM. 16 
 
 
More structurally complicated quinones were studied by Marchand at al. 
Madurahydroxylactone (MHL, 10) is a secondary metabolite from the soil bacterium 
Nonomuraea rubra, that belongs to the family of benzo[a]naphthacenequinone 
antibiotics. 17  
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Despite 10 has a broad spectrum of action, a series of semi-synthetic derivatives 
were evaluated for dual inhibition of HIV-1 IN and RNase H. While most of the 
compounds exhibited similar potencies for both enzymes (IC50 ranging from 0.3 to 
22 µM), some derivatives showed 10- to 100-fold higher selectivity for each enzyme. 
The most potent and selective MHL derivative identified within this series was the 
hydrazone 11, which showed IC50 values of 0.69 and 122 µM against RNase H and 
IN, respectively. 
 
NUCLEOTIDES AND OLIGONUCLEOTIDES 
Some nucleotides were proven to be weak inhibitors of HIV RNase H activity in 
enzyme assays. In particular, AZT-MP (12), inhibited the HIV RNase H activity 
more potently than other nucleotide monophosphates. 18 Its inhibitory potency was 
dependent on the divalent metal ion used, changing in the assay. In fact, the 
measured IC50 values were 5 µM and 0.05 µM when Mn2+ or Mg2+ were used as 
divalent cation activator, respectively. 2’,3’-Dideoxyadenosine 5’-monophosphate 
(ddAMP) and 2’,3’-dideoxyguanosine 5’-monophosphate (ddGMP), also inhibited 
the RNase H activity with IC50 values of 0.2 and 0.5 µM, respectively, in the 
presence of Mn2+, while they were inactive in the presence of Mg2+. 19  
      
A selective inhibitor of RNase H and influenza endonuclease was the dinucleotide 
dimer diguanosine (rGrG). Infact it is not an inhibitor of either RNase H of 
Escherichia coli and a nuclear extract of Hela cell; despite it showed an IC50 value of 
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15 µM against RNase H of HIV-1. Also its derivative 13 evidence a similar activity 
but is more potent then parent compound showing an IC50 value of 5 µM against 
RNase H of HIV-1. This compound is obtained replacing the 3’-5’-phosphodiester 
linker with a 2’-5’-formacetal of the parent compound. 20 
 
HYDRAZONES 
The N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone (BBNH, 14) 
was discovered after a random screening of a large number of molecules which has 
in common the capacity to chelate metal ions, resulting active against RNase H and 
RT of HIV-1 with IC50 value between 0.8 and 15 µM, respectivly. To the contrary, 
RNase H and RT of HIV-2 are resistant to the inhibition induced by BBNH (IC50 
>50 µM). Interestingly, 14 was also active in cell-based assays, showing EC50 value 
of 1.5 µM for the inhibition of HIV-1 replication in cord blood mononuclear cells. 
BBNH inhibited both RNase H and RDDP activities of HIV-1 RTs mutated in 
residues K103N, Y181I, Y188H, Y188L with potency similar to the one obtained for 
wild type RT. Differently, when assayed on the mutated RT Y181C, 14 was not 
active on the RNase H activity while it inhibited the RDDP function with an IC50 
value of 1.6 µM. Therefore, BBNH (14) was hypothesized to bind to two different 
sites on HIV-1 RT. The first one in the polymerase domain possibly nearby the 
NNRTI-binding site and the second one possibly located in the RNase H domain. 
After a molecular modeling study was suggested that the compound 14 makes two 
main interactions with the enzyme in the RNase H function active site: the first 
chelating the divalent metal ions presents in the active site of the enzyme and the 
second making a π-stacking interaction with the aromating ring of Tyr 501 and its 
second ring of naphthyl group. For validate this theory was sintetized the analogue of 
14 changing the naphthyl moiety with a phenole group obtained the compound 15 
which loss the inhibitory potency against RNase H function (IC50> 50 µM), while 
retain the ability to inhibit RT function (IC50= 2.5 µM). 21 Further studies on the 
mechanism of action of BBNH (14) led to hypothesize that its binding to RT could 
impact with the protein-protein interactions of the heterodimeric enzyme. To 
evaluate whether this observed phenomenon was mediated by 14 binding to one or 
more sites in RT, a random screening was conduced over 100 molecules structurally 
analogue of 14, and the compound 16 was resulted the most selective against RNase 
 85 
H function then RT function (IC50 RNase H = 4 µM, IC50 RT >40 µM). The 
identification of these specific inhibitors, in combination with other biochemical 
data, suggested a model in which two molecules of BBNH bind the RT heterodimer. 
On this regard, only the binding of hydrazone molecules in the DNA polymerase 
active domain elicits the observed destabilization of the HIV-1 RT heterodimer. 
Finally, the strain to increased the selectivity of this molecules against RNase H 
domine lead to the synthesis of dihydroxy-benzoyl-naphthyl-hydrazone 17 
(DHBNH), which is revealed a potent and selective inhibitor of RNase H function 
(IC50= 0.5 µM, IC50 RT= 50 µM). To better elucidate the mechanism of action of this 
compound, the crystal structure of HIV-1 RT in complex with DHBNH was solved, 
showing that it binds near the polymerase active site in a pocket different from the 
NNRTI-binding site, and also >50 Å away from the RNase H active site. It was 
hypothesized that 17 perturbs the trajectory of the template–primer so that RNase H 
cannot operate on its substrate. Alternatively, 17 may also bind to a second site in or 
near the RNase H domain that was not seen in the crystal. 21 
 
 
MAPPICINE ANALOGUES 
Mappicine is a minor alkaloid from Mappia foetida Miers that is related to 
camptothecin. A few analogs (18-20) of this natural product have been described as 
selective HIV RNase H inhibitors. 22 In fact, these compounds inhibited the HIV 
RNase H activity in enzyme assay with IC50 values between 2.1 and 10 µM. The 
mappicine analogs may bind to a binding site on the HIV-1 RT not overlapping with 
the NNRTI binding site. 
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2.2.2 B-Inhibitors with known binding site 
 
TROPOLONES 
Tropolone and derivatives are natural compounds isolated from the heartwood of 
cupressaceous plants (Thuja plicata, Thuja occidentalis and Chamaecyparis obtusal) 
that are endowed of many biological activities including antifungal, antitumor, 
insecticide and antimicrobial effects. During a high-throughput screening of the 
American National Cancer Institute was identified the hydroxylated tropolone 
derivatives β-thujaplicinol (2,7-dihydroxy-4-1(methylethyl)-2,4,6-cycloheptatrien-1-
one) (21) and manicol (1,2,3,4-tetrahydro-5-7-dihydroxy-9-methyl-2-(1-
methylethenyl)-6Hbenzocyclohepten-6-one) (22), as potent and selective inhibitors 
of the HIV-1 RNase H. 23  
 
21 inhibited in vitro the HIV-1, HIV-2, E. coli and human RNase Hs with IC50 values 
of 0.2 µM, 0.7 µM, 50 µM and 5.7 µM, respectively. Similarly, 22 inhibited the HIV-
1 and E. coli RNases H with IC50 of 1.5 µM and 40 µM, respectively. Both 21 and 22 
failed to inhibit RDDP activity of HIV-1 RT at a concentration of 50 µM, suggesting 
that they are specific for the C-terminal RNase H domain. SAR studies within this 
class of compounds, led to conclude that the 2,7-dihydroxy function of these 
tropolone analogs is very relevant for the anti-RNase H activity, through a role in 
metal chelation at the RNase H active site. The vital role the 2,7-dihydroxy function 
of these tropolone analogues was definitively proven by the means of RX diffraction 
studies performed on a crystal structure of 21 bound to the RNase H active site of 
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both HIV-1 RT and an isolated RNase H domain. In fact, 21 was found to chelate the 
two divalent metal ions at the RNase H active site. 24 
 
N-HYDROXYIMIDES 
A series of N-hydroxyimides was previously synthesized as inhibitor of influenza 
endonuclease enzyme, but after the identification of the analogies between 
endonuclease and RNase H active sites, these compound was tested also aganst the 
RNase H function of HIV-1. The compound 23 was identified as the most active of 
this series showing an inhibitory activity against RNase H function with an IC50 
value of 0.6-1 µM in enzymatic assay, while the inhibition of RDDP function was 
more mild with an IC50 value of 40 µM; this compound was unaffected against 
RNase H of E. coli. 25 
 
Interesting SAR were described within this series. First, all three N-hydroxyimide 
oxygens were essential for inhibitory activity of the compounds and substitutions on 
the hydroxyl group were not tolerated, as well as its replacement with an amino 
group. The possibility to obtain an enolizable form was vital for the anti-RNase H 
activity, too. In fact, derivatives in which the structure blocked the tautomerization, 
were totally inactive (see compound 24 and 25). After these coniderations, a large 
number of derivatives was synthesized aimed for enhance the inhibitory activity. All 
the synthesized compounds were weaker inhibitors of the RNase H activity (IC50 
ranged from 5.7 to 58 µM among the active compounds) if compared to the 
prototype 23 and no clear structure-activity relationship emerged from the IC50 
values. Thus the pharmaco-modulation of the isoquinoline ring in position 7 did not 
yield better candidates than 23, and did not give compounds active in the 
submicromolar range against RNase H. 26 Only the compond 26, the 5-chloro 
derivative, has demonstrated better activity then 23 (IC50= 0.3 µM). 27 
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The enzymatic inhibitory properties of these N-hydroxyimides may be related to the 
metal binding abilities of the compounds. Infact, physicochemical studies performed 
by the means of NMR and UV-vis experiments, were consistent with a 1/1 
stoichiometry of the magnesium complexes in solution, and the metal complexation 
was strictly dependent on the enolization abilities of the compounds. Unfortunately, 
all tested compounds exhibited high cellular cytotoxicity in cell culture which limits 
their applications as antiviral agents.  
 
HYDROXYPYRIMIDINE CARBOXYLATE 
Based on an electronical analysis of three different classes of RNase H inhibitors 
(DKA, N-hydroxyimides and hydroxytropolones) was designed new inhibitors 
characterized by the pyrimidinolcarboxylate moiety. 28 
SAR studies within this series as RNase H inhibitors in enzyme assays were focused 
on variations of the 2-substituent and led to the following conclusions: i) the best 
linker between the pyrimidinol ring and the 2-substituent as a second aromatic ring 
was a methylene group; ii) disubstituted compounds on this aryl portion were more 
potent than unsubsituted or monosubstituted analogues; iii) the best activity was 
obtained with a substituted benzothiophene ring as the aryl moiety. The most potent 
compound was the thiophene derivative 27, that showed an IC50 value of 0.17 µM 
against HIV-1 RNase H and 70 µM against human RNase H. 29 
 
It is worth to note that the compounds reported in this work were inactive in a multi-
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cycle MT-4 HIV infectivity assays at concentrations up to 100 µM. This could be 
ascribed to: insufficient intrinsic potency, low cell permeability, or high protein 
binding. 
 
NITROFURAN-2-CARBOXYLIC ACID CARBAMOYLMETHYL ESTER 
(NACME) DERIVATIVES 
During a screening for RNase H inhibitors, 20000 small molecules were tested and a 
novel RNase H inhibiting group of compounds was identified that was characterized 
by a 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester (NACME) moiety. 30  
5-Nitro-furan-2-carboxylic acid adamantan-1-carbamoylmethyl ester (28) and 5-
nitro-furan-2-carboxylic acid [[4-(4-bromo-phenyl)-thiazol-2-yl]-(tetrahydro-furan-
2-ylmethyl)-carbamoyl]-methyl ester (29) were the most interesting NACMEs. They 
effectively blocked HIV-1 and MLV RT-associated RNase H activities with IC50 
values of 3-30 µM but had little effect on bacterial RNase H activity in biochemical 
assays.  
 
Both HIV-1 IN and RT RDDP enzymatic activities were not detectably affected by 
these compounds, therefore, they could be considered specific RNase H inhibitors. 
Docking studies indicated that the nitrofuran group of 28 chelates the two Mg2+ ions 
and orients toward the conserved His539 residue to form a possible hydrogen bond. 
For compound 29, in addition to the above interactions, the nitrogen atom of the 
thiazole ring binds the Asp549 by hydrogen bond. 
The SAR within this series led to conclude that: i) derivatives carrying various 
substituents at the end of the carbamoylmethyl ester group retained RNase H 
inhibitory activity; ii) substitution of the 5-nitrofuran moiety with various 
heterocycles resulted in a loss of RNase H inhibition, indicating a critical role for the 
5-nitrofuran group within this series of RNase H inhibitiors; iii) derivatives with 
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relatively long and bulky groups at the end of the carbamoylmethyl ester group, 
displayed RNase H inhibitory activity; iv) compounds with relatively small volume 
groups in the same position showed no inhibitory activity. 
 
VINYLOGOUS UREA 
A high-throughput screening of National Cancer Institute libraries of synthetic and 
natural compounds was carried out and were identified the vinylogous ureas 2-
amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (NSC727447, 
30) and N-[3-(aminocarbonyl)-4,5-dimethyl-2-thienyl]-2-furancarboxamide 
(NSC727448, 31), as novel HIV-1 and HIV-2 RNase H inhibitors.  
 
NSC727447 (30) did not inhibit DNA polymerase and pyrophosphorolysis activities 
at a concentration of 50 µM, indicating preferential inhibition of RNase H function. 
31 A mass spectrometric protein footprinting based on biotin modification of exposed 
lysine residues in the free protein and the protein-inhibitor complex, revealed that 
Cys280 and Lys281, located in helix I of the thumb subdomain, were protected from 
modification by inhibitor binding. Proximity between the p51 (thumb) and the p66 
domains implies that the urea vinylog binds near the catalytic center affecting either 
positioning of the nucleic acid substrate in the active site or divalent metal 
coordination. Site-directed mutagenesis using reconstituted p66/p51 heterodimers 
substituted with various amino acids shows that the alteration of the p66 RNase H 
primer grip, significantly affects inhibitor sensitivity. The above data suggested that 
regions within the RNase H domain distinct from the catalytic center can be targeted 
by small-molecule antagonists. The vinylogous ureas occupy a binding pocket 
outside the RNase H catalytic center and represent a novel class of allosteric RNase 
H antagonists to complement active-site directed, metal-chelating inhibitor. 
 
DIKETOACID (DKA) 
The DKA represents a significant class of RNase H inhibitors of HIV-1. Infact these 
compound, like N-hydroxyimides and tropolones, are able to chelate divalent metal 
ions which are presented in the active site of RNase H function. The idea of the 
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possible activity of DKA on RNase H function born from the known activity of these 
compounds on IN enzyme of HIV-1, which belonges to the same enzymatic class of 
RNase H enzyme; infact either enzyme are classified as polynucleotidyl transferases 
within high similarity in the catalytic site. In the active site of both enzyme are 
presented two metal ions, such as Mg2+ and the chelation of these bring to an 
inhibition of the catalytic activity. In in vitro test the α,γ-diketoacid mojety has 
dimonstred the ability to compete for the bond to the active site with native substrate 
because are able to form a ligand-metal-enzyme complex. Given the structural 
similarities between the domains of the two viral enzymes (IN and RNase H), several 
DKAs initially developed as IN inhibitors were also screened against the HIV-1 
RNase H activity. Among them, the 4-[5-(benzoylamino)thien-2-yl]-2,4-
dioxobutanoic acid (BTDBA, 32) was the first HIV RNase H inhibitor reported. 32 It 
inhibited HIV-1 RNase H as part of full-length HIV RT showing an IC50 value of 3.2 
µM, and also inhibited the isolated HIV-1 RNase H domain chimera carrying the E. 
coli RNase H basic helix loop motif with a similar IC50 value of 4.7 µM, while the 
IC50 values for HIV RT and E. coli RNase H inhibition were above 50 µM. However, 
BTDBA (32) also inhibited the HIV-1 IN with an IC50 value of 1.9 µM, showing to 
be not able to discriminate between the two HIV-1 targets, and most importantly, it 
did not block the viral replication in cell-based assays. 32 Further characterizations 
with isothermal titration calorimetry demonstrated that i) BTDBA requires the 
presence of a divalent cation in order to bind to the RNase H domain; ii) its metal-
dependent Kd value is comparable to its IC50 value; iii) the nucleic acid substrate is 
not needed for its binding to RNase H. 
Interestingly, 32 inhibited the strand transfer activity of HIV-RT synergistically with 
either a NNRTI, a nucleoside inhibitor (AZTTP), or a polymerase active site binding 
inhibitor (phosphonoformic acid, PFA, Foscarnet). These results are consistent with 
the requirement of both polymerase and RNase H activity for strand transfer and 
suggest that regimens combining polymerase and RNase H inhibitors may be 
therapeutically beneficial. 33  
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More recently another DKA (33) was identify as RNase H inhibitors. 34 This 
compound is structurally correlated with BTDBA for the presence of α,γ-diketoacid 
mojety and the aromatic portion, a pyrrole ring, responsable for the bound with the 
enzyme. RDS 1643 (33), inhibited the HIV-1 RNase H activity in enzyme assays 
with an IC50 value of 13 µM, showing lower potency if compared to BTDBA (32). It 
did not affect neither the HIV-1 RDDP function nor the AMV and E. coli RNase H 
activity, while it weakly inhibited the HIV-1 IN reaction (IC50 = 90 µM). Differently 
from BTDBA (32), RDS 1643 (33) inhibited the replication of wild type HIV-1 in 
cell-based assays showing an EC50 value of 13 µM and a CC50 value of 63 µM. 
Furthermore, 33 blocked the replication of three HIV-1 NNRTI resistant viral 
mutants (RT mutations were Y181C; K103N/Y181C; K103R/V179D/P225H) with 
EC50 values ranging from 7 to 19 µM. Mode of action studies demonstrated that 33 
maximum adsorbance shifted in the presence of the Mg2+ ions, suggesting a 
mechanism of action similar to that shown by BTDBA (32). The effective 
concentration of 33, although higher then some NNRT, is promised for outline an 
hypothetic association of DKAs with traditional therapy; moreover, the mutations of 
the amino acids in the active site of the enzyme less influence its activity then the 
drugs of HAART. 
In conclusion the results suggested that: i) the DKAs have a favourable orientation in 
the interaction with the two metal ions in the active site of RNase H function; ii) the 
base structure have a lipofilic aromatic portion no much hindered for the bound with 
the amino acids residues and the stabilization of the compound-enzyme complex.  
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2.3 Aim 
 
With the introduction of the HAART, the infection had partially lost the caracteristic 
of irreverible patology. The pharmacological association of several drugs has 
brought to the extention of the extimated life-time of the patients with infection of 
HIV, determined a decline of the incidence of desease correlated with the AIDS 
infection. However, the resistant viral strains to the chemotherapy and the toxicity of 
the utilized drugs have higlighted the necessity of a new associative scheme, with the 
introduction of new drugs able to target vital enzymes of the replicative viral cycle.  
RNase H of HIV-1 belonge to the superfamily of polinucleotidyl trasferase, that also 
include the core domine of IN of HIV-1, another essential retroviral enzyme. From a 
structural analysis is emerged that these two proteines share most similar catalytic 
core domines, even tough carried out different byological activities. By this 
observation, was proposed the possibility to test the active molecules on the IN of 
HIV-1 also on the RNase H function.  
The research group where I spent my PhD, by several years is involved in studies on 
integrase of HIV-1 inhibitors. Moreover, the decennal interest on pyrrole chemistry, 
has brought to development of pyrrolyldiketo acid derivative 33 analogue of 
compound 32, first reported in literature inhibitor of HIV-1 RNase H function. The 
α,γ-diketo acid mojety of 32 is the pharmacophoric group that form the ligand-metal-
enzyme tertiary complex with the two metal ions of catalytic active site, blocking the 
bound of naturale substrate. In a first time, we carried out a study of selectivity for 
Merck derivative L-731,988 on both RNase H function and polymerase function. 
Data furnished has higlighted that L-731,988 (34) does not selectivelly inhibits two 
catalytic domines of RT (also at concentration > 100 µM). Therefore in the structure 
of derivative 33 a vinilic mojety was been introduced between the diketo acid portion 
and the pyrrole ring, and was conserved DKA pharmacophoric mojety and aromatic 
portion allowing to value the importance of the distance between these two group in 
the molecule.  
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Our compound was tested on both RNase H function and RDDP function of RT, 
resulting a potent and selective inhibitor of RNase H function of HIV-1 (IC50 = 13 
µM, IC50 > 100 µM, respectively), representing a new lead compound. Starting from 
the structure of 33 we have firstly investigeted the benzyl portion introducing mono- 
or di-substituted benzyl groups, for designed N-benzylpyrroles 35a-r, 36a-q, 37a-k 
and 38a-k (Tables 1 and 2). 
 
Table 1. Compounds 35a-r and 36a-q 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cpd R2 R3 R4 X  Cpd R2 R3 R4 X 
35a H H H Et  36a H H H H 
35b Cl H H Et   
36b 
Cl H H H 
35c CN H H Et  36c CN H H H 
35d F H H Et  36d F H H H 
35e CH3 H H Et  36e CH3 H H H 
35f OC2H5 H H Et  36f OC2H5 H H H 
35g OCH3 H H Et  36g OCH3 H H H 
35h H Cl H Et  36h H Cl H H 
35i H CN H Et  36i H CN H H 
35j H F H Et  36j H F H H 
35k H Me H Et  36k H Me H H 
35l H OCH3 H Et  36l H OCH3 H H 
35m H H Cl Et  36m H H Cl H 
35n H H CN Et  36n H H CN H 
35o H H F Et  36o H H F H 
35p H H CH3 Et  36p H H CH3 H 
35q H H OCH3 Et  36q H H OCH3 H 
35r H H NO2 Et       
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Table 2. Compounds 37a-k and 38a-k 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cpd R2 R3 R4 R5 R6 X  Cpd R2 R3 R4 R5 R6 X 
37a F F H H H Et  37a F F H H H Et 
37b Cl H Cl H H Et  37b Cl H Cl H H Et 
37c F H F H H Et  37c F H F H H Et 
37d CH3 H CH3 H H Et  37d CH3 H CH3 H H Et 
37e F H H F H Et  37e F H H F H Et 
37f Cl H H H Cl Et  37f Cl H H H Cl Et 
37g F H H H F Et  37g F H H H F Et 
37h H F F H H Et  37h H F F H H Et 
37i H Cl H Cl H Et  37i H Cl H Cl H Et 
37j H F H F H Et  37j H F H F H Et 
37k H CH3 H CH3 H Et  37k H CH3 H CH3 H Et 
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2.3.1 Results and discussion 
 
Scheme 1, reported above, describes the synthesis of derivatives 35a-r, 36a-q 37a-k 
and 38a-k.  
The synthesis of compound 35a-r, 36a-q, 37a-k and 38a-k (Scheme 1) started from 
the commercially available pyrrole-2-carboxaldehyde, that was alkylated in alkaline 
medium (K2CO3) with the appropriate benzylbromide to obtain 39a-r and 41a-k N-
substuted-pyrrole-2-carboxaldehyde. The aldehydes 39a-r and 41a-k were converted 
to the corresponding 3-buten-2-ones 40a-p and 42a-k in a condensation reaction 
with acetone in presence of sodium hydroxyde (NaOH). To afford ethyl esters 35a-r 
and 37a-k, 3-buten-2-ones 40a-p and 42a-k was treated with diethyl oxalate 
utilyzing a weak base like sodium ethoxyde (NaOEt). The hydrolysis of esters 
function led to the corresonding acids 36a-q and 38a-k. 
 
Scheme 1. a Synthesis of derivatives 35a-r, 36a-q 37a-k and 38a-k.  
 
 
a Reagents and conditions: i: benzyl bromide, K2CO3, 110 °C; ii: acetone, NaOH 5 N, 50 °C; iii: 
diethyl oxalate, sodium ethoxyde, THFa, rt; iv: NaOH 1 N, 1:1 THF-Methanol, rt. 
 
All synthesized compounds are tested in in vitro assay on ricombinant RT and in 
cell-base assay on MT-4 cells by Prof. Enzo Tramontano of Cagliari University. 
Table 3 and 4 report the enzyme inhibitory activities (IC50), cell inhibitory activities 
(EC50), citotoxic concentration (CC50) and selective index (SI). For the evaluation of 
inhibitory selectivity on RNase H function, compounds 35a-r, 36a-q 37a-k and 38a-
k are also tested on IN of HIV-1 (Table 5 and 6) by Prof. Yves Pommier of National 
Institute of Healt in Bethesda, and on RDDP function of RT by Prof. Enzo 
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Tramontano (data not shown). 
Analizing synthesized compounds IC50 values on RNase H function, it stands to 
reason that acids compounds are not always more active then the corresponding 
esters (Tables 3 and 4). This kind of reactivity is different confronting with the 
inhibition of IN of HIV-1 and NS5B of HCV by DKAs. Infact, in the series of DKAs 
inhibitors of IN of HIV-1 (see chapter 1) and NS5B of HCV (see chapter 3) the acids 
compounds are always more actives then the corresponding esters; furthemore, the 
IC50 values of acids are greater 10- 100-folds then the corresponding values of esters. 
Infact, when compounds 35a-r, 36a-q 37a-k and 38a-k was tested on IN (Tables 5 
and 6), its IC50 values mantaining this trend.  
The most active compounds of these two series (monosubstituted- and disubstituted-
N-benzyl-pyrrolyldiketohexenoic acids and esters) are compounds 35e, 36o and 37h, 
more active then the lead (35o). The first and the last one compound are esters, 
instead of 36o that is an acid: its IC50 values on RNase H in in vitro enzyme assay are 
comparables (3 µM, 2.5 µM and 3 µM, respectively), while its IC50 values on IN in 
in vitro enzyme assay are completely different (32 µM, 0.026 µM, 1.6 µM, 
respectively) because in this second case the acid compound, 36o, is more active 
then the other two. Compound 35e is more selective for RNase H function, because 
its IC50 value in in vitro enzyme assay is >10-folds lower then the IC50 value in in 
vitro enzyme assay on IN of HIV-1. Compouns 36o and 37h are not selective, 
because are able to inhibit both RNase H and IN enzymes: compound 36o is ≈100-
folds while compound 37h is twice-folds more active against IN enzyme.Therefore, 
in comparison with the lead, the new synthesized compound are more active but less 
selective. However, each of these compounds shows an EC50 value comparable with 
own IC50 value, therefore are able to across the cell membrane and all the 
synthesized compound does not inhibit the RDDP function of RT (data not shown).  
Among orto-benzylsubstituted pyrrolyldiketohexenoic esters and meta-
benzylsubstituted pyrrolyldiketohexenoic acids, the activity is correlated with the 
nature of substituent in the same manner. Infact in both case the activity decrease in 
the following order:  
CH3 > Cl, CN, F > OCH3, OEt 
Among orto-benzylsubstituted pyrrolyldiketohexenoic acids, the electron-
withdrawings substituents (36b,c,d, chloro, ciano and fluoro respectively) are the 
most tolerated then the electron-donors (36e,f,g, methyl, ethoxy and methoxy 
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respectively). This trend is overturn among the para-benzylsubstituted 
pyrrolyldiketohexenoic esters (Table 3). Among meta-benzylsubstituted 
pyrrolyldiketohexenoic esters and para-benzylsubstituted pyrrolyldiketohexenoic 
acids, the inhibitory activity are not well correlated with the nature of substituent. 
The modifications brought to disubstituted-N-benzyl-pyrrolyldiketohexenoic esters 
and acids do not give the whole picture for the structure-activity relationships (SAR), 
because substituents with differents electron effects and/or polarity was not bound in 
every position (Table 4). At this time are take into consideration chloro, fluoro and 
methyl groups in 2,4- and 3,5-disubstitution and chloro and fluoro groups in 2,6-
disubstitution. Only fluorine atom was also bound in 2,3- and 3,4-positions.  
 
Table 3. Inhibition of RNase H, enzymatic activities, cell activity, citotoxicity and 
selective index of compound 35a-r and 36a-q.  
 
Cpd R2 R3 R4 X IC50 (µM) 
RHa 
EC50 (µM)b Cititoxicityc SId 
35a H H H Et - 0.25 >50 >200 
36a H H H H 15 0.35 >50 >142 
35b Cl H H Et 9.8 3.00 >50 >16 
36b Cl H H H 5.0 1.3 >50 >38 
35c CN H H Et 32 4.50 32 >7 
36c CN H H H 6 21.00 >50 >2 
35d F H H Et 6.3 0.33 >50 >152 
36d F H H H 6.4 0.35 >50 >142 
35e CH3 H H Et 3.0 1.4 >50 >35 
36e CH3 H H H 26 3.7 >50 >13 
35f OC2H5 H H Et > 100 (56%) 0.6 40 66.6 
36f OC2H5 H H H 64 0.055  >50 >909 
35g OCH3 H H Et > 100 (55%) 0.2 46 124 
36g OCH3 H H H 16 0.057 >50 >877 
35h H Cl H Et 19 0.79 >50 >63 
36h H Cl H H 9 11.00 >50 >4 
35i H CN H Et 5 7.1 >50 >7 
36i H CN H H 5 >50 >50 - 
35j H F H Et 9.0 2.2 >50 >21 
36j H F H H 14 3.80 >50 >13 
35k H Me H Et 9.6 2.8 >50 >18 
36k H Me H H 4.6 1.9 >50 >26 
35l H OCH3 H Et 20 0.35 >50 >142 
36l H OCH3 H H > 100 (69%) 0.61 >50 >82 
35m H H Cl Et 8.0 26.3 >50 >2 
36m H H Cl H 5.0 >50 >50 - 
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35n H H CN Et 8.0 >50 >50 - 
36n H H CN H 6.0 8.00 >50 >6 
35o H H F Et 13.0 <0.2 >50 >250 
36o H H F H 2.5 0.63 >50 >80 
35p H H CH3 Et 7.3 17.4 >50 >2 
36p H H CH3 H 17.0 >50 >50 - 
35q H H OCH3 Et 6.7 >50 >50 - 
36q H H OCH3 H 3.0 17.4 >50 >2 
35r H H NO2 Et 12.0    
a = compound concentrations neaded for reduce to 50% the activity of RnaseH; 
b = effective concentration 50% on HIV-1 infected cell; 
c = citotoxic concentration 50%; 
d = selective index = CC50/EC50; 
 
 
Table 4. Inhibition of RNase H, enzymatic activities, cell activity, citotoxicity and 
selective index of compound 37a-k and 38a-k.  
 
a = compound concentrations neaded for reduce to 50% the activity of RnaseH; 
b = effective concentration 50% on HIV-1 infected cell; 
c = citotoxic concentration 50%; 
d = selective index = CC50/EC50; 
 
 
Table 5. Inhibition of IN (ST) of compound 35a-r and 36a-q. 
 
Cpd R2 R3 R4 X IC50 (µM) 
INa 
35a H H H Et 15 
36a H H H H 0.09 
35b Cl H H Et 8.0 
Cpd R2 R3 R4 R5 R6 X IC50 (µM) 
RHa 
EC50 (µM)b Cititoxicityc SId 
37a F F H H H Et 8 <0.2 >50 >250 
38a F F H H H H 6 0.39 >50 >128 
37b Cl H Cl H H Et 9 >50 38 - 
38b Cl H Cl H H H 7 16.2 >50 >2 
37c F H F H H Et 19 <0.2 50 >250 
38c F H F H H H 10 0.5 >50 >100 
37d CH3 H CH3 H H Et 13 2.5 >50 >20 
38d CH3 H CH3 H H H 100 17 30 - 
37e F H H F H Et 9 0.81 >50 >60 
38e F H H F H H 5 0.93 >50 >54 
37f Cl H H H Cl Et 22 2.5 27 - 
38f Cl H H H Cl H 28 1.4 42 16 
37g F H H H F Et 19 0.095 >50 >526 
38g F H H H F H 50 0.022 >50 >2273 
37h H F F H H Et 3 2 >50 >25 
38h H F F H H H 86 0.046 >50 >1087 
37i H Cl H Cl H Et - 3 >50 >16.6 
38i H Cl H Cl H H 30 30.00 >50 >1.7 
37j H F H F H Et 5 3.9 >50 >7 
38j H F H F H H 14 1.7 22 >10 
37k H CH3 H CH3 H Et 6 11.00  >50 >4 
38k H CH3 H CH3 H H 16 5.6 >50 >8 
 100 
36b Cl H H H 4.0 
35c CN H H Et 9.00 
36c CN H H H 6 
35d F H H Et 0.98 
36d F H H H 0.98 
35e CH3 H H Et 32 
36e CH3 H H H 0.17 
35f OC2H5 H H Et 12 
36f OC2H5 H H H 0.31 
35g OCH3 H H Et 23 
36g OCH3 H H H 0.53 
35h H Cl H Et 6 
36h H Cl H H 0.31 
35i H CN H Et - 
36i H CN H H 0.75 
35j H F H Et 11 
36j H F H H 0.92 
35k H Me H Et 8.0 
36k H Me H H 1.3 
35l H OCH3 H Et 60 
36l H OCH3 H H 0.49 
35m H H Cl Et 42 
36m H H Cl H >4.1 
35n H H CN Et >111 
36n H H CN H 1.7 
35o H H F Et 98 
36o H H F H 0.026 
35p H H CH3 Et >111 
36p H H CH3 H 1.2 
35q H H NO2 Et - 
35r H H OCH3 Et 110 
36r H H OCH3 H 4.1 
a = inhibitory concentrations 50% on ST determined by a dose-response curve. 
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Table 6. Inhibition of IN of compound 37a-k and 38a-k. 
 
 
Cpd R2 R3 R4 R5 R6 X IC50 (µM) 
INa 
37a F F H H H Et 0.53 
38a F F H H H H 0.059 
37b Cl H Cl H H Et >111 
38b Cl H Cl H H H 4.9 
37c F H F H H Et 1.00 
38c F H F H H H 0.042 
37d CH3 H CH3 H H Et >111 
38d CH3 H CH3 H H H 4.40 
37e F H H F H Et 0.45 
38e F H H F H H 0.052 
37f Cl H H H Cl Et 1.70 
38f Cl H H H Cl H 0.17 
37g F H H H F Et 4.00 
38g F H H H F H 0.15 
37h H F F H H Et 0.60 
38h H F F H H H 1.60 
37i H Cl H Cl H Et 8.0 
38i H Cl H Cl H H 0.97 
37j H F H F H Et 0.49 
38j H F H F H H 1.2 
37k H CH3 H CH3 H Et 19 
38k H CH3 H CH3 H H 1.6 
a = inhibitory concentrations 50% on ST determined by a dose-response curve. 
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2.3.2 Conclusion 
 
The high incidence of resistance in therapy-experienced and newly infected patients 
and the adverse effects of the existing treatments underscore the need for new HIV-1 
inhibitors. The RT polymerase and RNase H activities as well as the IN 3’-end 
processing and strand transfer activities all require divalent cations and are essential 
for viral replication. While several inhibitors of RT polymerase activity are in the 
clinic and inhibitors of IN strand transfer activity have been tested in clinical trials, 
RNase H inhibitors are only at the earlier steps of the drug discovery pipeline.  
The DKA represents a significant class of RNase H inhibitors of HIV-1. Infact these 
compound are able to chelate divalent metal ions which are presented in the active 
site of RNase H function. The idea of the possible activity of DKA on RNase H 
function born from the known activity of these compounds on IN enzyme of HIV-1, 
which belonges to the same enzymatic class of RNase H enzyme, the superfamily of 
polynucleotidyl transferases within high similarity in the catalytic site. Infact, in the 
active site of both enzyme are presented two metal ions, such as Mg2+ and the 
chelation of these bring to an inhibition of the catalytic activity. In in vitro test the 
α,γ-diketoacid mojety has dimonstred the ability to compete for the bond to the 
active site with native substrate because are able to form a ligand-metal-enzyme 
complex. 
The work presented in this second chapter reguards the designed, synthesis and 
biological evaluation of new pyrrolyldiketohexenoic esters and acids 35a-r, 36a-q 
37a-k and 38a-k, in own inhibitory activity on RT and IN of HIV-1, starting from 
compound 34 that represent our lead compoumd. Compounds 35e, 36o and 37h are 
the most active synthesized, more then lead compound (32 or 35o), but only 
compound 35e shows a selectivity on RNase H.  
From these initial data, the optimization of the pyrrolyl-derivatives structure is the 
base for future studies to develop more potent and selective inhibitors of RNase H 
function. 
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2.3.3 Experimental section 
 
Chemistry 
Melting points were determined with a Büchi 530 capillary apparatus and are 
uncorrected. Infrared (IR) spectra were recorded on a Perkin-Elmer Spectrum-one 
spectrophotometer. 1H NMR spectra were recorded on a bruker AC 400 
specrtometer. Merk silica gel 60 F254 plates were used for analytical TLC. Column 
chromatogrephies were performed on silica gel (Merck; 70-230 mesh) or alumina 
(Merck; 70-230 mesh). Concentration of solution after reactions and extractions 
involved the use of a rotary evaporator operating at reduced pressure of 
approximately 20 Torr. Analytical results agreed to within ±0.40% of the theoretical 
values. 
 
General procedure for the synthesis of N-[(phenyl)metyl]pyrrole-2-
carboxaldehyde 39a-r and 41a-k. A solution of pyrrole-2-carboxaldehyde (0.0092 
mol) in 20 mL of dry DMF was treated with K2CO3 (0.0147 mol). Than was added 
the appropriate benzyl alogenure (0.011 mol) and was stirred with bascular stirring in 
Büchi Syncore for 1 night at 110 °C. The solution was diluted with water and the 
solid that formed was filtered on flash vac. The solid was washed with water and 
light petroleum ether to give derivatives 39a-r and 41a-k. Chemical, physical, and 
analytical data of derivatives 39a-r and 41a-k are reported in Table 4.  
 
General procedure for the synthesis of 4-(pyrrol-3-yl)but-3-en-2-one 40a-r and 
42a-k. A solution of appropriate aldehyde 39a-r or 40a-k (0.0311 mol) in 105.7 mL 
of acetone was treated with 45.2 mL of NaOH 5 N and stirred at 50 °C for 2 night 
and then was treated with water. The mixture was extracted with ethyl acetate. The 
collected organic extract was washed with brine (three times), and dried, and the 
solvent was evaporated under reduced pressure to obtain pure derivatives 40a-r and 
42a-k. Chemical, physical, and analytical data of derivatives 40a-r and 42a-k are 
reported in Table 4.  
 
General procedure for the synthesis of Diketo Esters 35a-r and 37a-k. The 
appropriated acetyl derivative 40a-r or 42a-k (0.031 mol) and diethyl oxalate (0.062 
mol) were dissolved in 31 mL of dry THF and treated, under argon stream, with 
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NaOEt obtained by the dissolution of Na (0.063 mol) in 56.36 mL of absolute 
ethanol. The mixture was stirred at room temperature for 1 h 30 min, then was pured 
into n-hexane (704 mL). The collected precipitate was vigorously stirred for 30 min 
in 1 N HCl (704 mL). The solid that formed was filtered, washed with water and 
light petroleum ether and dried under IR lamp to efford the pure diketo ester 35a-r 
and 37a-k. Yield (%), melting point (°C), recrystallization solvent, IR, 1H NMR, and 
analytical data are reported for each of the following compounds. 
 
6-[1-(Phenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl ester (35a). 
68%; 79-81 °C; ligroina; IR: ν 3400 (OH), 1732 (COOC2H5), 1621 (CO) cm-1; 1H 
NMR (CDCl3): δ 1.38-1.45 (t, 3H, CH3), 4.33-4.43 (q, 2H, CH2), 5.27 (s, 2H, CH2), 
6.33-6.43 (m, 3H, pyrrole β, hexanoate C3-H and hexanoate C5-H), 6.90-6.97 (m, 
1H, pyrrole β), 7.11 (m, 1H, pyrrole α), 7.30-7.38 (m, 5H, benzene H), 7.64-7.72 (d, 
1H, Jt = 15.0, hexanoate C6-H). 
 
6-[1-(2-Chlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35b). 100%; 98-99 °C; ligroina; IR: ν 3400 (OH), 1720 (COOC2H5), 1600 
(CO) cm-1; 1H NMR (CDCl3): δ 1.35-1.38 (t, 3H, CH3), 4.34-4.40 (q, 2H, CH2), 5.33 
(s, 2H, CH2), 6.33-6.40 (m, 3H, pyrrole β, hexanoate C3-H and hexanoate C5-H), 
6.64 (m, 1H, pyrrole β), 6.85-6.92 (m, 2H, benzene H and pyrrole α), 7.13-7.27 (m, 
2H, benzene 2H), 7.44-7.48 (m, 1H, benzene H), 7.56-7.60 (d, 1H, Jt = 15.0, 
hexanoate C6-H). 
 
6-[1-(2-Cianophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35c). 80%; 179-180 °C; benzene/cyclohexane; IR: ν 3400 (OH), 2227 (CN), 
1746 (COOC2H5), 1578 (CO) cm-1; 1H NMR (CDCl3): δ 1.42-1.45 (t, 3H, CH3), 
4.38-4.43 (q, 2H, CH2), 5.52 (s, 2H, CH2), 6.41-6.46 (m, 3H, pyrrole β, hexanoate 
C3-H and hexanoate C5-H), 6.82-6.84 (d, 1H, benzene H), 6.94-6.95 (m, 1H, pyrrole 
β) 7.01-7.02 (m, 1H, pyrrole α), 7.44-7.48 (m, 1H, benzene H), 7.56-7.60 (m, 2H, 
benzene H and hexanoate C6-H), 7.77-7.79 (m, 1H, benzene H). 
 
6-[1-(2-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35d). 87%; 103-105 °C; benzene; IR: ν 3400 (OH), 1731 (COOC2H5), 1680 
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(CO) cm-1; 1H NMR (CDCl3): δ 1.41-1.46 (t, 3H, CH3), 4.38-4.44 (q, 2H, CH2), 5.34 
(s, 2H, CH2), 6.36-6.38 (t, 1H, pyrrole β), 6.41-6.46 (m, 2H, Jt = 15.2, hexanoate C5-
H and hexanoate C3-H), 6.86-6.92 (m, 2H, benzene 1H, pyrrole β), 7.00 (s, 1H, 
pyrrole α), 7.12-7.18 (m, 2H, benzene 2H), 7.32-7.37 (m, 1H benzene H), 7.71-7.75 
(d, 1H, Jt = 15.2, hexanoate C6-H). 
 
6-[1-(2-Methylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35e). 89%; 104-105 °C; benzene/cyclohexane; IR: ν 3400 (OH), 1720 
(COOC2H5), 1610 (CO) cm-1; 1H NMR (CDCl3): δ 1.41-1.46 (t, 3H, CH3), 2.36 (s, 
1H, CH3), 4.38-4.44 (q, 2H, CH2), 5.22 (s, 2H, CH2), 6.27-6.45 (m, 3H, Jt = 15.3, 
hexanoate C5-H, hexanoate C3-H and pyrrole β), 6.69-6.72 (m, 3H, benzene 1H, 
pyrrole α, β), 7.16-7.31 (m, 3H, benzene 3H), 7.61-7.69 (d, 1H, Jt = 15.3, hexanoate 
C6-H). 
 
6-[1-(2-Ethoxyphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35f). 85%; 73-75 °C; benzene/cyclohexane; IR: ν 3400 (OH), 1731 
(COOC2H5), 1680 (CO) cm-1; 1H NMR (CDCl3): δ 1.38-1.37 (t, 3H, CH3), 1.45-1.46 
(t, 3H, CH3), 4.11-4.13 (q, 2H, CH2), 4.33-4.37 (q, 2H, CH2), 5.25 (s, 2H, CH2), 
6.26-6.28 (t, 1H, pyrrole β), 6.33 (s, 1H, hexanoate C3-H), 6.33-6.37 (d, 1H, Jt = 
15.3, hexanoate C5-H), 6.83-6.89 (m, 3H, benzene 2H, pyrrole β), 6.97 (s, 1H, 
pyrrole α), 7.21-7.23 (d, 1H, benzene H), 7.71-7.74 (d, 1H, Jt = 15.4, hexanoate C6-
H). 
 
6-[1-(2-Methoxyphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35g). 100%; 116-118 °C; benzene/cyclohexane; IR: ν 3400 (OH), 1730 
(COOC2H5), 1620 (CO) cm-1; 1H NMR (CDCl3): δ 1.38-1.37 (t, 3H, CH3), 3.90 (s, 
3H, CH3), 4.31-4.37 (q, 2H, CH2), 5.21 (s, 2H, CH2), 6.26-6.28 (t, 1H, pyrrole β), 
6.32-6.36 (d, 1H, Jt = 15.3, hexanoate C5-H), 6.37 (s, 1H, hexanoate C3-H), 6.72-
6.74 (m, 1H, pyrrole β), 6.83-6.94 (m, 4H, benzene 2H, pyrrole β and pyrrole α), 
7.24-7.28 (m, 1H, benzene H), 7.72-7.76 (d, 1H, Jt = 15.4, hexanoate C6-H). 
 
6-[1-(3-Chlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35h). 75%; 93-95 °C; ligroina; IR: ν 3400 (OH), 1721 (COOC2H5), 1574 
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(CO) cm-1; 1H NMR (CDCl3): δ 1.34-1.41 (t, 3H, CH3), 4.29-4.40 (q, 2H, CH2), 5.21 
(s, 2H, CH2), 6.32-6.40 (m, 3H, pyrrole β, hexanoate C3-H and hexanoate C5-H), 
6.86-7.01 (m, 4H, benzene 2H and pyrrole α, β), 7.25-7.28 (m, 2H, benzene 2H), 
7.54-7.62 (d, 1H, Jt = 15.3 hexanoate C6-H). 
 
6-[1-(3-Cianophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35i). 83%; 105-106 °C; acetone; IR: ν 3400 (OH), 2227 (CN), 1746 
(COOC2H5), 1578 (CO) cm-1; 1H NMR (DMSO-d6): δ 1.80-1.84 (t, 3H, CH3), 4.77-
4.82 (q, 2H, CH2), 6.11 (s, 2H, CH2), 6.87 (m, 1H, pyrrole β), 6.92 (s, 1H, hexanoate 
C3-H), 7.13-7.17 (d, 1H, Jt = 15.5, hexanoate C5-H), 7.55 (m, 1H, pyrrole α), 7.18 
(s, 1H, pyrrole β) 7.95-8.12 (m, 3H, benzene 3H), 8.17-8.21 (m, 2H, benzene H, Jt = 
15.4 hexanoate C6-H). 
 
6-[1-(3-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35j). 76%; 84-86 °C; ligroina; IR: ν 3400 (OH), 1700 (COOC2H5), 1600 (CO) 
cm-1; 1H NMR (CDCl3): δ 1.35-1.38 (t, 3H, CH3), 4.30-4.36 (q, 2H, CH2), 5.25 (s, 
2H, CH2), 6.33-6.41 (m, 3H, pyrrole β, hexanoate C3-H and hexanoate C5-H), 6.71 
(s, 1H, pyrrole β), 6.82-7.06 (m, 4H, benzene 3H and pyrrole α), 7.27-7.38 (m, 1H, 
benzene H), 7.53-7.61 (d, 1H, Jt = 15.4 hexanoate C6-H). 
 
6-[1-(3-Methylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35k). 71%; 76-78 °C; cyclohexane; IR: ν 3400 (OH), 1700 (COOC2H5), 1590 
(CO) cm-1; 1H NMR (CDCl3): δ 1.35-1.38 (t, 3H, CH3), 2.32 (s, 3H, CH3),  4.30-4.36 
(q, 2H, CH2), 5.19 (s, 2H, CH2), 6.32-6.40 (m, 3H, pyrrole β, hexanoate C3-H and 
hexanoate C5-H), 6.38-7.26 (m, 6H, benzene 4 H, pyrrole α, β), 7.61-7.65 (d, 1H, Jt 
= 15.3 hexanoate C6-H). 
 
6-[1-(3-Methoxyphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35l). 100%; 80-82 °C; ligroina; IR: ν 3400 (OH), 1729 (COOC2H5), 1585 
(CO) cm-1; 1H NMR (CDCl3): δ 1.35-1.38 (t, 3H, CH3), 3.76 (s, 3H, CH3),  4.30-4.36 
(q, 2H, CH2), 5.20 (s, 2H, CH2), 6.30 (s, 1H, pyrrole β), 6.34-6.37 (m, 2H, hexanoate 
C3-H and hexanoate C5-H), 6.56-6.68 (m, 2H, benzene H), 6.80-6.85 (m, 2H, 
benzene H and pyrrole β), 6.92 (s, 1H, pyrrole α), 7.21-7.28 (m, 1H, benzene H), 
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7.61-7.65 (d, 1H, Jt = 15.3 hexanoate C6-H). 
 
6-[1-(4-Chlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35m). 60%; 134-136 °C; ligroina; IR: ν 3400 (OH), 1700 (COOC2H5), 1600 
(CO) cm-1; 1H NMR (CDCl3): δ 1.37-1.46 (t, 3H, CH3), 4.33-4.40 (q, 2H, CH2), 5.24 
(s, 2H, CH2), 6.35-6.43 (m, 3H, hexanoate C3-H, hexanoate C5-H and pyrrole β), 
6.88-7.04 (m, 4H, benzene 2H and pyrrole α, β), 7.30-7.36 (m, 2H, benzene 2H), 
7.58-7.66 (m, 1H, Jt = 15.4, hexanoate C6-H). 
 
6-[1-(4-Cianophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35n). 82%; 128-130 °C; ligroina; IR: ν 3400 (OH), 2227 (CN), 1746 
(COOC2H5), 1578 (CO) cm-1; 1H NMR (DMSO-d6): δ 1.80-1.84 (t, 3H, CH3), 4.77-
4.82 (q, 2H, CH2), 6.11 (s, 2H, CH2), 6.87 (m, 1H, pyrrole β), 6.92 (s, 1H, hexanoate 
C3-H), 7.13-7.17 (d, 1H, Jt = 15.5, hexanoate C5-H), 7.55 (m, 1H, pyrrole α), 7.18 
(s, 1H, pyrrole β), 7.95-8.12 (m, 3H, benzene H), 8.17-8.21 (m, 2H, benzene H, Jt = 
15.4, hexanoate C6-H). 
 
6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35o). 78%; 96-97 °C; ligroina; IR: ν 3400 (OH), 1698 (COOC2H5), 1605 (CO) 
cm-1; 1H NMR (CDCl3): δ 1.38-1.46 (t, 3H, CH3), 4.37-4.41 (q, 2H, CH2), 5.25 (s, 
2H, CH2), 6.36-6.44 (m, 3H, Jt = 15.5, pyrrole β, hexanoate C3-H, hexanoate C5-H), 
6.80 (m, 1H, pyrrole β), 6.96 (m, 1H, pyrrole α), 7.05-7.09 (m, 4H, benzene H), 
7.65-7.73 (d, 1H, Jt = 15.5, hexanoate C6-H). 
 
6-[1-(4-Methylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35p). 60%; 85-86 °C; n-hexane; IR: ν 3400 (OH), 1721 (COOC2H5), 1605 
(CO) cm-1; 1H NMR (CDCl3): δ 1.38-1.45 (t, 3H, CH3), 2.36 (s, 3H, CH3), 4.33-4.44 
(q, 2H, CH2), 5.23 (s, 2H, CH2), 6.32-6.43 (m, 3H, Jt = 15.4, pyrrole β, hexanoate 
C3-H, hexanoate C5-H), 6.90-6.96 (m, 2H, pyrrole α, β), 6.98-7.02 (d, 2H, benzene 
H), 7.16-7.20 (m, 2H, benzene H), 7.65-7.73 (d, 1H, Jt = 15.4, hexanoate C6-H). 
 
6-[1-(4-Methoxyphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35q). 64%; 84-86 °C; ethanol; IR: ν 3400 (OH), 1701 (COOC2H5), 1598 (CO) 
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cm-1; 1H NMR (CDCl3): δ 1.38-1.45 (t, 3H, CH3), 3.82 (s, 3H, CH3), 4.33-4.44 (q, 
2H, CH2), 5.20 (s, 2H, CH2), 6.32-6.43 (m, 3H, Jt = 15.4, pyrrole β, hexanoate C3-H, 
hexanoate C5-H), 6.86-7.08 (m, 6H, benzene 4H and pyrrole α, β), 7.67-7.75 (d, 1H, 
Jt = 15.4, hexanoate C6-H). 
 
6-[1-(4-Nitrophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (35r). 61%; 61-63 °C; ligroina; IR: ν 3400 (OH), 1700 (COOC2H5), 1580 (CO) 
cm-1; 1H NMR (CDCl3): δ 1.37-1.44 (t, 3H, CH3), 4.33-4.43 (q, 2H, CH2), 5.39 (s, 
2H, CH2), 6.37-6.45 (m, 3H, pyrrole β, hexanoate C3-H, hexanoate C5-H), 6.90-7.10 
(m, 2H, pyrrole α, β), 7.18-8.30 (m, 2H, benzene H), 7.50 (d, 1H, hexanoate C6-H), 
8.21-8.25 (m, 2H, benzene H). 
 
6-[1-(2,3-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (37a). 79%; 67-69 °C; acetone; IR: ν 3400 (OH), 1727 (COOC2H5), 1611 (CO) 
cm-1; 1H NMR (DMSO-d6): δ 1.79-1.81 (t, 3H, CH3), 4.76-4.78 (q, 2H, CH2), 6.05 
(s, 2H, CH2), 6.81-6.87 (m, 2H, pyrrole β and hexanoate C3-H), 7.11-7.26 (m, 2H, 
pyrrole α and Jt = 14.9 hexanoate C5-H), 7.48 (s, 1H, pyrrole β), 7.61-7.84 (m, 3H, 
benzene 3H), 8.19-8.27 (d, 1H, Jt = 14.9 hexanoate C6-H). 
 
6-[1-(2,4-Dichlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
ethyl ester (37b). 100%; 110-113 °C; benzene/cyclohexane; IR: ν 3400 (OH), 1773 
(COOC2H5), 1610 (CO) cm-1; 1H NMR (DMSO-d6): δ 1.28-1.31 (t, 3H, CH3), 4.22-
4.28 (q, 2H, CH2), 5.48 (s, 2H, CH2), 6.35-6.36 (m, 2H, pyrrole β and hexanoate C3-
H), 6.51-6.53 (d, 1H, benzene H), 6.76-6.78 (m, 1H, hexanoate C5-H), 7.02 (s, 1H, 
pyrrole β), 7.26 (s, 1H, pyrrole α) 7.41-7.47 (m, 2H, benzene H and hexanoate C6-
H), 7.74-7.75 d, 1H, benzene H). 
 
6-[1-(2,4-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (37c). 82%; 119-121 °C; ligroina; IR: ν 3400 (OH), 1737 (COOC2H5), 1601 
(CO) cm-1; 1H NMR (CDCl3): δ 1.42-1.48 (t, 3H, CH3), 4.38-4.40 (q, 2H, CH2), 5.29 
(s, 2H, CH2), 6.36-6.38 (m, 1H, pyrrole β), 6.41-6.46 (m, 2H, hexanoate C5-H and 
hexanoate C3-H), 6.85-6.99 (m, 5H, pyrrole α, pyrrole β and benzene 3H) 7.68-7.62 
(d, 1H, Jt = 15.27 hexanoate C6-H). 
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6-[1-(2,4-Dimethylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
ethyl ester (37d). 98%; 102-104 °C; benzene/cyclohexane; IR: ν 3400 (OH), 1747 
(COO C2H5), 1711 (CO) cm-1; 1H NMR (DMF): δ 1.42-1.46 (t, 3H, CH3), 2.33 (s, 
3H, CH3), 2.36 (s, 3H, CH3), 4.38-4.43 (q, 2H, CH2), 5.21 (s, 2H, CH2), 6.33-6.34 
(m, 1H, pyrrole β), 6.40-6.44 (m, 2H, Jt = 15.3 hexanoate C5-H and hexanoate C3-
H), 6.65-6.67 (d, 1H, benzene H), 6.81-6.82 (m, 1H, pyrrole β), 6.92-6.93 (m, 1H, 
pyrrole α), 7.00-7.02 (d, 1H, benzene H), 7.09 (s, 1H, benzene H), 7.68-7.72 (d, 1H, 
Jt = 15.3 hexanoate C6-H,), 12-18 (sb, 1H, COOH). 
 
6-[1-(2,5-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (37e). 82%; 84-85 °C; acetone; IR: ν 3400 (OH), 1724 (COOC2H5), 1618 (CO) 
cm-1; 1H NMR (DMSO-d6): δ 1.81-1.85 (t, 3H, CH3), 4.77-4.83 (q, 2H, CH2), 6.04 
(s, 2H, CH2), 6.86 (s, 1H, pyrrole β) 6.96 (s, 1H, hexanoate C3-H), 7.01-7.19 (m, 2H, 
pyrrole α and Jt = 15.3 hexanoate C5-H), 7.55 (s, 1H, pyrrole β), 7.64-7.78 (m, 3H, 
benzene 3H), 8.24-8.28 (d, 1H, Jt = 15.3 hexanoate C6-H). 
 
6-[1-(2,6-Dichlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
ethyl ester (37f). 69%; 146-148 °C; ligroina; IR: ν 3400 (OH), 1730 (COOC2H5), 
1578 (CO) cm-1; 1H NMR (CDCl3): δ 1.42-1.47 (t, 3H, CH3), 4.40-4.45 (q, 2H, CH2), 
5.51 (s, 2H, CH2), 6.26-6.28 (m, 1H, pyrrole β), 6.49-6.53 (m, 2H, Jt = 15.24 
hexanoate C5-H and hexanoate C3-H), 6.64 (s, 1H, pyrrole β), 6.89-6.90 (m, 1H, 
pyrrole α), 7.35-7.37 (t, 1H, benzene H), 7.45-7.47 (d, 2H, benzene 2H), 7.96-8.00 
(d, 1H, Jt = 15.24 hexanoate C6-H). 
 
6-[1-(2,6-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (37g). 50%; 125-127 °C; ligroina; IR: ν 3400 (OH), 1710 (COOC2H5), 1610 
(CO) cm-1; 1H NMR (CDCl3): δ 1.40-1.44 (t, 3H, CH3), 4.32-4.42 (q, 2H, CH2), 5.27 
(s, 2H, CH2), 6.25-6.26 (m, 1H, pyrrole β), 6.37-6-45 (d, 1H, Jt = 15.2 hexanoate C5-
H), 6.48 (s, 1H, hexanoate C3-H), 6.80 (m, 1H, pyrrole β), 6.91-7.01 (m, 3H, 
benzene 2H and pyrrole α), 7.27-7.40 (m, 1H, benzene H), 7.91-7.99 (d, 1H, Jt = 
15.2 hexanoate C6-H). 
 
 
 110 
6-[1-(3,4-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (37h). 60%; 74-75 °C; acetone; IR: ν 3400 (OH), 1737 (COOC2H5), 1633 (CO) 
cm-1; 1H NMR (DMSO-d6): δ 1.81-1.84 (t, 3H, CH3), 4.77-4.82 (q, 2H, CH2), 6.01 
(s, 2H, CH2), 6.84-6.85 (m, 1H, pyrrole β) 6.93 (s, 1H, hexanoate C3-H), 7.12-7.16 
(d, 1H, Jt = 15.4 hexanoate C5-H), 7.51-7.63 (m, 3H, benzene 2H and pyrrole β), 
7.78-7.86 (m, 2H, benzene H and pyrrole α) 8.18-8.22 (d, 1H, Jt = 15.4 hexanoate 
C6-H). 
 
6-[1-(3,5-Dichlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
ethyl ester (37i). 62%; 112-113 °C; ligroina; IR: ν 3400 (OH), 1723 (COOC2H5), 
1646 (CO) cm-1; 1H NMR (CDCl3): δ 1.35-1.42 (t, 3H, CH3), 4.33-4.37 (q, 2H, CH2), 
5.20 (s, 2H, CH2), 6.35-6.42 (m, 3H, pyrrole β, hexanoate C3-H and hexanoate C5-
H), 6.88-6.91 (m, 4H, benzene 3H and pyrrole β), 7.27-7.29 (m, 1H, pyrrole α), 
7.49-7.57 (d, 1H, Jt = 15.3 hexanoate C6-H).  
 
6-[1-(3,5-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl 
ester (37j). 58%; 75-78 °C; ligroina; IR: ν 3400 (OH), 1735 (COOC2H5), 1630 (CO) 
cm-1; 1H NMR (DMSO-d6): δ 1.42-1.48 (t, 3H, CH3), 4.37-4.43 (q, 2H, CH2), 5.28 
(s, 2H, CH2), 6.40-6.45 (m, 3H, pyrrole β, hexanoate C3-H and hexanoate C5-H), 
6.57-6.59 (m, 2H, pyrrole α and pyrrole β), 6.76-6.80 (m, 1H, benzene 1H), 6.92-
6.93 (m, 1H, benzene 1H), 6.97-6.98 (m, 1H, benzene H) 7.55-7.59 (d, 1H, Jt = 15.29 
hexanoate C6-H). 
 
6-[1-(3,5-Dimethylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
ethyl ester (37k). 46%; 99-101 °C; ligroina; IR: ν 3400 (OH), 1729 (COOC2H5), 
1616 (CO) cm-1; 1H NMR (CDCl3): δ 1.35-1.42 (t, 3H, CH3), 2.27 (s, 6H, CH3), 
4.31-4.37 (q, 2H, CH2), 5.14 (s, 2H, CH2), 6.29-6.32 (m, 1H, pyrrole β), 6.33-6.37 
(m, 2H, Jt = 15.1 hexanoate C5-H and hexanoate C3-H), 6.67 (s, 1H, benzene H), 
6.84-6.85 (m, 1H, pyrrole β), 6.90-6.91 (m, 2H, pyrrole α and benzene H), 7.64-7.67 
(d, 1H, Jt = 15.1 hexanoate C6-H), 12-18 (sb, 1H, COOH). 
 
General procedure for the synthesis of Diketo Acids 36a-q and 38a-k.  A mixture 
of 1 N NaOH (9.48 mL) and the appropriated ester 35a-q or 37a-k (0.0019 mol) in 
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1:1 THF-Methanol (9.32 mL) was stirred at room temperature for 30 min and then 
pured into crushed ice. The acquous mixture was treated with 1 N HCl until Ph 3 was 
reached, and extracted with ethyl acetate (three times). The collected organic extract 
was washed with brine (three times), and dried, and the solvent was evaporated under 
reduced pressure to give the pure diketo acids 36a-r and 38a-k. Yield (%), melting 
point (°C), recrystallization solvent, IR, 1H NMR, and analytical data are reported for 
each of the following compounds. 
 
6-[1-(Phenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36a). 68%; 146-
148 °C; toluene; IR: ν 3400 (OH), 1710 (COOH), 1598 (CO) cm-1; 1H NMR 
(DMSO-d6): δ 5.43 (s, 2H, CH2), 6.30-6.33 (m, 1H, pyrrole β), 6.45 (s, 1H, 
hexanoate C3-H), 6.58-6.67 (d, 1H, Jt = 15.4, hexanoate C5-H), 7.00-7.02 (m, 1H, 
pyrrole β), 7.08-7.12 (m, 1H, pyrrole α), 7.27-7.40 (m, 5H, benzene H), 7.61-7.79 (d, 
1H, Jt = 15.4, hexanoate C6-H). 
 
6-[1-(2-Chlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36b). 
61%; 157-159 °C; toluene; IR: ν 3400 (OH), 1688 (COOH), 1588 (CO) cm-1; 1H 
NMR (DMSO-d6): δ 5.47 (s, 2H, CH2), 6.30-6.34 (m, 1H, pyrrole β), 6.43 (s, 1H, 
hexanoate C3-H), 6.52-6.57 (m, 1H, pyrrole β), 6.65-6.70 (d, 1H, Jt = 15.5, 
hexanoate C5-H), 7.02-7.03 (s, 1H, pyrrole α), 7.25-7.32 (m, 3H, benzene 3H), 7.48-
7.58 (m, 2H, Jt = 15.5, benzene H and hexanoate C6-H). 
 
6-[1-(2-Cianophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36c). 
58%; 179-180 °C; isopropanole; IR: ν 3400 (OH), 2227 (CN), 1746 (COOH), 1578 
(CO) cm-1; 1H NMR (DMSO-d6): δ 5.71 (s, 2H, CH2), 6.39-6.46 (m, 1H, pyrrole β), 
6.53 (s, 1H, hexanoate C3-H), 6.72-6.76 (m, 2H, hexanoate C5-H and benzene H), 
7.09 (s, 1H, pyrrole β), 7.31 (s, 1H, pyrrole α), 7.50-7.55 (m, 1H, benzene H), 7.63-
7.71 (m, 2H, benzene H and hexanoate C6-H), 7.96-7.94 (m, 1H, benzene H). 
 
6-[1-(2-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36d). 
85%; 132-133 °C; benzene/toluene; IR: ν 3400 (OH), 1710 (COOH), 1590 (CO) cm-
1; 1H NMR (DMSO-d6): δ 5.46 (s, 2H, CH2), 6.30-6.34 (m, 1H, pyrrole β), 6.66-6.70 
(d, 1H, Jt = 16.02 hexanoate C5-H), 6.87-6.95 (m, 2H, hexanoate C3-H and pyrrole 
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β), 7.14-7.38 (m, 5H, benzene 4H and pyrrole α), 7.62-7.68 (m, 1H, Jt = 16.02, 
hexanoate C6-H). 
 
6-[1-(2-Methylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36e). 
95%; 146-147 °C; benzene/toluene; IR: ν 2923 (OH), 1700 (COOH), 1580 (CO) cm-
1; 1H NMR (DMSO-d6): δ 2.35 (s, 3H, CH3), 5.39 (s, 2H, CH2), 6.30-6.43 (m, 3H, 
pyrrole β and hexanoate C3-H), 6.62-6.69 (d, 1H, Jt = 15.2, hexanoate C5-H), 6.98 
(s, 1H, pyrrole β), 7.06-7.25 (m, 5H, benzene 4H and pyrrole α), 7.45-7.52 (d, 1H, Jt 
= 15.2, hexanoate C6-H), 12-18 (sb, 1H, COOH). 
 
6-[1-(2-Ethoxyphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36f). 
80%; 159-160 °C; toluene; IR: ν 2923 (OH), 1731 (COOH), 1601 (CO) cm-1; 1H 
NMR (DMSO-d6): δ 1.32-1.38 (t, 3H, CH3), 4.05-4.10 (q, 2H, CH2), 5.33 (s, 2H, 
CH2), 6.23-6.25 (t, 1H, pyrrole β), 6.42 (s, 1H, hexanoate C3-H), 6.60-6.64 (d, 1H, Jt 
= 15.4, hexanoate C5-H), 6.73-6.75 (d, 1H, benzene H), 6.80-6.85 (t, 1H, bezene H), 
6.95 (s, 1H, pyrrole β), 6.98-7.00 (d, 1H, benzene H), 7.20-7.23 (m, 2H, benzene H, 
pyrrole α), 7.64-7.68 (d, 1H, Jt = 15.4, hexanoate C6-H), 12-18 (sb, 1H, COOH). 
 
6-[1-(2-Methoxyphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36g). 
100%; 142-143 °C; toluene; IR: ν 3400 (OH), 1732 (COOH), 1601 (CO) cm-1; 1H 
NMR (DMSO-d6): δ 3.85 (s, 3H, CH3), 5.21 (s, 2H, CH2), 6.25 (m, 1H, pyrrole β), 
6.41 (s, 1H, hexanoate C3-H), 6.60-6.64 (d, 1H, Jt = 15.3, hexanoate C5-H), 6.69-
7.03 (m, 4H, benzene 3H and pyrrole β), 7.20-7.23 (m, 2H, benzene H, pyrrole α), 
7.64-7.68 (d,1H, Jt = 15.3, hexanoate C6-H), 12-18 (sb, 1H, COOH). 
 
6-[1-(3-Chlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36h). 
79%; 144-145 °C; toluene/cycloexane; IR: ν 3400 (OH), 1750 (COOH), 1610 (CO) 
cm-1; 1H NMR (DMSO-d6): δ 5.43 (s, 2H, CH2), 6.31 (m, 1H, pyrrole β), 6.38 (s, 1H, 
hexanoate C3-H), 6.62-6.70 (d, 1H, Jt = 15.2, hexanoate C5-H), 6.97-7.40 (m, 6H, 
benzene 4H and pyrrole β, α), 7.54-7.62 (d, 1H, Jt = 15.3, hexanoate C6-H), 12-18 
(sb, 1H, COOH). 
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6-[1-(3-Cianophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36i). 
44%; 126-128 °C; isopropanol/isopropylic ether; IR: ν 3400 (OH), 2231 (CN), 1717 
(COOH), 1582 (CO) cm-1; 1H NMR (DMSO-d6): δ 5.52 (s, 2H, CH2), 6.34 (m, 1H, 
pyrrole β), 6.46 (s, 1H, hexanoate C3-H), 6.66-6.71 (d, 1H, Jt = 15.3, hexanoate C5-
H), 7.01 (s, 1H, pyrrole β), 7.34-7.37 (m, 2H, benzene H), 7.52-7.66 (m, 3H, benzene 
H, Jt = 15.3 hexanoate C6-H, pyrrole α), 7.76-7.82 (d, 1H, benzene H), 12-18 (sb, 
1H, COOH). 
 
6-[1-(3-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36j). 
76%; 132-135 °C; toluene; IR: ν 3400 (OH), 1700 (COOH), 1600 (CO) cm-1; 1H 
NMR (DMSO-d6): δ 5.44 (s, 2H, CH2), 6.31 (m, 1H, pyrrole β), 6.40 (s, 1H, 
hexanoate C3-H), 6.60-6.68 (d, 1H, Jt ≈ 15, hexanoate C5-H), 7.79-7.19 (m, 4H, 
benzene 4H and pyrrole β), 7.26-7.47 (m, 2H, benzene 2H), 7.58-7.66 (d, 1H, Jt ≈ 15, 
hexanoate C6-H), 12-18 (sb, 1H, COOH). 
 
6-[1-(3-Methylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36k). 
95%; 121-123 °C; benzene/cyclohexane; IR: ν 3400 (OH), 1700 (COOH), 1590 
(CO) cm-1; 1H NMR (DMSO-d6): δ 2.49 (s, 3H, CH3), 5.33 (s, 2H, CH2), 6.28 (m, 
2H, hexanoate C3-H and pyrrole β), 6.63 (d, 1H, Jt = 15.7, hexanoate C5-H), 6.79-
7.34 (m, 6H, benzene 4H, pyrrole α, β), 7.58 (d, 1H, Jt = 15.7, hexanoate C6-H), 12-
18 (sb, 1H, COOH). 
 
6-[1-(3-Methoxyphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36l). 
100%; 145-147 °C; toluene; IR: ν 3400 (OH), 1713 (COOH), 1614 (CO) cm-1; 1H 
NMR (DMSO-d6): δ 3.70 (s, 3H, CH3), 5.36 (s, 2H, CH2), 6.27 (m, 1H, pyrrole β), 
6.43 (s, 1H, hexanoate C3-H), 6.60-6.64 (m, 3H, benzene 2H and hexanoate C5-H), 
6.82 (m, 1H, benzene H), 6.97 (m, 1H, pyrrole β), 7.22 (m, 1H, benzene 1H), 7.29 
(m, 1H, pyrrole α), 7.60-7.66 (d, 1H, Jt = 15.4, hexanoate C6-H), 12-18 (sb, 1H, 
COOH). 
 
6-[1-(4-Chlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36m). 
76%; 170-172 °C; benzene/toluene; IR: ν 3400 (OH), 1685 (COOH), 1548 (CO) cm-
1; 1H NMR (DMSO-d6): δ 5.44 (s, 2H, CH2), 6.36-6.38 (m, 1H, pyrrole β), 6.48 (s, 
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1H, hexanoate C3-H), 6.69-6.73 (d, 1H, Jt = 15.5, hexanoate C5-H), 7.05 (s, 1H, 
pyrrole β), 7.08-7.12 (m, 2H, benzene H), 7.32 (m, 1H, pyrrole α), 7.40-7.44 (m, 2H, 
benzene H), 7.55-7.65 (d, 1H, Jt = 15.5 hexanoate C6-H). 
  
6-[1-(4-Cianophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36n). 
93%; >250 °C; washed with isopropylic ether; IR: ν 3400 (OH), 2227 (CN), 1746 
(COOH), 1578 (CO) cm-1; 1H NMR (DMSO-d6): δ 5.59 (s, 2H, CH2), 6.36-6.38 (m, 
1H, pyrrole β), 6.48 (s, 1H, hexanoate C3-H), 6.69-6.73 (d, 1H, Jt = 15.4, hexanoate 
C5-H), 7.05 (s, 1H, pyrrole β), 7.22-7.24 (m, 2H, benzene H), 7.36 (m, 1H, pyrrole 
α), 7.58-7.62 (d, 1H, Jt = 15.4 hexanoate C6-H), 7.85-7.87 (m, 2H, benzene H,). 
 
6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36o). 
54%; 98-99 °C; benzene/toluene; IR: ν 3400 (OH), 1689 (COOH), 1598 (CO) cm-1; 
1H NMR (DMSO-d6): δ 5.38 (s, 2H, CH2), 6.25 (m, 2H, pyrrole β and hexanoate C3-
H), 6.58-6.66 (d, 1H, Jt = 15.6, hexanoate C5-H), 6.93-7.01 (m, 3H, benzene 2H and 
pyrrole β), 7.13-7.17 (d, 2H, benzene H), 7.26 (s, 1H, pyrrole α), 7.42-7.50 (d, 1H, Jt 
= 15.6, hexanoate C6-H,), 12-18 (sb, 1H, COOH). 
 
6-[1-(4-Methylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36p). 
72%; 149-151 °C; benzene/toluene; IR: ν 3400 (OH), 1705 (COOH), 1575 (CO) cm-
1; 1H NMR (DMSO-d6): δ 2.27 (s, 3H, CH3), 5.34 (s, 2H, CH2), 6.27 (m, H, pyrrole 
β) 6.37 (d, 1H, hexanoate C5-H), 6.55 (s, 1H, hexanoate C3-H), 6.90 (m, 1H, pyrrole 
β), 7.13-7.24 (m, 5H, benzene 4H and pyrrole α), 7.42-7.50 (d, 1H, Jt = 15.6, 
hexanoate C6-H,), 12-18 (sb, 1H, COOH). 
 
6-[1-(4-Methoxyphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid (36q). 
64%; >300 °C; washed with isopropylic ether; IR: ν 3400 (OH), 1698 (COOH), 
1600 (CO) cm-1; 1H NMR (DMSO-d6): δ 3.73 (s, 3H, CH3), 5.34 (s, 2H, CH2), 6.27-
6.40 (m, 2H, pyrrole β and hexanoate C3-H) 6.62-6.68 (d, 1H, hexanoate C5-H), 
6.89-6.93 (m, 3H, benzene 2H and pyrrole β), 7.05-7.09 (d, 2H, benzene H), 7.28 (s, 
1H, pyrrole α), 7.62-7.68 (d, 1H, Jt = 15.6, hexanoate C6-H,), 12-18 (sb, 1H, 
COOH). 
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6-[1-(2,3-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38a). 47%; 147-148 °C; isopropanole/n-hexane; IR: ν 3400 (OH), 1758 (COOH), 
1630 (CO) cm-1; 1H NMR (DMSO-d6): δ 5.54 (s, 2H, CH2), 6.35 (m, 1H, pyrrole β), 
6.50 (s, 1H, hexanoate C3-H), 6.69-6.75 (m, 2H, pyrrole β and hexanoate C5-H), 
7.03 (s, 1H, pyrrole α), 7.19-7.45 (m, 3H, benzene 3H), 7.70-7.73 (d, 1H, Jt = 15.3, 
hexanoate C6-H,), 12-18 (sb, 1H, COOH). 
 
6-[1-(2,4-Dichlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38b). 68%; 145-146 °C; toluen; IR: ν 3400 (OH), 1758 (COOH), 1630 (CO) cm-1; 
1H NMR (DMSO-d6): δ 5.51 (s, 2H, CH2), 6.36-6.38 (m, 1H, pyrrole β), 6.47 (s, 1H, 
hexanoate C3-H), 6.55-6.57 (m, 1H, benzene H), 6.61-6.65 (d, 1H, Jt = 15.32 
hexanoate C5-H), 7.07 (s, 1H, pyrrole β), 7.29 (s, 1H, pyrrole α), 7.41-7.44 (m, 1H, 
benzene 1H), 7.55-7.59 (d, 1H, Jt = 15.32 hexanoate C6-H and), 7.73-7.74 (d, 1H, 
benzene 1H), 12-18 (sb, 1H, COOH).  
 
6-[1-(2,4-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38c). 67%; 130-132 °C; ethyl acetate; IR: ν 3400 (OH), 1758 (COOH), 1630 (CO) 
cm-1; 1H NMR (DMSO-d6): δ 5.46 (s, 2H, CH2), 6.31-6.32 (m, 1H, pyrrole β), 6.50 
(s, 1H, hexanoate C3-H), 6.70-6.74 (d, 1H, Jt = 13.68 and hexanoate C5-H), 6.97-
7.03 (m, 2H, pyrrole β and benzene H), 7.08-7.13 (m, 1H, benzene H) 7.28-7.37 (m, 
2H, pyrrole α and benzene H), 7.67-7.72 (d, 1H, Jt = 13.68 hexanoate C6-H,), 12-18 
(sb, 1H, COOH). 
 
6-[1-(2,4-Dimethylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38d). 59%; 151-153°C; toluene; IR: ν 3400 (OH), 1747 (COOH), 1711 (CO) cm-1; 
1H NMR (DMF): δ 2.47 (s, 3H, CH3), 2.57 (s, 3H, CH3), 5.68 (s, 2H, CH2), 6.55-
6.57 (m, 1H, pyrrole β), 6.69-6.73 (m, 2H, benzene H and hexanoate C3-H), 6.93-
6.97 (d, 1H, Jt = 15.7 hexanoate C5-H), 7.16-7.18 (d, 1H, benzene H), 7.28 (s, 1H, 
benzene H), 7.33 (s, 1H, pyrrole β), 7.42 (s, 1H pyrrole α), 7.92-7.96 (d, 1H, Jt = 
15.7 hexanoate C6-H,), 12-18 (sb, 1H, COOH). 
 
6-[1-(2,5-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38e). 51%; 141-143 °C; toluene/n-hexane; IR: ν 3400 (OH), 1747 (COOH), 1711 
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(CO) cm-1; 1H NMR (DMSO-d6): δ 5.50 (s, 2H, CH2), 6.34-6.37 (m, 1H, pyrrole β), 
6.51 (s, 1H, hexanoate C3-H), 6.68-6.77 (m, 2H, pyrrole β and hexanoate C5-H), 
7.04 (s, 1H, pyrrole α), 7.21-7.39 (m, 3H, benzene 3H), 7.70-7.74 (d, 1H, Jt = 15.2 
hexanoate C6-H,), 12-18 (sb, 1H, COOH). 
 
6-[1-(2,6-Dichlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38f). 84%; 132-134 °C; toluene; IR: ν 3400 (OH), 1758 (COOH), 1630 (CO) cm-1; 
1H NMR (DMSO-d6): δ 5.55 (s, 2H, CH2), 6.21-6.25 (m, 1H, pyrrole β), 6.61 (s, 1H, 
hexanoate C3-H), 6.67 (s, 1H, pyrrole β), 6.79-6.83 (d, 1H, Jt = 15.7 hexanoate C5-
H), 7.01 (s, 1H, pyrrole α), 7.50-7.54 (m, 1H, benzene H), 7.63-7.65 (m, 2H, 
benzene 2H), 7.93-7.96 (d, 1H, Jt = 15.7 hexanoate C6-H), 12-18 (sb, 1H, COOH).  
 
6-[1-(2,6-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38g). 64%; 182-183 °C; toluene; IR: ν 3400 (OH), 1720 (COOH), 1610 (CO) cm-1; 
1H NMR (DMSO-d6): δ 5.40 (s, 2H, CH2), 6.20-6.24 (m, 1H, pyrrole β), 6.50 (s, 1H, 
hexanoate C3-H), 6.68-72 (d, 1H, Jt = 15.4 hexanoate C5-H), 6.91-6.92 (m, 1H, 
pyrrole β), 7.10-7.20 (m, 2H, pyrrole α and benzene H), 7.41-7.49 (m, 1H, benzene 
H), 7.83-7.91 (d, 1H, Jt = 15.4 hexanoate C6-H and), 12-18 (sb, 1H, COOH).  
 
6-[1-(3,4-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38h). 100%; >270 °C; DMF/H2O; IR: ν 3400 (OH), 1758 (COOH), 1630 (CO) cm-
1; 1H NMR (DMSO-d6): δ 5.38 (s, 2H, CH2), 5.80 (s, 1H, pyrrole β), 6.30 (s, 1H, 
hexanoate C3-H), 6.53 (m, 1H, hexanoate C5-H), 6.80-6.90 (m, 2H, pyrrole β and 
benzene H), 7.14-7.60 (m, 4H, benzene 2H, hexanoate C6-H and pyrrole α), 12-18 
(sb, 1H, COOH).  
 
6-[1-(3,5-Dichlorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38i). 95%; >300 °C; toluene/cyclohexane; IR: ν 3400 (OH), 1743 (COOH), 1521 
(CO) cm-1; 1H NMR (DMSO-d6): δ 5.38 (s, 2H, CH2), 6.24 (s, 1H, pyrrole β), 6.50-
6.58 (m, 1H, hexanoate C5-H), 6.33 (s, 1H, hexanoate C3-H), 7.02-7.35 (m, 5H, 
benzene 3H, pyrrole β and hexanoate C6-H), 7.50 (s, 1H, pyrrole α), 12-18 (sb, 1H, 
COOH). 
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6-[1-(3,5-Difluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38j). 60%; 146-149 °C; washed with ethanol; IR: ν 3400 (OH), 1712 (COOH), 1595 
(CO) cm-1; 1H NMR (DMSO-d6): δ 6.29 (s, 2H, CH2), 6.36 (s, 1H, pyrrole β), 6.47 
(s, 1H, hexanoate C3-H), 6.70-6.78 (m, 3H, benzene 2H and hexanoate C5-H), 7.03 
(s, 1H, pyrrole β), 7.18-7.22 (m, 1H, benzene 1H), 7.35 (s, 1H, pyrrole α), 7.59-7.62 
(d, 1H, hexanoate C6-H and), 12-18 (sb, 1H, COOH). 
 
6-[1-(3,5-Dimethylphenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid 
(38k). 78%; 145-147 °C; benzene; IR: ν 3400 (OH), 1713 (COOH), 1608 (CO) cm-1; 
1H NMR (DMF): δ 2.18 (s, 6H, CH3), 5.29 (s, 2H, CH2), 6.25-6.27 (m, 1H, pyrrole 
β), 6.44 (s, 1H, hexanoate C3-H), 6.59-6.63 (d, 1H, Jt = 15.4 hexanoate C5-H), 6.68 
(s, 1H, benzene H),6.86 (s, 1H, pyrrole β), 6.95-6.96 (d, 1H, benzene H), 7.26 (s, 1H, 
pyrrole α), 7.59-7.63 (d, 1H, Jt = 15.4 hexanoate C6-H,), 12-18 (sb, 1H, COOH). 
In the table 4 are reported the chemical-physical characteristic of the syntetic 
intermediete 39a-r, 40a-r, 41a-k, and 42a-k. 
 
Table 4. Chemical, Physical, and Analytical Data of Derivatives 39a-r, 40a-r, 41a-
k, and 42a-k 
Cpd R2 R3 R4 R5 R6 mp (°C) 
recryst 
solventa 
Yeld 
(%) 
39a H H H H H oil oil 76 
39b Cl H H H H 81-82 b 100 
39c CN H H H H 138-140  85 
39d F H H H H 34-36 b 100 
39e CH3 H H H H 38-40 b 100 
39f OC2H5 H H H H oil oil 71 
39g OCH3 H H H H 56-58 b 100 
39h H Cl H H H oil oil 100 
39i H CN H H H 98-100 c 70 
39j H F H H H oil oil 100 
39k H CH3 H H H oil oil 82 
39l H OCH3 H H H oil oil 69 
39m H H Cl H H 78-80 b 96 
39n H H CN H H - - 100 
39o H H F H H oil oil 65 
39p H H CH3 H H 49-51 b 86 
39q H H OCH3 H H oil oil 77 
39r H H NO2 H H 110-112 - 52 
40a H H H H H oil oil 100 
40b Cl H H H H 54-56 a 85 
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40c CN H H H H 87-89 c 75 
40d F H H H H 46-47 a 92 
40e CH3 H H H H 76-77 a 58 
40f OC2H5 H H H H 81-82 a 47 
40g OCH3 H H H H 120-122 a 37 
40h H Cl H H H 78-80 a 63 
40i H CN H H H oil oil 68 
40j H F H H H oil oil 69 
40k H CH3 H H H 65-67 a 81 
40l H OCH3 H H H 50-52 b 66 
40m H H Cl H H oil oil 100 
40n H H CN H H 95-98 c 32 
40o H H F H H oil oil 83 
40p H H CH3 H H oil oil 87 
40q H H OCH3 H H oil oil 100 
40r H H NO2 H H 90-92 - 32 
41a F F H H H oil oil 71 
41b Cl H Cl H H 75-77 c 100 
41c F H F H H 40-41 b 100 
41d CH3 H CH3 H H oil oil 98 
41e F H H F H 50-52 b 87 
41f Cl H H H Cl 70-72 b 72 
41g F H H H F oil oil 87 
41h H F F H H 47-49 b 69 
41i H Cl H Cl H 61-63 b 100 
41j H F H F H 56-58 b 100 
41k H CH3 H CH3 H oil oil 52 
42a F F H H H oil oil 81 
42b Cl H Cl H H 88-90 c 58 
42c F H F H H 63-65 c 28 
42d CH3 H CH3 H H 79-80 c 84 
42e F H H F H oil oil 72 
42f Cl H H H Cl 89-90 c 47 
42g F H H H F 86-88 a 100 
42h H F F H H oil oil 87 
42i H Cl H Cl H 75-77 a 85 
42j H F H F H 62-64 c 35 
42k H CH3 H CH3 H 76-78 b 72 
a Recrystallization solvent: (a) ligroina; (b) n-hexane; (c) cyclohexan 
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Biology  
HIV-1 rRT purification 
Heterodimeric rRT was expressed essentially as described. Briefly, E. coli strain 
M15 containing the P6HRT-prot vector were grown up to an OD600 of 0.8 and 
induced with IPTG 1.7 mM for 5 h. Protein purification was carried out with an 
AKTA-prime FPLC (Amersham Biosciences) with a Ni2+-sepharose 
chromatography. Briefly, cell pellets were resuspended in Lyses buffer (20mM 
Hepes pH 7.5, 0.5 M NaCl, 5mM β-mercaptoethanol, 5mM imidazole, 0.4 mg/mL 
lysozime), incubated on ice for 20 min, sonicated and centrifuged at 30,000 X g for 1 
h. The supernatant was applied to a His-binding resin column and washed thoroughly 
withWash buffer (20 mM Hepes pH 7.5, 0.3 M NaCl, 5 mM β-mercaptoethanol, 60 
mM imidazole, 10% glycerol). rRT was gradient-eluted with Elute buffer (Wash 
buffer with 0.5 M imidazole), fractions were collected and enzyme activity was 
assessed; protein purity was checked by SDS-PAGE and found to be higher than 
90%. Enzyme containing fractions were pooled and loaded onto a Hi-Trap desalting 
column equilibrated with Storage buffer (50 mM Tris–Hcl pH 7.0, 25 mM NaCl, 1 
mM EDTA, 10% glycerol). Fractions were collected, catalytic activities and protein 
concentration were determined. Enzyme-containing fractions were pooled and 
aliquots were stored at −80 ◦C. 
 
RNase H polymerase-independent cleavage assay 
When the tC5U/p12 hybrid was used as reaction substrate the RNase H activity was 
measured as described. Briefly, the tC5U RNA oligonucleotide was labeled at its 5’-
end with [γ32P]-ATP and T4 polynucleotide kinase. The unincorporated [γ32P]-ATP 
was separated from the labeled RNA by running the sample through a G-25 
Sephadex quick spin column. The labeled tC5U oligonucleotide was annealed to the 
p12 DNA oligonucleotide in 0.1 M NaCl by heating at 80 °C and slowly cooling to 
room temperature overnight. RNase H activity was measured in 15 µL reaction 
volume containing 50 mM Tris–HCl pH 7.8, 6 mM MgCl2, 1 mM dithiothreitol 
(DTT), 80 mM KCl, 50 nM tC5U/p12 labeled hybrid, 2 nM rRT and different drug 
concentrations. The reaction mixture was incubated for 30 min at 37 °C and stopped 
by the addition of 7.5 µL of sample buffer (96% formamide, 20 mM EDTA, 0.08 % 
Bromophenol blue and 0.08 % Xylene cyanol). Samples were heated at 100 °C for 3 
 120 
min, and 10 µL of them were layered onto a denaturing 20 % polyacrylamide gel (7 
M urea, 0.09 M Tris–borate (pH 8.3), 2 m MEDTA, 20 % acrylamide) and run for 
1.5 h at 80 W. The gel was dried and reaction products were visualized and 
quantified by a Bio-Rad FX Phosphoimager. When the poly(dC)-[3H]poly(rG) 
hybridwas used as reaction substrate the RNaseH activitywas measured as described 
(Starnes and Cheng, 1989). Briefly, RNaseH activity was measured in 50 µL reaction 
volume containing the same reaction mixture as above with the exception of 4 nM 
poly(dC)-[3H]poly(rG) and 1 nM rRT. The reaction mixture was incubated for 30 
min at 37 °C and 40 µL aliquots were spotted on glass fiber filters (Whatman GF/A) 
and processed for determination of trichloroacetic acid-insoluble radioactivity. When 
AMV and E. coli RNase H activities were measured, the poly(dC)-[3H]poly(rG) 
hybrid was used as reaction substrate with the buffer conditions indicated by the 
manufacturer, and the trichloroacetic acidinsoluble radioactivity was determined as 
above. 
RNA-dependent DNA polymerase assay 
The RDDP activity of HIV-1 rRT was measured as described in 50 µL volume 
containing 50 mM Tris–HCl pH 7.8, 80 mM KCl, 6 mM MgCl2, 1 mM DTT, 0.1 
mg/mL bovine serum albumine, 0.3 O.D./mL poly(rC)-oligo(dG)12–18, 10 µM [3H]-
dGTP (1 Ci mmol−1). The reaction mixture was incubated for 30 min at 37 °C, 40 µL 
aliquots were spotted on glass fiber filters (Whatman GF/A) and processed for 
determination of trichloroacetic acid-insoluble radioactivity. 
HIV-1 replication assay 
Wt and resistant HIV-1 strains stock solutions had titers of (2–4.5) X 106 50% cell 
culture infectious dose (CCID50)/mL. Cytotoxicity evaluation was based on the 
viability of mock-infected MT-4 cells, as monitored by the 3-(4,5-dimethylthiazol-1-
yl)-2,5-diphenyltetrazolium bromide (MTT) method. Activity of the compounds 
against the HIV-1 multiplication in acutely infected cells was based on inhibition of 
virus-induced cytopathicity in MT-4 cells and was determined by the MTT method. 
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Third Chapter 
 
NS5B RNA-DEPENDENT RNA POLYMERASE OF HCV 
 
Due to the similarity of its genomic organization to that of pesti- and flaviviruses, 
HCV has been classified as one of three genera constituting the family Flaviviridae. 1 
Since the identification and molecular cloning of hepatitis C virus (HCV) in the late 
1980s, it has been estimated that more than 170 million people are infected with the 
virus. In approximately 80% of infections the virus is able to elude the body’s 
immune response and succeeds in establishing a chronic infection. 2 The number of 
individuals infected with HCV continues to increase and persistently infected 
persons are at risk of developing cirrhosis and hepatocellular carcinoma. 
HCV has a single-stranded positive sense, 9.6 kb RNA genome that is flanked at 
each terminus by a 5’ and 3’ non-translated region (NTR) and contains one long 
open reading frame that encodes a precursor polyprotein of about 3000 amino acids. 
3 Translation of the polyprotein is directed by the internal ribosome entry site (IRES) 
located within the 5’ end.  
The polyprotein is subsequently processed into both structural (core, envelope 1, 
envelope 2) and non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins 
by cellular and viral proteases. 4 Core protein is a highly basic protein that forms the 
nucleocapsid. The envelope proteins E1 and E2 are highly glycosylated 
transmembrane proteins that are non-covalently associated to form the viral 
envelope. Protein p7 is a highly hydrophobic polypeptide that forms hexamers and 
has been reported to have ion channel activity. NS2 is a cis-acting autoprotease that 
is essential for viral replication. NS2 catalyzes the cleavage of the polyprotein 
precursor at the NS2/NS3 junction, and also plays an essential role in virus assembly. 
NS3 is a bifunctional protein with serine protease activity in the N-terminus, which is 
responsible for cleavage at the NS3/NS4A, NS4A/NS4B, NS4b/NS5A and 
NS5A/NS5B sites, and NTPase/helicase activities in the C-terminus of the protein. 
The NS4A polypeptide functions as a cofactor for NS3 protease activity. NS4B was 
demonstrated to induce specific cellular membrane changes, creating a membranous 
web that serves as a scaffold for the formation of the viral replication complex. 
NS5A is a phosphoprotein with multiple functions and is essential for viral 
replication and assembly. NS5B catalyzes the synthesis of both minus-strand and 
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plus-strand RNA. 5 
The most attractive targets for future anti-HCV agents are those that specifically 
target the viral replication cycle (Figure 2): internal ribosome entry site (IRES) 
inhibitors, viral protease inhibitors and transcription (polymerase) inhibitors and 
virus assembly inhibitors.  
It is known that translation of HCV RNA is initiated by internal entry of the 50 non-
coding region or IRES into ribosomes in vitro. 6 IRES inhibitors are RNA structures 
that lead to inhibition of HCV polyprotein translation and includes anti-sense 
oligonucleotides (e.g., ISIS 14803; Isis Pharmaceuticals, Carlsbad, CA), small 
interfering RNAs (siRNA) and ribozymes. To date, the clinical experience with 
oligonucleotides has been disappointing, due to evidence of toxicity 7 and poor 
antiviral activity. The most promising recent advances have come in molecules that 
target the NS3/4A serine protease and the NS5B RNA-dependent RNA polymerase. 
The structural solution of the NS3/4A protease and the HCV NS5B polymerase and 
the development of a (sub)genomic replicon system have enabled the development 
and testing of HCV specific compounds. As other viral infections, it is widely 
recognized that combinations of drugs that act via different mechanisms are required 
to suppress the emergence of resistance effectively, and agents that inhibit the RNA 
polymerase NS5B are, therefore, of great research interest. 
 
3.1 Biology of NS5B polymerase enzyme 
3.1.1 Structure and function of NS5B polymerase enzyme  
HCV, like other (+)-strand RNA viruses, uses its viral genomic RNA as a template 
for both translation and generation of a complementary (-)-stranded RNA 
intermediate. The (-)-stranded RNA is then used as the template for the synthesis of 
molar excess of (+)-stranded progeny RNA molecules.  
A membrane-associated replicase enzyme complex consisting of virally encoded and 
host proteins is responsible for the replication of viral RNA. The catalytic subunit of 
the replicase complex is the HCV encoded non structural 5B protein (NS5B), which 
contains all the sequence motifs highly conserved among all the known RNA-
dependent RNA polymerases (RdRps). 8 By extension of studies from the HIV-1 and 
-2, where the reverse transcriptase is a primary target for effective antivirals, the 
HCV RdRp is considered an important target for drug development. 9 
The NS5B is an enzyme of 65 kDa and contains six conserved motifs designated A-
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F. The HCV RdRp has discernable fingers, palm and thumb subdomains. Anusual 
feature of this polymerase is that, due to the extensive interactions between the finger 
and thumb subdomains, the HCV RdRp has an encircled active site. 10 These 
contacts restrict the flexibility of each subdomains and between them. Structural 
studies with RdRp from the HCV genotype 2a indicate the presence of two 
conformations of the protein even in the absence of template RNA, where the key 
difference between the two forms is the relative orientation of the thumb domain in 
relation to fingers and palm domains. 11 Since both conformations lacked RNA, 
remains to be determined whether the template RNA will induce the same structural 
change. Another unusual feature of NS5B is a β-hairpin loop that protrudes into the 
active site located at the base of the palm subdomain. This 12 amino acid loop was 
suggested to interfere with binding to double stranded RNA due to steric hindrance. 
12 The poliovirus RdRp lacks a similar β-loop, a feature that may be related to the 
poliovirus RdRp normally directing genome replication with a protein-nucleotide 
primer. 13 It was suggested that the β-loop could be involved in positioning the 3' 
terminus of the viral RNA for correct initiation. 12 
The C-terminal region of NS5B also lines the RNA binding cleft in the active site. 
This region, which immediately precedes the C-terminal membrane anchorage 
domain, forms a hydrophobic pocket and interacts extensively with several important 
structural elements including the β-loop. 14 Deletions of up to 55 residues of the C-
terminal tail resulted in increased RdRp activity, suggesting a direct role for the C-
terminal tail in RNA synthesis activity and providing evidence for regulation at the 
active site. 15 
The active sites of HCV NS5B and HIV-1 RT are very similar and can be 
superimposed without significant steric clashes. The residues involved in nucleotidyl 
transfer are found in palm motifs A and C. Motif A harbors the metal binding residue 
D220 which is a part of conserved D-X4-D motif, while motif C has the conserved 
metal binding and nucleotidyl transfer residues D318 and D319.  
D225 within motif A, forms a H-bond with the ribose 2'-hydroxyl group of the 
nucleotidyl triphosphate natural substrate (NTP) and is thought to discriminate 
against the use of dNTPs. Crystal soaking experiments of HCV NS5B with 
ribonucleoside triphosphates (rNTPs) revealed several residues in the catalytic 
pocket that contact the triphosphates of rNTPs. These include R158, S367, R386, 
T390 and R394. 
 128 
Unfortunately, it was not possible to identify the base-interacting residues. Soaked 
NS5B crystals with GTP also revealed a low affinity GTP binding site on the surface 
of the protein. 16 This second site, which is apparently specific for GTP, lies between 
the fingers and thumb subdomains, approximately 30 Å away from the catalytic 
pocket. By virtue of its position and the requirement of higher GTP concentrations to 
saturate the pocket, it was suggested that it might play a regulatory role in RNA 
synthesis. 16 To date, any allosteric properties of this low affinity site in response to 
GTP has not been determined. 
 
3.1.2 Activity of NS5B polymerase 
The activity of NS5B polymerase can be synthesized as followed: 
• coupled of RNA template molucule and of NTD; 
• initiation; 
• elongation; 
• ending and release of template. 
The NS5B polymerase can begin the synthesis of a new molecule of RNA depending 
on three mechanisms: 
• primer-dipendent; 
• copy back; 
• de novo. 
The initiation primer-dependent is a method utilized by several viruses for a faithful 
and effective replication. In this case is a viral protein to act as a primer, to which the 
polymerase addes the NTD depending on the complementarity with the template. 
The copy-back mechanism is highlight in in vitro experiment for the lack of the RNA 
primer. The 3’-OH teminus of the template molecule is used as a primer for a 
replication process that lead to synthesis of a new double strand molecule. The de 
novo synthesis is highlight in in vitro experiment too.  
The synthesis of a new molecule of RNA started from the 3’ end of the genome by 
the utilization of NTP. The terminal cytidyne is responsible for the specificity in the 
entry of RNA template in the catalytic active site of the polymerase. Infact the steric 
hindrance in the binding pocket block the entrance of more voluminouse base like 
adenine and guanosine, and the electrostatic interaction do not favour the binding of 
uracil. Furthermore, the β-hairpin is able to correctly direct the RNA template, which 
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is caught in a vice like a grip into the catalytic active site. The hypitesis of the de 
novo mechanism is confemed by the tridimentional structure of NS5B in a complex 
with NTD. In the catalytic active site was been identified three different binding site 
for the NTD, called initiation site, elongation site, and interrogation site. The 
initiation phase of the replication of the viral genome is the more difficult phase, 
because the ending sequence responsable of the entry of the RNA template must be 
highly conserved in every replicative cycle. 10 
To the initiation follows the elongation, that is a rapid process which is repeated 
thousend times in the replication of the viral genome. This long time intervall allows 
the selective inhibition by the traditional HIV antiviral drugs, like AZT and 3TC. At 
the end of the elongation phase the new RNA molecule goes out from the catalytic 
active site of the polymerase. 17  
Polymerase require divalent metal ions for activity. RNA synthesis by NS5B is 
increased by 4-20 fold when Mn2+ is present in the reaction in comparison to a 
reaction with only Mg2+. However, other divalent metal ions such as Co2+, Cu2+, Ni2+ 
and Zn2+ did not support RdRp activity. 15 Recently it was shown that iron binds 
specifically to the Mg2+ binding site of NS5B and can inhibit RNA synthesis. 18 Mn2+ 
appears to more specifically contribute to de novo initiation by lowering the KM for 
GTP by about 30-fold. While the concentration of Mn2+ used in vitro is far higher 
than concentrations present in the cell, physiologically relevant Mn2+ levels can 
increase de novo initiation with GTP.  
Analysis of proteins with C-terminal deletions revealed that the C-terminus of the 
HCV RdRp plays a role in Mn2+ induced de novo initiation and can contribute to the 
suppression of primer extension. Spectroscopy examining the intrinsic tryptophan 
and tyrosine fluorescence of the HCV RdRp produced results consistent with the 
protein undergoing a conformational change in the presence of divalent metals. 15 
 
3.2 Inhibitors of NS5B polymerase 
In the past decade, intensive efforts have focused on the discovery of both 
nucleos(t)ide and non-nucleoside inhibitors of the HCV NS5B polymerase. These 
efforts have resulted in several promising agents advancing in clinical development.  
The crystal structure of the catalytic domain of N5SB (lacking the C-terminal 
membrane-anchoring region) has revealed several significant features. A helix at the 
tip of the fingers domain binds to a lipophilic pocket in the back of the thumb 
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domain; it is this interaction that is disrupted by inhibitors that bind at the thumb 
pocket I site. Two other notable features of the apo structure are the presence of a β-
hairpin from the thumb domain that reaches down into the palm domain, and the 
residual C-terminal strand that folds over the palm domain. Both of these features 
have to move to enable processive synthesis of RNA. Thumb pocket II inhibitors 
bind to a remote region of the thumb domain and are presumed to affect the 
flexibility of this region. Palm pocket I inhibitors bind to elements of the β-hairpin 
and the palm domain simultaneously. Palm pocket II inhibitors, the binding site of 
which overlaps partially with the palm pocket I site, do not interact directly with the 
β-hairpin, but occlude the region that would be occupied by the incoming nucleotide 
prior to ligation. Thus, the selectivity that is evident in non-nucleoside inhibitors 
(NNIs) for NS5B compared with other polymerases is understandable in the context 
of the unique structural features of NS5B. 19  
 
3.2.1 Nucleos(t)ide inhibitors 
The key residues in the HCV NS5B polymerase active site are conserved across 
genotypes, and replicon systems containing resistance mutations for nucleos(t)ide 
analogs demonstrate greatly reduced replication capacity, indicating a high barrier to 
resistance generation. 20 Nucleos(t)ide analogs served as the cornerstone of 
successful antiviral therapy for herpes viruses, HBV and HIV. Reflecting the success 
of these compounds, more then 20 distinct nucleos(t)ide agents have been approved 
by regulatory agencies globally. Nucleos(t)ide analogs may therefore play a critical 
role in virally targeted HCV combination therapy in the future. The major approved 
nucleos(t)ide analog antiviral compounds are endogenous 2'-deoxynucleos(t)ides, 
whereas the inhibition of the RNA-dependent RNA polymerase activity of HCV 
NS5B requires ribonucleos(t)ide analogs, which typically have a greater potential 
toxicity than 2'-deoxynucleos(t)ides and poorly defined mechanism(s) of toxicity. 
The explanation of the high preclinical and clinical problems, observed for the 
nucleos(t)ide class of compounds in the treatment of HCV infections, is the 
inadequate tolerability.  
Nucleos(t)ide analogs that directly target the viral polymerase have a unique 
pharmacology, and require phosphorylation to generate the triphosphate (TP) forms 
to demonstrate antiviral activity; therefore the activity of these compounds depend 
on successive interactions with the cellular enzymes involved in the regulation of 
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endogenous nucleotide pools for activation to their respective TP forms. The first 
phosphorylation step, catalyzed by nucleoside kinases and phosphotransferases, can 
be bypassed effectively by administration of a monophosphate (MP) prodrug. 21 The 
levels of the phosphorylated forms are regulated by nucleotidases and phosphatases. 
Although nucleos(t)ides can be catabolized by diverse pathways, cytochrome P450 
(CYP) enzymes have not been demonstrated to play a role in the degradation of these 
molecules, and many nucleos(t)ide analogs are unchanged when eliminated in the 
urine. 
In the late 1960s, approximately 20 years before the identification of HCV, a 
research group at Merck described several ribonucleoside analogs, including 
branched-chain sugar nucleosides with 2'-alkyl substitutions, as antiviral agents. 22 
2'-C-Methyl ribonucleos(t)ides were the first to be reported to have potent anti-HCV 
activity; 23 the EC50 value of 2'-C-(CH3)-adenosine in a replicon system was 0.3 µM, 
and 2'-C-(CH3)-ATP inhibited purified NS5B by non-obligate chain termination 
with an IC50 value of 1.9 µM. Idenix Pharmaceuticals Inc (formerly Novirio 
Pharmaceuticals Ltd) was the first company to advance a member of this class of 
compounds into clinical trials: a prodrug of NM 107 (2'-C-(CH3)-cytidine), 
valopicitabine dihydrochloride (NM 283) was investigated in phase II clinical trials, 
but this compound is no longer being developed.  
An investigation into various base modifications led to the identification of MK 
0608 (2'-C-(CH3)-7-deaza-adenosine), which is stable against adenosine deaminase 
(the enzyme that limits the oral bioavailability of 2'-C-(CH3)-A), maintains replicon 
activity, and was demonstrated to result in a 20-fold improvement in the IC50 of the 
TP form against NS5B, compared with 2'-C-(CH3)-A. 24 Administration of MK 
0608 (1 mg/kg qd, po) for 37 days to two chimpanzees infected with HCV caused a 
4.6-log reduction in viral load in one animal and reduced viral load to undetectable 
levels in the other. Although clinical development of MK 0608 did not progress 
beyond a phase I clinical trial, these preclinical results established the potential of 
nucleos(t)ide analogs as potent HCV inhibitors. 
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azido-cytidine), a nucleos(t)ide analogue lacking the 2'-C-(CH3) group, 
demonstrated selective replicon potency that was caused by non-obligate chain 
termination of NS5B activity. 25 In addition, analogues with a 2'-deoxy-2'-fluoro-2'-
C-(CH3) ribose sugar moiety have been demonstrated to have anti-HCV activity: the 
cytidine analog PSI 6130 exhibited the greatest potency, with an EC90 value of 5.4 
µM. 26 Medivir has described 4'-azido-2'-deoxy nucleoside analogs (eg, 2'-C-(CH3)-
2'-deoxy-4'-azido-cytidine analogs) 27 as potentially useful in the treatment of HCV 
infection. 
 
 
 
 
 
 
 
 
 
 
 
 
Adopting a tactic used successfully for acyclovir, a 3'-valyl ester prodrug of NM 
107, valopicitabine dihydrochloride (NM 283), was produced. It has demonstrated a 
markedly improved oral bioavailability compared with the original drug. This result 
was presumably attribute to the uptake by peptide transporters in the intestine. 28 
Capping the free hydroxyl groups of R 1479 and PSI 6130 as isobutyryl esters 
yielded the prodrugs Balapiravir (R 1626) and RG 7128, 29 respectively. Both 
compounds were advanced to clinical trials; Balapiravir is no longer being 
developed, while RG 7128 (EC50 = 1340 nm) is in phase II trials. 30 
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The initial phosphorylation step for most nucleoside analogs is limiting; thus, high 
doses of the prodrug agents were required to observe clinical efficacy.  
 
3.2.2 Non nucleoside inhibitors 
Several non nucleosedi inhibitors of the NS5B recently has been described and some 
of them are the object of preclinic and clinic study. Great interest is focused to 
compounds caracterized by a benzimidazole or benzothiadiazine based. 
The non nucleoside inhibitors can be distinguished in according to the binding site 
with the enzyme. Therefore, the non nucleoside inhibitors are classify into: 
• NS5B thumb pocket I inhibitors; 
• NS5B thumb pocket II inhibitors; 
• NS5B palm pocket I inhibitors; 
• NS5B palm pocket II inhibitors; 
• NS5B inhibitors binding the metal ions chelating site. 
 
NS5B thumb pocket I inhibitors: 
Ligands binding to the thumb pocket I site form a salt bridge with a guanidinium 
residue (Arg503) and several lipophilic interactions with neighboring regions of the 
protein (1, 2).  
 
            1                                     2 
The best characterized resistance mutations are variants of Pro495, which is exposed 
on the protein surface and forms van der Waals interactions with the inhibitors. This 
pocket has been widely studied by several pharmaceutical companies that carried out 
lead optimization researches, that led to a substitution of the early benzimidazole 
based (3, 4) with a more lipophilic indole core, and a introduction of a ring 
connecting the indole with the 2-aryl substituent; this changes led to improve cellular 
activity (5, 6). 31 
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             3 (Japan Tobacco)                                      4 (Boehringer Ingelheim Corp) 
 
                5 (IRBM)                                 6 (Bristol-Myers Squibb Co) 
 
NS5B thumb pocket II inhibitors: 
The thumb pocket II binding site is formed by changes in the conformation of 
residues Met423 and Leu497. Inhibitors occupy the resultant spaces with lipophilic 
substituents and form polar interactions with the backbone amides of Ser476 and 
Tyr477, either directly or via a bridging water molecule. Mutations at Met423 have 
been observed clinically. Initial research on inhibitors binding at this site was first 
reported at approximately the same time as research on thumb pocket I compounds 
and early leads also contained an acidic group with an adjacent lipophilic substituent, 
with stringent demands on geometry and shape. However, over time, several 
chemotypes have emerged that have reached clinical trials. The most advanced of 
these compounds is filibuvir (7, EC50 = 52nM), which is characterized by a weakly 
acidic dihydropyranone core. 33 
 
7 (Pfizer Inc.) 
IC50 = 52 nM 
 
NS5B palm pocket I inhibitors: 
Ligands for the palm pocket I binding site contain lipophilic substituents suitably 
disposed relative to a group that forms a polar interaction with the backbone amide 
of Tyr448. While many resistance mutations have been reported in in vitro studies, 
Met414, Tyr448, Gly554 and Cys316 are associated with clinical isolates from 
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patients treated with drugs binding at this site. 
An early series of palm pocket I inhibitors are the acyl pyrrolidines. Research on this 
series culminated in the identification of GSK-625433 (8), which reached phase I 
clinical trials. 
 
8 
Around the same period, a series of quinolone-benzothiadiazines (9) was discovered 
at GSK, and further details of the optimization program, which explored heterocyclic 
alternatives to phenyl rings in the original lead, have been described. 34  
 
9 
 
A common feature that greatly improves cellular potency and that has been broadly 
adopted is the incorporation of a hydrogen bond donor group (typically sulfonamide) 
at the 7-position of the benzothiadiazine or a related heterocycle. 
Further studies led to identification of tetramic acids (10) 35 and pyridinones (11) 36 
as core for NS5B palm pocket I inhibitors.  
                  
10 (La Roche)                                               11 (La Roche) 
 
 
NS5B palm pocket II inhibitors: 
The palm pocket II site is formed upon movement of the side chain of Arg200, 
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creating a space that can be filled by an aromatic substituent on a molecule also 
bearing a polar group to interact with the side chain hydroxyl of Ser365. The most 
notable historical example of NS5B palm pocket II inhibitors is HCV-796 (12), 
which demonstrated the potential for clinical efficacy via this mechanism of 
inhibition, but was subsequently withdrawn from development because of liver 
toxicity. Mutations at Cys316 have been observed clinically for resistance to this 
compound. 
 
12 
 
A research group at Roche has filed a patent application claiming more complicated 
2-substituents on the benzofuran core (13). 37  
 
13 
 
NS5B inhibitors binding the metal ions chelating site: 
During a screening of more then 200000 compounds, the Merck & co. has been 
identify the α,γ-diketoacids (DKA) (14) as reversible inhibitor, with submicromolar 
and selective activity against NS5B polymerase. 38 The bond of the DKAs to the 
active site of the RdRp is mediated by divalent cations, like Mg2+ or Mn2+, and 
occurred with a non competitive mechanism toward the RNA template molecule. 
Probably its activity is dued to a direct interaction of the diketo acid mojety with the 
divalent metal ions, which are essential for the activity of the polymerase.  
 
In the 2003 SAR studies begun by Summa et al. 39 on this new class of inhibitors, 
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has been demonstrated the importance of the arilic ring; infact the introduction of 
alifatic mojety like methyl or t-buthyl group determined a decrease of the activity. 
The substitution of phenil with a thiophene ring brought to a compound with 
comparable activity, while the introduction of more polar etherocycles, like 3-
pyridine and 2-furane, was not well tolerated; the diketo acid mojety was largely 
investigated too: simple modifications lead to a compounds completly inactives. 39 
Recently the Merck & co. has descibed a new class of NS5B inhibitors 2-aril-4,5-
dihydroxypyrimidin-6-carboxilyc acids (15) highly selective for the polymerase.  
 
A study by Pacini et al has expanded the SAR of dihydroxypyrimidine carboxylic 
acids that inhibit NS5B by chelating to the associated Mg2+ ions; this study 
demonstrated, using the weak cellular activity of analogs such as compound 16 that 
mutations adjacent to this site (Pro156Ser and Gly152Glu) conferred resistance 
against the series. 40 
 
16 
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3.3 Aim 
After a screening on 200000 α,γ-diketo acid compounds, the Merck reserchers have 
concluded that molecules with this mojety are selective inhibitors of NS5B 
polymerase of HCV. 38 Among them, three compounds (17: IC50 = 0.056 µM; 18: 
IC50 = 7.9 µM; 19: IC50 = 12.8 µM) have demonstrated micromolar IC50 values 
against NS5B.  
       
 
 
 
Therefore 17, 18 and 19 are not selective because are able to inhibite also the 
polymerase of hepatitis B and integrase of HIV-1. The inhibitory activity are dued to 
their ability to chelate the Mg2+ ions, and in conseguence to interfere with the bond 
of the phosphoric group of the nucleotidic substrate with the catalytic active site of 
the polymerase, preventing the formation of phosphodiester bond catalyzed by the 
enzyme.  
The research group where I spent my Ph.D., by several years is involved in studies 
on integrase of HIV-1 inhibitors. Moreover, the decennal interest on the pyrrole 
chemistry, has brought to the development of pyrrolyldiketo acids derivatives 
analogues of 19 compound, for testing their inhibitory activity against NS5B. 
Starting from 19 compound, a vinilic mojety was been introduced between the diketo 
acid portion and the pyrrole ring, obtaining compounds with general structure 20.  
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The IC50 values obtained in in vitro assay against the NS5B polymerase are included 
between 72.2 and 272 µM. To elaborate SAR study, the pyrrole ring was substituted 
with other etherocycle rings like indole. For that derivatives was studied the 
importance of the substitution on the nitrogen atom of the eterocycle ring: the 
indolyldiketoexenoic derivatives it was been substituted with aliphatic (alkylic and 
alkenylic) and aromatic (benzyl and phenil) groups, obtaining compounds 21a-p,s-t 
and 22a-p,s-t (Table 1). 
 
Table 1. Compound 21a-p,s-t and 22a-p,s-t 
 
 
 
Cpd R R1 X  Cpd R R1 X 
21a - (CH2)2CH3 Et  22a - (CH2)2CH3 H 
21b - (CH2)3CH3 Et  22b - (CH2)3CH3 H 
21c - (CH2)2CH(CH3)2 Et  22c - (CH2)2CH(CH3)2 H 
21d - CH=CHCH3 Et  22d - CH=CHCH3 H 
21e - CH2CH=CHCH3 Et  22e - CH2CH=CHCH3 H 
21f - CH=C(CH3)2 Et  22f - CH=C(CH3)2 H 
21g - CH2C(CH=CH)CH3 Et  22g - CH2C(CH=CH)CH3 H 
21h - Bna Et  22h - Bna H 
21i - 4-Cl-Bna Et  22i - 4-Cl-Bna H 
21j - 4-F-Bna Et  22j - 4-F-Bna H 
21k - 4-CN-Bna Et  22k - 4-CN-Bna H 
21l - 4-OCH3-Bna Et  22l - 4-OCH3-Bna H 
21m - 4-OH-Bna Et  22m - 4-OH-Bna H 
21n - Phb Et  22n - Phb H 
21o - 4-OH-Phb Et  22o - 4-OH-Phb H 
21p - 4-Cl-Phb Et  22p - 4-Cl-Phb H 
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21s - CH2(C=O)N(CH3)2 Et  22s - CH2(C=O)N(CH3)2 H 
21t - CH2(C=O)Morphc Et  22t - CH2(C=O)Morphc H 
a Bn: benzyl; b Ph: Phenyl; c Morph: morpholine. 
 
All these compounds are tested in in vitro assay on ricombinant RdRp. 
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3.3.1 Results and discussion 
 
Scheme 1, 2 and 3 reported above, describes the synthesis of derivatives 21a-p,s-t, 
22a-p,s-t. 
The synthesis of compound 21a-p and 22a-p (Scheme 1) started from the 
commercially available indole-3-carboxaldehyde, that was alkylated in alkaline 
medium (NaH) on the nitrogen atom with the appropriate alkyl, alkenyl or benzyl 
bromide to obtain 25a-l N-substuted-indole-3-carboxaldehyde. To obtain the 25n-p 
derivatives the indole-3-carboxaldehyde was allowed to react with the appropriate 
phenylboronic acid in a coupling reaction in presence of cupric acetate  as catalyst, 
that was carried out utilyzing microwaves irradiation in an open-vessel experiment. 
In comparison with the betch reaction, in the microwave reaction the yield was 
increased. The 4-methoxybenzyl derivative 5l afforded 4-hydroxybenzyl derivative 
5m after treatment with boron tribromide (BBr3). The aldehydes 25a-p were 
converted to the corresponding 3-buten-2-ones 26a-p in a condensation reaction with 
acetone in presence of sodium hydroxyde (NaOH). To afford ethyl esters 21a-p, 3-
buten-2-ones 26a-p was treated with diethyl oxalate utilyzing a weak base like 
sodium ethoxyde (NaOEt). The esters was converted to the corresonding acids 22a-p 
for hydrolysis. 
 
Scheme 1. a 
 
 
aReagents and conditions: (a) DMF, NaH, alkylic or benzylic alogenure, 1 h, r.t; (b) phenylboronic 
acid, cupric acetate, NMP-pyridine, MW (60W, 120 °C, 50s, open vessel); (c) BBr3, CH2Cl2, -45 °C, 
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1 h; (d) NaOH 5 N, acetone, 2 night, 50 °C; (e) diethyl oxalate, NaOEt, THF, 1 h 30 min, r.t.; (f) 
NaOH 1 N, THF-Methanol, 30 min, r.t. 
 
 
The amides 25s-t (Scheme 2) was obtained allowed a reaction between the indole-3-
carboxaledehyde with tert-butylbromo acetate; the ester function now formed (25q) 
was hydrolysed in acidic ambient afforded the corresponding acid 25r. The amides 
formation was performer on acid 25r in presence of HATU and DIEA as catalysts. 
The successive passages are the same described for the Scheme 1.  
 
Scheme 2. a 
 
 
aReagents and conditions: (a) DMF, NaH, tert-butylbromo acetate, 1 h, r.t.; (b) dichloromethane-
trifluoroacetic acid mixture 1:1, 16 h, r.t.; (c) base, HATU, DIEA, 2 days, r.t.; (e) NaOH 5 N, acetone, 
2 night, 50 °C; (f) diethyl oxalate, NaOEt, THF, 1 h 30 min, r.t.; (g) NaOH 1 N, THF-Methanol, 30 
min, r.t. 
 
All these compounds are tested in in vitro assay on ricombinant RdRp. Table 3 and 4 
reports the enzyme inhibitory activities in in vitro assay on ricombinant NS5B of 
HCV.  
 
Table 3. Activities data of compound 21a-p,s-t and 22a-p,s-t 
 
Cpd R R1 
X NS5B 
(µM) 
 Cpd R R1 X NS5B 
(µM) 
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IC50 IC50 
21a - (CH2)2CH3 Et 45  22a - (CH2)2CH3 H 25 
21b - (CH2)3CH3 Et 25  22b - (CH2)3CH3 H 15 
21c - (CH2)2CH(CH3)2 Et 52  22c - (CH2)2CH(CH3)2 H 48 
21d - CH=CHCH3 Et 12  22d - CH=CHCH3 H 12.5 
21e - CH2CH=CHCH3 Et 33  22e - CH2CH=CHCH3 H 21 
21f - CH=C(CH3)2 Et 62  22f - CH=C(CH3)2 H 32 
21g - CH2C(CH=CH)CH3 
Et 73.3  22g - CH2C(CH=CH)CH3 
H 46.6 
21h - Bna Et 97.3  22h - Bna H 27.5 
21i - 4-Cl-Bna Et 36.5  22i - 4-Cl-Bna H 27.3 
21j - 4-F-Bna Et 180  22j - 4-F-Bna H 76.4 
21k - 4-CN-Bna Et 32.3  22k - 4-CN-Bna H 23.6 
21l - 4-OCH3-Bna Et 72  22l - 4-OCH3-Bna H 10.7 
21m - 4-OH-Bna Et 29.6  22m - 4-OH-Bna H 30 
21n - Phb Et 99.4  22n - Phb H 30 
21o - 4-OH-Phb Et >200  22o - 4-OH-Phb H 21 
21p - 4-Cl-Phb Et 83  22p - 4-Cl-Phb H 34.6 
21s - CH2(C=O)N(CH3)2 Et NA  22s - CH2(C=O)N(CH3)2 H 42 
21t - CH2(C=O)Morphc Et NA  22t - CH2(C=O)Morphd H NA 
a Bn: benzyl; b Ph: Phenyl; c Morph: morpholine. 
 
In the enzymatic assay are tested both esters and acids derivatives. By a first analysis 
are evident that the diketo acid mojety are essential for the biological activity, infact 
the acid derivatives are always more active then the corresponding esters. The 
discrepance between these two result may be attribuite to the capacity of the acids 
function to chelate the metal ions presents in the active site. The IC50 values for the 
indolyldiketohexenoic esters 21a-p,s,t are ranging from 12 to >200 µM, while, the 
indolyldiketohexenoic acids 22a-p,s-t have IC50 values ranging from 10.7 to 46.6 
µM.  
In the serie of indolyldiketohexenoic acids the best substituent of the nitrogen atom 
of the indole ring is the 4-methoxybenzoyl group; infact the derivative 22l presenting 
this substituent, has a IC50 value of 10.7 and is the compound that inhibit the NS5B 
polymerase with lower IC50. Among the N-benzyl substituted indolyldiketohexenoic 
acids, all the substituent in position 4 of the benzyl group are well tolerated, with the 
exception of the fluorine atom that influence negativelly the inhibitory activity (IC50 
= 76.4 µM). The IC50 value for the N-benzyl substituted indolyldiketohexenoic acids 
22h,i,k-m are ranging from 10.7 to 30 µM.  
The N-alkyl and -alkenyl substituted indolyldiketohexenoic acids 22a-g shows a 
good NS5B inhibitory activities; in particular the N-allyl indolyldiketohexenoic acids 
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22d exhibit IC50 value of 12.5 µM, comparable with the IC50 value of the more active 
compound 22l.  
The substitution on nitrogen atom of indole ring with phenyl (22n-p) and acetamide 
(22s,t) groups does not lead to any improvement in the NS5B inhibitory activity. 22o 
has a similar IC50 value of the N-alkyl and -alkenyl substituted derivatives 22a,b,e 
(21 µM), whereas 22n,p,s,t are slightly less inhibitory activity (30-42 µM) (Table 3). 
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3.3.2 Conclusion 
The hepatitis C virus (HCV) is an RNA virus, belonging to the flaviviride family, 
responsable of the insorgence of non-A and non-B hepatitis. About 3% of the world 
population are infected by HCV virus and developed a cronic epatitis, that lead to 
cirrhosis and hepatocellular cancer. Actually does not exist a really effective care for 
the eradication of the cronic hepatitis associated with the infection of the HCV virus. 
This disease are treated mainly with an association of interferon and ribavirine, that 
mostly bringh to a failure of the cure. Is evident the necessity of new drugs that are 
able to block the viral replication. 
The NS5B polymerase of HCV represent a interesting target for the development of 
new potent and selective drugs.  
The work presented in this third chapter reguards the development, synthesis and 
evaluation of biological activity of new indolyldiketohexenoic acids. Some of the 
new derivatives synthesized (22l and 22d) have demonstated a IC50 values (10.7 and 
12.5 µM respectively) comparable with the IC50 values of more promising compound 
known in letterature. 
On the bases of these data, it is possible to claim that the derivative 22l and 22d can 
be considered new lead compound for future study. 
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3.3.3 Experimental section 
Chemistry 
General.Melting points were determined with a Büchi 530 capillary apparatus and 
are uncorrected. Infrared (IR) spectra were recorded on a Perkin-Elmer Spectrum-
one spectrophotometer. 1H NMR spectra were recorded on a bruker AC 400 
specrtometer. Merk silica gel 60 F254 plates were used for analytical TLC. Column 
chromatogrephies were performed on silica gel (Merck; 70-230 mesh) or alumina 
(Merck; 70-230 mesh). Concentration of solution after reactions and extractions 
involved the use of a rotary evaporator operating at reduced pressure of 
approximately 20 Torr. Analytical results agreed to within ±0.40% of the theoretical 
values. 
Microwave irradiation experiments. Microwave reactions were conduced using a 
CEM Discover system unit (CEM. Corp., Matthews, NC). The machine consists of a 
continuous focused microwave-power delivery system with operator selectable 
power output from 0 to 300 W. The temperature of the contents of the vessel was 
monitored using a calibrated infrared temperature control mounted under the reaction 
vessel. All experiments were performed using a stirring option whereby the contents 
of the vessel are stirred by means of a rotating magnetic plate located below the floor 
of the microwave cavity and a Teflon-coated magnetic stir bar in the vessel. 
 
General procedure for the synthesis of N-substituted indole-3-carboxaldehyde 
(25a-p). A solution of indole-3-carboxaldehyde (1.34 g – 0.0092 mol) in 20 mL of 
dry DMF was treated with NaH (580 mg – 0.0147 mol). After development of H2, 
the solution was treated with the appropriate alogenure (0.011 mol) and was stirred 
with bascular stirring in Büchi Syncore for 1 h at room temperature. The solution 
was diluted with water and the solid that formed was filtered on flash vac. The solid 
was washed with water and light petroleum ether to give derivatives 25a-p. 
Chemical, physical, and analytical data of derivatives 25a-p are reported in Table 3.  
 
1-(4-hydroxybenzyl)-1H-indole-3-carboxaldehyde (25m). A solution of 25l (6 g- 
0.0226 mol) in 246 mL of CH2Cl2 was added dropwise to a solution of BBr3 1 M in 
CH2Cl2 (0.0063 mol, 119.25 mL) cooled at -45 °C under argon stream. The mixture 
was stirred at -45 °C for 1 h and then was treated with water. After placing the 
reaction at room temperature, the formed precipitate was collected by filtration. The 
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solid was washed with water and light petroleum ether to give 4.96 g (76%) of pure 
25m as a red solid. Chemical, physical, and analytical data of derivative 25m are 
reported in Table 3.  
 
General procedure for the synthesis of 1-(4-phenyl)-1H-indole-3-
carboxaldehyde (25n-p). In a 100 mL round bottom flask were placed appropriate 
phenylboronic acid (0.0084 mol), cupric acetate (0.012 mol), indole-3-
carboxaldehyde (0.0048 mol) and 1:1 NMP:Pyridine mixture (5 mL). The bottom 
was placed into the microwave cavity (60 W, 120 °C, 50 s, open vessel). The 
reaction was repeat for six times and after each cycle, the reaction bottom was cooled 
and cupric acetate (0.012 mol), phenylboronic acid (0.0084 mol) and NMP:Pyridine 
mixture (5 ml) was added. After cooling the mixture was diluted with 
tetrahydrofuran and filtered off, and the solvent was evaporated. The residue was 
dissolved in ethyl acetate, washed with 1N HCl (20 times) and brine (three times), 
dried, and the solvent was evaporated under reduced pressure. The crude product was 
chromatographed on silica gel (ethyl acetate-chloroform in differents ratio) to furnish 
the derivatives 25n-p. Chemical, physical, and analytical data of derivatives 25n-p 
are reported in Table 3.  
 
tert-Butyl 2-(3-formyl-1H-indol-1-yl)acetate (25q). A solution of indole-3-
carboxaldehyde (4 g, 0.0276 mol) in 90 mL of dry DMF, was treated with NaH (1.55 
g, 0.039 mol). After development of H2, the solution was treated with tert-
butylbromo acetate  (10.75 g, 0.055 mol) and was stirred with bascular stirring in 
Büchi Syncore for 1 h at room temperature. The residue was dissolved in ethyl 
acetate, washed with 1 N HCl (3 times) and brine (three times), dried, and the solvent 
was evaporated under reduced pressure. The crude product was chromatographed 
with flash chromatography on silica gel (ethyl acetate-n-exane mixture 1:5 as eluent) 
to furnish 4.05 g (56.6%) of pure 25q as a white solid. Chemical, physical, and 
analytical data of derivative 25q are reported in Table 3.  
 
2-(3-formyl-1H-indol-1-yl)acetic acid (25r). 25q (3.95 g, 0.0152 mol) was treated 
with dichloromethane-trifluoroacetic acid mixture 1:1 (305 mL) to obtain a solution 
0.05 M. The mixture was stirred for 16 h at room temperature. After removal of the 
solvent, the residue was triturated with diethyl ether for 1 h. The solid was filtered 
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and washed with diethyl ether to obtain 2.83 g (92%) of pure 25r as a pink solid. 
Chemical, physical, and analytical data of derivative 25r are reported in Table 3.  
 
General procedure for the synthesis of 3-formyl-1H-indole 25s-t. 25r (0.0026 
mol) is solubilized in 13 mL of dry DMF to obtain a 0.2 M solution. The solution 
was trited with base (0.0026 mol) and HATU (0.0026 mol). The solution was cooled 
at 0 °C and treated with DIEA (0.0078 mol). After the addiction, the mixture was 
stirred for 2 days at room temperature. Ethyl acetate was added to the reacton and the 
obtained mixture was washed with HCl 1 N (three times), NaHCO3ss (three times) 
and brine (three times), dred and the solvent was evaporated under reduced pressure 
to obtain derivatives 25s-t. Chemical, physical, and analytical data of derivatives 
25s-t are reported in Table 3.  
 
General procedure for the synthesis of 4-(indol-3-yl)but-3-en-2-one 26a-p,s-t. A 
solution of appropriate aldehyde 25a-p or 25s-t (0.0311 mol) in 105.7 mL of acetone 
was treated with 45.2 mL of NaOH 5 N and stirred at 50 °C for 2 night and then was 
treated with water. The mixture was extracted with ethyl acetate. The collected 
organic extract was washed with brine (three times), and dried, and the solvent was 
evaporated under reduced pressure to obtain pure derivatives 26a-p,s-t. Chemical, 
physical, and analytical data of derivatives 6a-p,s-t are reported in Table 3.  
 
General procedure for the synthesis of Diketo Esters 21a-p,s-t. The appropriated 
acetyl derivative 26a-p,s-t (0.031 mol) and diethyl oxalate (0.062 mol) were 
dissolved in 31 mL of dry THF and treated, under argon stream, with NaOEt 
obtained by the dissolution of Na (0.063 mol) in 56.36 mL of absolute ethanol. The 
mixture was stirred at room temperature for 1 h 30 min, then was pured into n-
hexane (704 mL). The collected precipitate was vigorously stirred for 30 min in 1 N 
HCl (704 mL). The solid that formed was filtered, washed with water and light 
petroleum ether and dried under IR lamp to efford the pure diketo ester 21a-p,s-t. 
Yield (%), melting point (°C), recrystallization solvent, IR, 1H NMR, and analytical 
data are reported for each of the following compounds. 
 
6-(1-propyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid Ethyl Ester 
(21a). 76%; 105-107°C; toluene/cyclohexane; IR: ν 3400 (OH), 1750 (COOC2H5), 
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1725 (CO) cm-1. 1H NMR (DMSO-d6): δ 0.88-0.92 (t, 3H, CH3), 1.27-1.36 (t, 3H, 
CH3), 1.83-1.88 (q, 2H, CH2), 4.23-4.35 (m, 4H, CH2), 6.72 (s, 1H, hexanoate C3-
H), 6.95-6.99 (d, 1H, Jt = 14.8 Hz, hexanoate C5-H), 7.28-7.37 (m, 2H, indole C5-H, 
C6-H), 7.66-7.68 (d, 1H, indole C7-H), 8.05-8.09 (d, 1H, Jt = 14.8 Hz, hexanoate 
C6-H), 8.18 (m, 2H, indole C2-H, C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-butyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid Ethyl Ester 
(21b). 14%; 90-92°C; washed with isopropylic ether; IR: ν 3400 (OH), 1745 
(COOC2H5), 1715 (CO) cm-1. 1H NMR (DMSO-d6): δ 0.92-0.95 (t, 3H, CH3), 1.28-
1.36 (m, 5H, CH2 and CH3), 1.80-1.83 (q, 2H, CH2), 4.26-4.34 (m, 4H, CH2), 6.72 (s, 
1H, hexanoate C3-H), 6.95-6.99 (d, 1H, Jt = 15.7 Hz, hexanoate C5-H), 7.28-7.37 
(m, 2H, indole C5-H, C6-H), 7.66-7.68 (d, 1H, indole C7-H), 8.05-8.09 (d, 1H, Jt = 
15.7 Hz, hexanoate C6-H), 8.18 (m, 2H, indole C2-H, C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-isopentyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid Ethyl Ester 
(21c). 58%; 107-109°C; washed with isopropylic ether; IR: ν 3400 (OH), 1725 
(COOC2H5), 1617 (CO) cm-1. 1H NMR (DMSO-d6): δ 0.92-0.98 (m, 6H, CH3), 1.32-
1.38 (t, 3H, CH3), 1.55-1.58 (m, 1H, CH), 1.72-1.74 (q, 2H, CH2), 4.28-4.29 (m, 4H, 
CH2), 6.57 (s, 1H, hexanoate C3-H), 7.06 (sb, 1H, hexanoate C5-H), 7.27-7.36 (m, 
2H, indole C5-H, C6-H), 7.62-7.64 (d, 1H, indole C7-H), 7.97-8.01 (d, 1H, 
hexanoate C6-H), 8.13 (s, 2H, indole C2-H, C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-(prop-1-enyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid Ethyl 
Ester (21d). 62%; 81-82°C; washed with isopropylic ether; IR: ν 3400 (OH), 1725 
(COOC2H5), 1617 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.33-1.37 (t, 3H, CH3), 1.83-
1.86 (m, 3H, CH3), 4.31-4.36 (m, 4H, CH2), 5.78-5.82 (m, 1H, CH), 6.76 (s, 1H, 
hexanoate C3-H), 7.07-7.11 (m, 2H, hexanoate C5-H and CH), 7.33-7.41 (m, 2H, 
indole C5-H, C6-H), 7.55-7.57 (d, 1H, indole C7-H), 8.11-8.15 (d, 1H, Jt = 15.9 Hz, 
hexanoate C6-H), 8.21-8.23 ( s, 1H, indole C4-H), 8.29 (s, 1H, indole C2-H), 12-18 
(sb, 1H, OH). 
 
6-(1-(but-2-enyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid Ethyl 
Ester (21e). 66%; 124-126°C; washed with isopropylic ether; IR: ν 3400 (OH), 1729 
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(COOC2H5), 1611 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.33-1.36 (t, 3H, CH3), 1.69-
1.70 (d, 3H, CH3), 4.30-4.36 (q, 2H, CH2), 4.84-4.85 (d, 2H, CH2), 5.72-5.76 (m, 2H, 
CH), 6.73 (s, 1H, hexanoate C3-H), 6.69-7.00 (d, 1H, Jt = 15.8 Hz, hexanoate C5-
H), 7.28-7.36 (m, 2H, indole C5-H, C6-H), 7.62-7.64 (d, 1H, indole C7-H), 8.06-
8.10 (d, 1H, Jt = 15.8 Hz, hexanoate C6-H), 8.13 (s, 1H, indole C2-H), 8.16-8.18 ( d, 
1H, indole C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-(2-methylprop-1-enyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic 
Acid Ethyl Ester (21f). 56%; 130-132°C; washed with isopropanol; IR: ν 3400 
(OH), 1729 (COOC2H5), 1611 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.32-1.36 (t, 3H, 
CH3), 1.73 (s, 3H, CH3), 1.98 (s, 3H, CH3), 4.31-4.32 (q, 2H, CH2), 6.73 (sb, 1H, 
hexanoate C3-H), 6.83 (s, 1H, CH), 7.08 (sb, 1H, hexanoate C5-H), 7.32-7.39 (m, 
2H, indole C5-H, C6-H), 7.45-7.47 (d, 1H, indole C7-H), 8.05 (sb, 1H, hexanoate 
C6-H), 8.13 (s, 1H, indole C2-H), 8.23-8.24 (d, 1H, indole C4-H), 12-18 (sb, 1H, 
OH). 
 
6-(1-(2-methylallyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid Ethyl 
Ester (1g). 74%; 81-84°C; washed with isopropylic ether; IR: ν 3400 (OH), 1729 
(COOC2H5), 1611 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.32-1.36 (t, 3H, CH3), 1.73 
(s, 3H, CH3), 1.98 (s, 3H, CH3), 4.31-4.32 (q, 2H, CH2), 6.73 (sb, 1H, hexanoate C3-
H), 6.83 (s, 1H, CH), 7.08 (sb, 1H, hexanoate C5-H), 7.32-7.39 (m, 2H, indole C5-H, 
C6-H), 7.45-7.47 (d, 1H, indole C7-H), 8.05 (sb, 1H, hexanoate C6-H), 8.13 (s, 1H, 
indole C2-H), 8.23-8.24 (d, 1H, indole C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-benzyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid Ethyl Ester 
(21h). 100%; 118-120°C; Toluene; IR: ν 3400 (OH), 1727 (COOC2H5), 1630 (CO) 
cm-1. 1H NMR (DMSO-d6): δ 1.24-1.28 (t, 3H, CH3), 4.21-4.22 (q, 2H, CH2), 5.46 
(s, 2H, CH2), 6.53 (sb, 1H, hexanoate C3-H), 7.08 (sb, 1H, hexanoate C5-H), 7.18-
7.33 (m, 7H, benzene H, indole C5-H, C6-H), 7.55-7.57 (d, 1H, indole C7-H), 7.87 
(sb, 1H, hexanoate C6-H), 8.08 (s, 1H, indole C2-H), 8.14-8.16 (d, 1H, indole C4-
H), 12-18 (sb, 1H, OH). 
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6-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
Ethyl Ester (21i). 100%; 120-122°C; washed with isopropanol; IR: ν 3400 (OH), 
1724 (COOC2H5), 1608 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.31 (t, 3H, CH3), 4.28 
(q, 2H, CH2), 5.53 (s, 2H, CH2), 6.71 (sb, 1H, hexanoate C3-H), 7.00 (sb, 1H, 
hexanoate C5-H), 7.25-7.34 (m, 4H, benzene H, indole C5-H, C6-H), 7.43-7.45 (m, 
2H, benzene H), 7.60-7.62 (d, 1H, indole C7-H), 8.05 (s, 1H, Jt = 13.95 Hz, 
hexanoate C6-H), 8.16-8.23 (m, 2H, indole C2-H and C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-(4-fluorobenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
Ethyl Ester (21j). 91%; 116-119°C; washed with isopropanol; IR: ν 3400 (OH), 
1741 (COOC2H5), 1619 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.35 (t, 3H, CH3), 4.34 
(q, 2H, CH2), 5.53 (s, 2H, CH2), 6.75 (s, 1H, hexanoate C3-H), 7.00-7.02 (s, 1H, Jt = 
15.7 Hz, hexanoate C5-H), 7.19-7.22 (m, 4H, benzene H, indole C5-H, C6-H), 7.38-
7.42 (m, 2H, benzene H), 7.65-7.67 (d, 1H, indole C7-H), 8.05-8.08 (s, 1H, Jt = 15.7 
Hz, hexanoate C6-H), 8.18-8.20 (d, 1H, indole C4-H), 8.30 (s, 1H, indole C4-H), 12-
18 (sb, 1H, OH). 
 
6-(1-(4-cyanobenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
Ethyl Ester (21k). 100%; 108-110°C; washed with isopropanol; IR: ν 3400 (OH), 
2226 (CN), 1720 (COOC2H5), 1600 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.33 (t, 3H, 
CH3), 4.34 (q, 2H, CH2), 5.67 (s, 2H, CH2), 6.74 (s, 1H, hexanoate C3-H), 7.02-7.05 
(s, 1H, Jt = 16.8 Hz, hexanoate C5-H), 7.30-7.32 (m, 2H, indole C5-H, C6-H), 7.44-
7.45 (d, 2H, benzene H), 7.58-7.60 (d, 1H, indole C7-H), 7.85-7.86 (d, 2H, benzene 
H), 8.05-8.08 (s, 1H, Jt = 16.8 Hz, hexanoate C6-H), 8.18-8.20 (d, 1H, indole C4-H), 
8.32 (s, 1H, indole C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-(4-methoxybenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
Ethyl Ester (21l). 68%; 128-130°C; washed with isopropanol; IR: ν 3400 (OH), 
1718 (COOC2H5), 1608 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.30 (t, 3H, CH3), 3.74 
(s, 3H, CH3), 4.33 (q, 2H, CH2), 5.39 (s, 2H, CH2), 6.70-6.76 (m, 3H, benzene H and 
hexanoate C3-H), 6.98-7.01 (bs, 1H, hexanoate C5-H), 7.19-7.21 (d, 2H, benzene H), 
7.26-7.35 (m, 2H, indole C5-H, C6-H), 7.65-7.66 (d, 1H, indole C7-H), 8.06-8.08 
(bs, 1H, hexanoate C6-H), 8.15-8.16 (d, 1H, indole C4-H), 8.28 (s, 1H, indole C4-
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H), 12-18 (sb, 1H, OH). 
 
6-(1-(4-hydroxybenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
Ethyl Ester (21m). 80%; 148-150°C; washed with isopropanol; IR: ν 3400 (OH), 
1724 (COOC2H5), 1614 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.30 (t, 3H, CH3), 4.33 
(q, 2H, CH2), 5.39 (s, 2H, CH2), 6.70-6.76 (m, 3H, benzene H and hexanoate C3-H), 
6.98-7.01 (s, 1H, Jt = 15.9 Hz, hexanoate C5-H), 7.19-7.21 (d, 2H, benzene H), 7.26-
7.35 (m, 2H, indole C5-H, C6-H), 7.65-7.66 (d, 1H, indole C7-H), 8.06-8.08 (s, 1H, 
Jt = 15.9 Hz, hexanoate C6-H), 8.15-8.16 (d, 1H, indole C4-H), 8.28 (s, 1H, indole 
C4-H), 10.00 (sb, 1H OH fenole), 12-18 (sb, 1H, OH). 
 
6-(1-phenyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid Ethyl Ester 
(21n). 64%; °C; washed with isopropanol; IR: ν 3400 (OH), 1725 (COOC2H5), 1610 
(CO) cm-1. 1H NMR (DMSO-d6): δ 1.29 (t, 3H, CH3), 4.28 (q, 2H, CH2), 6.1 (s, 1H, 
hexanoate C3-H), 7.06-7.10 (s, 1H, Jt = 15.9 Hz, hexanoate C5-H), 7.32-7.34 (m, 
2H, indole C5-H, C6-H), 7.47-7.63 (m, 6H, benzene H and indole C7-H), 8.05-8.11 
(s, 1H, Jt = 15.9 Hz, hexanoate C6-H), 8.22 (s, 1H, indole C4-H), 8.37 (s, 1H, indole 
C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-(4-hydroxyphenyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
Ethyl Ester (21o). 73%; 151-153°C; toluene; IR: ν 3400 (OH), 1726 (COOC2H5), 
1618 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.35 (t, 3H, CH3), 4.33 (q, 2H, CH2), 6.76 
(s, 1H, hexanoate C3-H), 7.00-7.03 (d, 2H, benzene H), 7.08-7.12 (d, 1H, Jt = 15.9 
Hz, hexanoate C5-H), 7.36-7.37 (m, 2H, indole C5-H, C6-H), 7.45-7.49 (m, 4H, 
benzene H and indole C7-H), 8.11-8.15 (s, 1H, Jt = 15.9 Hz, hexanoate C6-H), 8.26 
(m, 1H, indole C4-H), 8.32 (s, 1H, indole C4-H), 10.00 (bs, 1H, OH fenole), 12-18 
(sb, 1H, OH). 
 
6-(1-(4-chlorophenyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
Ethyl Ester (21p). 74%; 142-144°C; washed with isopropanol; IR: ν 3400 (OH), 
1726 (COOC2H5), 1618 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.35 (t, 3H, CH3), 4.33 
(q, 2H, CH2), 6.76 (s, 1H, hexanoate C3-H), 7.00-7.03 (d, 2H, benzene H), 7.08-7.11 
(d, 1H, Jt = 15.6 Hz, hexanoate C5-H), 7.36-7.37 (m, 2H, indole C5-H, C6-H), 7.45-
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7.49 (m, 4H, benzene H and indole C7-H), 8.11-8.14 (s, 1H, Jt = 15.6 Hz, hexanoate 
C6-H), 8.26 (m, 1H, indole C4-H), 8.32 (s, 1H, indole C4-H), 12-18 (sb, 1H, OH). 
 
6-(1-((dimethylcarbamoyl)methyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-
hexadienoic Acid Ethyl Ester (21s). 100%; 188-190°C; washed with isopropylic 
ether; IR: ν 3400 (OH), 1734 (COOH), 1618 (CO) cm-1. 1H NMR (DMSO-d6): δ 
4.78-4.81 (m, 6H, CH3), 6.69 (sb, 1H, hexanoate C3-H), 6.80 (s, 1H, CH2), 7.00 (sb, 
1H, hexanoate C5-H), 7.31-7.38 (m, 2H, indole C5-H, C6-H), 7.45-7.47 (d, 1H, 
indole C7-H), 8.06-8.10 (d, 1H, hexanoate C6-H), 8.12 (s, 1H, indole C2-H), 8.18-
8.20 (d, 1H, indole C4-H), 12-18 (sb, 2H, OH). 
 
6-(1-(2-morpholino-2-oxoethyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic 
Acid Ethyl Ester (21t). 74%; 183°C; washed with isopropylic ether; IR: ν 3400 
(OH), 1730 (COOH), 1620 (CO) cm-1. 1H NMR (DMSO-d6): δ 3.24 (m, 4H, 
morpholine H), 3.72 (m, 4H, morpholine H), 6.69 (sb, 1H, hexanoate C3-H), 6.85 (s, 
1H, CH2), 7.00 (sb, 1H, hexanoate C5-H), 7.31-7.38 (m, 2H, indole C5-H, C6-H), 
7.45-7.47 (d, 1H, indole C7-H), 8.06-8.10 (d, 1H, hexanoate C6-H), 8.12 (s, 1H, 
indole C2-H), 8.18-8.20 (d, 1H, indole C4-H), 12-18 (sb, 2H, OH). 
 
General procedure for the synthesis of Diketo Acids 22a-p,s-t.  A mixture of 1 N 
NaOH (9.48 mL) and the appropriated ester 21a-p,s-t (0.0019 mol) in 1:1 THF-
Methanol (9.32 mL) was stirred at room temperature for 30 min and then pured into 
crushed ice. The acquous mixture was treated with 1 N HCl until Ph 3 was reached, 
and extracted with ethyl acetate (three times). The collected organic extract was 
washed with brine (three times), and dried, and the solvent was evaporated under 
reduced pressure to give the pure diketo acids 22a-p,s-t. Yield (%), melting point 
(°C), recrystallization solvent, IR, 1H NMR, and analytical data are reported for each 
of the following compounds. 
 
6-(1-(2-morpholino-2-oxoethyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic 
Acid Ethyl Ester (21t). 74%; 183°C; washed with isopropylic ether; IR: ν 3400 
(OH), 1730 (COOH), 1620 (CO) cm-1. 1H NMR (DMSO-d6): δ 3.24 (m, 4H, 
morpholine H), 3.72 (m, 4H, morpholine H), 6.69 (sb, 1H, hexanoate C3-H), 6.85 (s, 
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1H, CH2), 7.00 (sb, 1H, hexanoate C5-H), 7.31-7.38 (m, 2H, indole C5-H, C6-H), 
7.45-7.47 (d, 1H, indole C7-H), 8.06-8.10 (d, 1H, hexanoate C6-H), 8.12 (s, 1H, 
indole C2-H), 8.18-8.20 (d, 1H, indole C4-H), 12-18 (sb, 2H, OH). 
 
6-(1-propyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid (22a).  93%; 
153-155°C; washed with isopropanol; IR: ν 3400 (OH), 1720 (COOH), 1591 (CO) 
cm-1. 1H NMR (DMSO-d6): δ 0.88-0.92 (t, 3H, CH3), 1.27-1.36 (t, 3H, CH3), 1.83-
1.88 (q, 2H, CH2), 4.23-4.35 (m, 4H, CH2), 6.69 (s, 1H, hexanoate C3-H), 6.92-6.95 
(d, 1H, Jt = 15.5 Hz, hexanoate C5-H), 7.27-7.36 (m, 2H, indole C5-H, C6-H), 7.65-
7.67 (d, 1H, indole C7-H), 8.03-8.07 (d, 1H, Jt = 15.5 Hz, hexanoate C6-H), 8.16 (m, 
2H, indole C2-H, C4-H), 12-18 (sb, 2H, OH) 
 
6-(1-butyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid (22b). 87%; 
144-146°C; washed with hot absolute ethanol; IR: ν 3400 (OH), 1754 (COOH), 1586 
(CO) cm-1. 1H NMR (DMSO-d6): δ 0.92-0.95 (t, 3H, CH3), 1.28-1.32 (q, 2H, CH2), 
1.80-1.83 (q, 2H, CH2), 4.26-4.29 (q, 2H, CH2), 6.68 (s, 1H, hexanoate C3-H), 6.96 
(d, 1H, hexanoate C5-H), 7.27-7.36 (m, 2H, indole C5-H, C6-H), 7.65-7.67 (d, 1H, 
indole C7-H), 8.02-8.06 (d, 1H, Jt = 15.7 Hz, hexanoate C6-H), 8.18 (m, 2H, indole 
C2-H, C4-H), 12-18 (sb, 2H, OH). 
 
6-(1-isopentyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid (22c). 30%; 
134-136°C; washed with hot absolute ethanol; IR: ν 3400 (OH), 1707 (COOH), 1570 
(CO) cm-1. 1H NMR (DMSO-d6): δ 0.96-0.98 (m, 6H, CH3), 1.57-1.58 (m, 1H, CH), 
1.72-1.76 (q, 2H, CH2), 4.27-4.31 (q, 2H, CH2), 6.74 (s, 1H, hexanoate C3-H), 6.94 
(sb, 1H, hexanoate C5-H), 7.27-7.37 (m, 2H, indole C5-H, C6-H), 7.64-7.66 (d, 1H, 
indole C7-H), 8.03-8.05 (d, 1H, hexanoate C6-H), 8.18 (s, 2H, indole C2-H, C4-H), 
12-18 (sb, 2H, OH). 
 
6-(1-(prop-1-enyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid (22d). 
64%; 126-128°C; washed with isopranol; IR: ν 3400 (OH), 1728 (COOH), 1663 
(CO) cm-1. 1H NMR (DMSO-d6): δ 1.84-1.86 (m, 3H, CH3), 5.76-5.80 (m, 1H, CH), 
6.76 (s, 1H, hexanoate C3-H), 7.04-7.09 (m, 2H, hexanoate C5-H and CH), 7.32-
7.40 (m, 2H, indole C5-H, C6-H), 7.54-7.56 (d, 1H, indole C7-H), 8.05 (sb, 1H, 
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hexanoate C6-H), 8.18-8.24 (m, 2H, indole C2-H and C4-H), 12-18 (sb, 2H, OH). 
 
6-(1-(but-2-enyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid (22e). 
88%; 163-165°C; washed with hot absolute ethanol; IR: ν 3400 (OH), 1754 
(COOH), 1588 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.69-1.70 (d, 3H, CH3), 4.84-4.85 
(d, 2H, CH2), 5.68-5.79 (m, 2H, CH), 6.71 (s, 1H, hexanoate C3-H), 6.93-6.97 (d, 
1H, Jt = 15.6 Hz, hexanoate C5-H), 7.27-7.36 (m, 2H, indole C5-H, C6-H), 7.61-
7.63 (d, 1H, indole C7-H), 8.05-8.09 (d, 1H, Jt = 15.6 Hz, hexanoate C6-H), 8.12 (s, 
1H, indole C2-H), 8.14-8.16 ( d, 1H, indole C4-H), 12-18 (sb, 2H, OH). 
 
6-(1-(2-methylprop-1-enyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic 
Acid (22f). 78%; 165°C; washed with hot absolute ethanol; IR: ν 3400 (OH), 1719 
(COOH), 1588 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.73 (s, 3H, CH3), 1.98 (s, 3H, 
CH3), 6.71 (sb, 1H, hexanoate C3-H), 6.83 (s, 1H, CH), 7.04 (sb, 1H, hexanoate C5-
H), 7.31-7.38 (m, 2H, indole C5-H, C6-H), 7.45-7.47 (d, 1H, indole C7-H), 8.06-
8.10 (d, 1H, Jt = 15.8 Hz, hexanoate C6-H), 8.12 (s, 1H, indole C2-H), 8.18-8.20 (d, 
1H, indole C4-H), 12-18 (sb, 2H, OH). 
 
6-(1-(2-methylallyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid (22g). 
86%; 149-151°C; washed with hot absolute ethanol; IR: ν 3400 (OH), 1719 
(COOH), 1588 (CO) cm-1. 1H NMR (DMSO-d6): δ 1.73 (s, 3H, CH3), 1.98 (s, 3H, 
CH3), 6.71 (sb, 1H, hexanoate C3-H), 6.83 (s, 1H, CH), 7.04 (sb, 1H, hexanoate C5-
H), 7.31-7.38 (m, 2H, indole C5-H, C6-H), 7.45-7.47 (d, 1H, indole C7-H), 8.06-
8.10 (d, 1H, Jt = 15.8 Hz, hexanoate C6-H), 8.12 (s, 1H, indole C2-H), 8.18-8.20 (d, 
1H, indole C4-H), 12-18 (sb, 2H, OH). 
 
6-(1-benzyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid (22h).  68%; 
178-180°C; DMF/H2O; IR: ν 3400 (OH), 1754 (COOH), 1619 (CO) cm-1. 1H NMR 
(DMSO-d6): δ 5.48 (s, 2H, CH2), 6.64 (sb, 1H, hexanoate C3-H), 6.93 (sb, 1H, 
hexanoate C5-H), 7.20-7.33 (m, 7H, benzene H, indole C5-H, C6-H), 7.55-7.57 (d, 
1H, indole C7-H), 7.99 (sb, 1H, hexanoate C6-H), 8.09 (d, 1H, indole C4-H), 8.21 (s, 
1H, indole C2-H), 12-18 (sb, 2H, OH). 
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6-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
(22i). 64%; 192-194°C; DMF/H2O; IR: ν 3400 (OH), 1727 (COOH), 1607 (CO) cm-
1. 1H NMR (DMSO-d6): δ 5.59 (s, 2H, CH2), 6.71 (sb, 1H, hexanoate C3-H), 6.96-
6.98 (s, 1H, Jt = 13.95 Hz, hexanoate C5-H), 7.23-7.25 (m, 4H, benzene H, indole 
C5-H, C6-H), 7.41-7.46 (m, 2H, benzene H), 7.60-7.62 (d, 1H, indole C7-H), 8.05 (s, 
1H, Jt = 13.95 Hz, hexanoate C6-H), 8.16 (d, 1H, indole C4-H), 8.27 (s, 1H, indole 
C2-H), 12-18 (sb, 2H, OH). 
 
6-(1-(4-fluorobenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
(22j). 77%; 168-170°C; DMF/H2O; IR: ν 3400 (OH), 1725 (COOH), 1603 (CO) cm-
1. 1H NMR (DMSO-d6): δ 5.60 (s, 2H, CH2), 6.71 (sb, 1H, hexanoate C3-H), 6.96-
6.99 (s, 1H, Jt = 15.5 Hz, hexanoate C5-H), 7.19-7.24 (m, 2H, benzene H), 7.27-7.34 
(m, 2H, indole C5-H, C6-H), 7.39-7.41 (m, 2H, benzene H), 7.60-7.62 (d, 1H, indole 
C7-H), 8.05 (s, 1H, Jt = 15.5 Hz, hexanoate C6-H), 8.16 (d, 1H, indole C4-H), 8.28 
(s, 1H, indole C2-H), 12-18 (sb, 2H, OH). 
 
6-(1-(4-cyanobenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
(22k). 91%; 168-170°C; ethanol; IR: ν 3400 (OH), 2227 (CN), 1708 (COOH), 1600 
(CO) cm-1. 1H NMR (DMSO-d6): δ 5.60 (s, 2H, CH2), 6.73 (sb, 1H, hexanoate C3-
H), 6.96-7.00 (s, 1H, Jt = 15.7 Hz, hexanoate C5-H), 7.30-7.33 (m, 2H, indole C5-H, 
C6-H), 7.43-7.44 (d, 2H, benzene H), 7.59-7.61 (d, 1H, indole C7-H), 7.86 (d, 2H, 
benzene H), 8.05-8.08 (s, 1H, Jt = 15.7 Hz, hexanoate C6-H), 8.19 (d, 1H, indole 
C4-H), 8.29 (s, 1H, indole C2-H), 12-18 (sb, 2H, OH). 
 
6-(1-(4-methoxybenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
(22l). 60%; 182-184°C; DMF/H2O; IR: ν 3400 (OH), 1727 (COOH), 1604 (CO) cm-
1. 1H NMR (DMSO-d6): δ 3.75 (s, 3H, CH3), 5.39 (s, 2H, CH2), 6.71-6.76 (m, 3H, 
benzene H and hexanoate C3-H), 6.96-7.00 (s, 1H, Jt = 15.8 Hz, hexanoate C5-H), 
7.20 (d, 2H, benzene H), 7.26-7.33 (m, 2H, indole C5-H, C6-H), 7.65-7.66 (d, 1H, 
indole C7-H), 8.05-8.09 (s, 1H, Jt = 15.8 Hz, hexanoate C6-H), 8.25 (d, 1H, indole 
C4-H), 8.29 (s, 1H, indole C2-H), 12-18 (sb, 2H, OH). 
 
 
 157 
6-(1-(4-hydroxybenzyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
(22m). 100%; 158-160°C; DMF/H2O; IR: ν 3400 (OH), 1723 (COOH), 1606 (CO) 
cm-1. 1H NMR (DMSO-d6): δ 5.39 (s, 2H, CH2), 6.71-6.76 (m, 3H, benzene H and 
hexanoate C3-H), 6.96-7.00 (s, 1H, Jt = 15.8 Hz, hexanoate C5-H), 7.20 (d, 2H, 
benzene H), 7.26-7.33 (m, 2H, indole C5-H, C6-H), 7.65-7.66 (d, 1H, indole C7-H), 
8.05-8.09 (s, 1H, Jt = 15.8 Hz, hexanoate C6-H), 8.25 (d, 1H, indole C4-H), 8.29 (s, 
1H, indole C2-H), 9.5 (sb, 1H, OH fenole), 12-18 (sb, 2H, OH). 
 
6-(1-phenyl-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid (22n). 98%; 
°C; washed with isopropanol; IR: ν 3400 (OH), 1754 (COOH), 1616 (CO) cm-1. 1H 
NMR (DMSO-d6): δ 6.57 (bs, 1H, hexanoate C3-H), 7.05 (bs, 1H, hexanoate C5-H), 
7.30-7.32 (m, 2H, indole C5-H, C6-H), 7.46-7.64 (m, 6H, benzene H and indole C7-
H), 8.01 (s, 1H, hexanoate C6-H), 8.20 (d, 1H, indole C4-H), 8.33 (s, 1H, indole C2-
H), 12-18 (sb, 2H, OH). 
 
6-(1-(4-hydroxyphenyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
(22o). 64&; 167-169°C; DMF/H2O; IR: ν 3400 (OH), 1764 (COOH), 1606 (CO) cm-
1. 1H NMR (DMSO-d6): δ 6.75 (bs, 1H, hexanoate C3-H), 7.00-7.08 (m, 3H, benzene 
H and hexanoate C5-H), 7.34-7.36 (m, 2H, indole C5-H, C6-H), 7.45-7.50 (m, 3H, 
benzene H and indole C7-H), 8.09 (bs, 1H, hexanoate C6-H), 8.24 (d, 1H, indole C4-
H), 8.30 (s, 1H, indole C2-H), 9.93 (s, 1H, OH fenole), 12-18 (sb, 2H, OH). 
 
6-(1-(4-chlorophenyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic Acid 
(22p). 97%; 168-170°C; washed with hot absolute ethanol; IR: ν 3400 (OH), 1764 
(COOH), 1606 (CO) cm-1. 1H NMR (DMSO-d6): δ 6.75 (bs, 1H, hexanoate C3-H), 
7.00-7.08 (m, 3H, benzene H and hexanoate C5-H), 7.34-7.36 (m, 2H, indole C5-H, 
C6-H), 7.45-7.50 (m, 3H, benzene H and indole C7-H), 8.09 (bs, 1H, hexanoate C6-
H), 8.24 (d, 1H, indole C4-H), 8.30 (s, 1H, indole C2-H), 12-18 (sb, 2H, OH). 
 
6-(1-((dimethylcarbamoyl)methyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-
hexadienoic Acid (22s). 72%; 185-187°C; washed with isopropylic ether; IR: ν 
3400 (OH), 1720 (COOH), 1598 (CO) cm-1. 1H NMR (DMSO-d6): δ 4.80-4.84 (m, 
6H, CH3), 6.71 (sb, 1H, hexanoate C3-H), 6.83 (s, 1H, CH2), 7.04 (sb, 1H, hexanoate 
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C5-H), 7.31-7.38 (m, 2H, indole C5-H, C6-H), 7.45-7.47 (d, 1H, indole C7-H), 8.06-
8.10 (d, 1H, hexanoate C6-H), 8.12 (s, 1H, indole C2-H), 8.18-8.20 (d, 1H, indole 
C4-H), 12-18 (sb, 2H, OH). 
 
6-(1-(2-morpholino-2-oxoethyl)-1H-indol-3-yl)-2-hydroxy-4-oxo-2,5-hexadienoic 
Acid (22t). 70%; 185°C; washed with hot absolute ethanol; IR: ν 3400 (OH), 1719 
(COOH), 1578 (CO) cm-1. 1H NMR (DMSO-d6): δ 3.24 (m, 4H, morpholine H), 3.72 
(m, 4H, morpholine H), 6.71 (sb, 1H, hexanoate C3-H), 6.78 (s, 1H, CH2), 7.00 (sb, 
1H, hexanoate C5-H), 7.31-7.38 (m, 2H, indole C5-H, C6-H), 7.45-7.47 (d, 1H, 
indole C7-H), 8.06-8.10 (d, 1H, hexanoate C6-H), 8.12 (s, 1H, indole C2-H), 8.18-
8.20 (d, 1H, indole C4-H), 12-18 (sb, 2H, OH). 
 
In Table 5 are reported the chemical-physical characteristic of the syntetic 
intermediete 25a-t, 26a-p,s,t. 
 
Table 5. Chemical, Physical, and Analytical Data of Derivatives 25a-t, 26a-p,s,t. 
Cpd R R1 mp (°C) 
recryst 
solventa 
Yeld 
(%) 
25a - (CH2)2CH3 104-106 a 76 
25b - (CH2)3CH3 oil oil 50 
25c - (CH2)2CH(CH3)2 oil oil 88 
25d - CH=CHCH3 oil oil 38 
25e - CH2CH=CHCH3 - - 18 
25f - CH=C(CH3)2 oil oil 32 
25g - CH2C(CH=CH)CH3 oil oil 88 
25h - Bnb 102-104 a 93 
25i - 4-Cl-Bnb 115-117 e 66 
25j - 4-F-Bnb 112-114 e 62 
25k - 4-CN-Bnb 146-148 b 81 
25l - 4-OCH3-Bnb 123-126 f 68 
25m - 4-OH-Bnb 180-182 b 76 
25n - Phc - - 47 
25o - 4-OH-Phc 233-234 c 12 
25p - 4-Cl-Phc 161-163 c 27 
25q - CH2COOtBu 125-127 h 56 
25r - CH2COOH 205-207 d 92 
25s - CH2(C=O)N(CH3)2 127-128 b 88 
25t - CH2(C=O)Morphd 105-106 b 100 
26a - (CH2)2CH3 oil oil 97 
26b - (CH2)3CH3 oil oil 100 
26c - (CH2)2CH(CH3)2 oil oil 87 
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26d - CH=CHCH3 oil oil 100 
26e - CH2CH=CHCH3 oil oil 100 
26f - CH=C(CH3)2 oil oil 99 
26g - CH2C(CH=CH)CH3 93-95 e 80 
26h - Bnb 127-129 b 92 
26i - 4-Cl-Bnb 147-149 g 98 
26j - 4-F-Bnb 126-128 g 83 
26k - 4-CN-Bnb 158-160 c 68 
26l - 4-OCH3-Bnb 126-128 g 60 
26m - 4-OH-Bnb 154-156 c 100 
26n - Phc oil oil 79 
26o - 4-OH-Phc 162-164 b 62 
26p - 4-Cl-Phc 153-155 g 92 
26s - CH2(C=O)N(CH3)2 oil oil 100 
26t - CH2(C=O)Morphd 179-181 g 32 
a Recrystallization solvent: (a) toluene/cyclohexane; (b) toluene; (c) ethanol; (d) DMF/H2O; (e) n-
exane; (f) cyclohexane;  (g) benzene; (h) toluene/benzene; (i) isopropanol/isopropylic ether b Bn: 
benzyl; c Ph: Phenyl; d Morph: morpholine. 
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Biology 
The RNA-dependent RNA polymerase assay was performed in a total volume of 40 
µL containing 1 nM enzyme, 20 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM DTT, 
1 mM EDTA, 20 units of RNase inhibitor, 50 µg/mL of actinomycin D, 5 µCi of [α-
32P]UTP, 0.5 mM each of remaining NTPs (ATP, CTP, GTP) with 10 µg/mL of 
RNA template. The concentration of the limiting nucleotide was adjusted to 10 µM. 
The reaction mixture were incubated at 30 °C for 2 h. After incubation, the reaction 
was stopped by digestion with 50 µg of protease K in a protease K buffer (150 mM 
NaCl, 50mM Tris-HCL (pH 7.5), and 0.5% SDS) for 30 min.The RNA products 
were extracted phenol/chloroform (1:1) before ethanol precipitation. After heat 
denaturation (94 °C, 2 min), these products were analized by 8M urea, 8% PAGE. 
The gels were dried and analyzed using a BAS 1000 Bioimage analyzer system 
(Fuji). 
 161 
BIBLIOGRAPHY 
 
1. Francki, R. I.; Fauquet, D. L.; Knudson, D. L.; Brown, F. Classification and 
nomenclature of viruses. Arch. Virol. Suppl., 1991, 2, 223-233. 
2. Marcellin, P.; Boyer, N.; Transition of care between paediatric and adult 
gastroenterology. Chronic viral hepatitis. Best Prac.t Re.s Clin. 
Gastroenterol., 2003, 17, 259-275. 
3. Bartenschlager, R.; Lohmann, V. Replication of the hepatitis C virus. 
Baillieres Best Pract. Res. Clin. Gastroenterol., 2000, 14, 241-254. 
4. Appel, N.; Schaller, T.; Penin, F.; Bartenschlager, R. From structure to 
function: new insights into hepatitis C virus RNA replication. J. Biol. Chem. 
2006, 281, 9833-9936. 
5. Brass, V.; Moradpour, D.; Blum, H. E. Molecular virology of hepatitis Cvirus 
(HCV): 2006 update. Int. J. Med. Sci., 2006, 3, 29-34. 
6. Fukushi, S.; Kurihara, C.; Ishiyama, N.; Hoshino, F. B.; Oya, A.; Katayama, 
K. The sequence element of the internal ribosome entry site and a 25-
kilodalton cellular protein contribute to efficient internal initiation of 
translation of hepatitis C virus RNA. J. Virol. 1997, 71, 1662-1666. 
7. McHutchison, J. G.; Patel, K.; Pockros, P.; Nyberg, L.; Pianko, S.; Yu, R. Z. 
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), 
administered to chronic hepatitis C patients. J. Hepatol. 2006, 44, 88-96. 
8. Poch, O.; Sauvaget, I.; Delarue, M.; Tordo, N. Identification of four 
conserved motifs among the RNA-dependent polymerase encoding elements. 
EMBO J., 1989, 8, 3867-3874. 
9. Beaulieu, P. L.; Tsantrizos, Y. S. Inhibitors of the HCV NS5B polymerase: 
new hope for the treatment of hepatitis C infections. Curr. Opin. Investig. 
Drugs., 2004, 5, 838-50. 
10. Bressanelli, S.; Tomei, I.; Roussel, A.; Incitti, I.; Vitale, R. L.; Mathieu, M.; 
De Francesco, R. Crystal structure of the RNA-dependent RNA polymerase 
of hepatitis C virus. Proc. Natl. Acad. Sci. USA, 1999, 96, 13034-13039. 
11. Biswal, B. K.; Cherney, M. M.; Wang, M.; Chan, L.; Yannopoulos, C. G.; 
Bilimoria, D.; Nicolas, O.; Bedard, J.; James, M. N. Crystal structures of the 
RNA dependent RNA polymerase genotype 2a of hepatitis C virus reveal two 
 162 
conformations and suggest mechanisms of inhibition by non-nucleoside 
inhibitors. J. Biol. Chem., 2005, 280, 18202-18210. 
12. Hong, Z.; Cameron, C. E.; Walker, M. P.; Castro, C.; Yao, N.; Lau, J. Y.; 
Zhong, W. A novel mechanism to ensure terminal initiation by hepatitis C 
virus NS5B polymerase. Virology, 2001, 285, 6-11. 
13. Paul, A. V.; van Boom, J. H.; Filippov, D.; Wimmer, E. Protein-primed RNA 
synthesis by purified poliovirus RNA polymerase. Nature, 1998, 393, 280-
284. 
14. Adachi, T.; Ago, H.; Habuka, N.; Okuda, K.; Komatsu, M.; Ikeda, S.; 
Yatsunami, K. The essential role of C-terminal residues in regulating the 
activity of hepatitis C virus RNA-dependent RNA polymerase. Biochim. 
Biophys. Acta., 2002, 1601, 38-48. 
15. Ranjith-Kumar, C. T.; Gutshall, L.; Kim, M. J.; Sarisky, R. T.; Kao, C. C. 
Requirements for de novo initiation of RNA synthesis by recombinant 
flaviviral RNA-dependent RNA polymerases. J. Virol., 2002, 76, 12526-
12536. 
16. Bressanelli, S.; Tomei, L.; Rey, F. A.; De Francesco, R. Structural analysisof 
the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. 
Virol., 2002, 76, 3482-3492. 
17. De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. 
Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-
4A serine protease and the NS5B RNA-dependent RNA polymerase, 
Antiviral Res., 2003, 58, 1-16. 
18. Fillebeen, C.; Rivas-Estilla, A. M.; Bisaillon, M.; Ponka, P.; Muckenthaler, 
M.; Hentze, M. W.; Koromilas, A. E.; Pantopoulos, K.. Iron inactivates the 
RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C 
Virus. J. Biol. Chem., 2005, 280, 9049-9057. 
19. Watkins, W. J.; Ray, A. S.; Chong, L. S. HCV NS5B polymerase inhibitors, 
Curr.Opin. Drug Discovery Dev., 2010, 13, 441-465. 
20. McCown, M. F.; Rajyaguru, S.; Le Pogam, S.; Ali, S.; Jiang, W. R.; Kang, 
H.; Symons, J.; Cammack, N.; Nájera, I. The hepatitis C virus replicon 
presents a higher barrier to resistance to nucleoside analogs than to 
nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents 
Chemother., 2008, 52, 1604-1612. 
 163 
21. Balzarini, J. Metabolism and mechanism of antiretroviral action of purine and 
pyrimidine derivatives. Pharm. World Sci. 1994, 16, 113-126. 
22. Walton, E.; Jenkins, S. R.; Nutt, R. F.; Holly, F. W. Branched-chain sugar 
nucleosides. V. Synthesis and antiviral properties of several branched-chain 
sugar nucleosides. J. Med. Chem., 1969, 12, 306-309. 
23. Carroll, S. S.; Tomassini, J. E.; Bosserman, M.; Getty, K.; Stahlhut, M. W.; 
Eldrup, A. B.; Bhat, B.; Hall, D.; Simcoe, A. L.; La Femina, R.; Rutkowski, 
C. A.; Inhibition of hepatitis C virus RNA replication by 2'-modified 
nucleoside analogs. J. Biol. Chem., 2003, 278, 11979-11984. 
24. Olsen, D. B.; Eldrup, A. B.; Bartholomew, L.; Bhat, B.; Bosserman, M. R.; 
Ceccacci, A.; Colwell, L. F.; Fay, J. F.; Flores, O. A.; Getty, K. L.; Grobler, J. 
A. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis 
C virus replication with excellent pharmacokinetic properties., Antimicrob. 
Agents Chemother,. 2004, 48, 3944-3953. 
25. Klumpp, K.; Lévêque, V.; Le Pogam, S.; Ma, H.; Jiang, W. R.; Kang, H.; 
Granycome, C.; Singer, M.; Laxton, C.; Hang, J. Q.; Sarma, K. The novel 
nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-
dependent RNA synthesis and hepatitis C virus replication in cell culture. J. 
Biol. Chem., 2006, 281, 3793-3799. 
26. Clark, J. L.; Hollecker, L.; Mason, J. C.; Stuyver, L. J.; Tharnish, P. M.; 
Lostia, S.; McBrayer, T. R.; Schinazi, R. F.; Watanabe, K. A.; Otto, M. J.; 
Furman, P. A. Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-
2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. 
Med. Chem. 2005, 48, 5504-5508. 
27. Johansson, N. G.; Kalayanov, G.; Martin, J. A.; Smith, D. B.: Winqvist, A. 
HCV nucleoside inhibitor. WO-2008043704 (2008). 
28. Pierra, C.; Amador, A.; Benzaria, S.; Cretton-Scott, E.; D'Amours, M.; Mao, 
J.; Mathieu, S.; Moussa, A.; Bridges, E. G.; Standring, D. N.; Sommadossi, J. 
P. Synthesis and pharmacokinetics of valopicitabine (NM 283), an efficient 
prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J. Med. Chem., 
2006, 49, 6614-6620. 
29. Wang, P.; Chun, B. K.; Rachakonda, S.; Du, J.; Khan, N.; Shi, J.; Stec, W.; 
Cleary, D.; Ross, B. S.; Sofia, M. J. An efficient and diastereoselective 
 164 
synthesis of PSI-6130: A clinically efficacious inhibitor of HCV NS5B 
polymerase. J. Org. Chem., 2009, 74, 6819-6824. 
30. Pharmasset Inc; Roche Holding AG, Roche and Pharmasset initiate phase IIb 
clinical trial of R7128, most advanced nucleoside polymerase inhibitor in 
development for chronic hepatitis C. Press. release, 2009, April 24. 
31. Stansfield, I.; Ercolani, C.; Mackay, A.; Conte, I.; Pompei, M.; Koch, U.; 
Gennari, N.; Giuliano, C.; Rowley, M.; Narjes, F. Tetracyclic indole 
inhibitors of hepatitis C virus NS5B-polymerase. Bioorg. Med. Chem. Lett., 
2009, 19, 627-632. 
32. Habermann, J.; Capitò, E.; Ferreira, M. R.; Koch. U.; Narjes, F. Discovery of 
pentacyclic compounds as potent inhibitors of hepatitis C virus NS5B RNA 
polymerase. Bioorg. Med. Chem. Lett., 2009, 19, 633-638. 
33. Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.; Ludlum, S.; 
Drowns, M.; Rahavendran, S. V.; Skor, H.; Hunter, R. Discovery of (R)-6-
cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-
[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-
one (PF-00868554) as a potent and orally available hepatitis C virus 
polymerase inhibitor. J. Med. Chem. 2009, 52, 1255-1258. 
34. Tedesco, R.; Chai, D.; Darcy, M. G.; Dhanak, D.; Fitch, D. M.; Gates, A.; 
Johnston, V. K.; Keenan, R. M.; Lin-Goerke, J.; Sarisky, R. T.; Shaw, A. N. 
Synthesis and biological activity of heteroaryl 3-(1,1-dioxo-2H-(1,2,4)-
benzothiadizin-3-yl)-4-hydroxy-2(1H)-quinolinone derivatives as hepatitis C 
virus NS5B polymerase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 4354-
4358. 
35. de Vicente, J.; Hendricks, R. T.; Smith, D. B.; Fell, J. B.; Fischer, J.; Spencer, 
S. R.; Stengel, P. J.; Mohr, P.; Robinson, J. E.; Blake, J. F.; Hilgenkamp, R. 
K. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: Structure-
based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-
dioxides. Bioorg. Med. Chem. Lett., 2009, 19, 5652-5656. 
36. Li, J.; Lui, A. S. T.; McCaleb, K. L.; Talamas, F. X.; Heterocyclic antiviral 
arylpyridone derivatives. WO-2010049331 (2010). 
37. Labadie, S. S.; Lin, C. J. J.; Talamas, F. X.; Weikert, R. J.; Heterocyclic 
antiviral compounds. WO-2009101022 (2009). 
 165 
38. Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. J.; Summa, V. Diketoacid-
derivatives as inhibitors of polymerase. PCT Int. Appl. WO 200006529, 
2000; CAN 132; 132323, 2000. 
39. De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. 
Approaching a new era for hepatitis C virus therapy: inhibitors of NS3-4A 
series protease and the NS5B RNA-dependent RNA polymerase. Antivir. Res. 
2003, 58, 1-16. 
40. Pacini, B.; Avolio, S.; Ercolani, C.; Koch, U.; Migliaccio, G.; Narjes, F.; 
Pacini, L.; Tomei, L.; Harper, S. 2-(3-Thienyl)-5,6-dihydroxy-pyrimidine-4-
carboxylic acids as inhibitors of HCV NS5B RdRp. Bioorg. Med. Chem. 
Lett., 2009, 19, 6245-6249. 
 
